UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 1 of 160 R-1 Line #126

Exhibit R-2, RDT&E Budget Item Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400: Research, Development, Test & Evaluation, Defense-Wide / BA 5:

System Development & Demonstration (SDD)

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL DEFENSE (EMD)

COST ($ in Millions)

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete

Total

Cost

Total Program Element

- 344.745 385.047 319.976 - 319.976 211.037 137.895 141.740 157.648 Continuing Continuing

CA5: Contamination Avoidance

(SDD)

- 102.827 127.833 128.954 - 128.954 64.217 32.247 28.065 29.730 Continuing Continuing

CM5: Homeland Defense (SDD)

- 4.775 10.146 0.000 - 0.000 0.000 0.000 0.000 0.000 0.000 14.921

CO5: Collective Protection

(SDD)

- 8.781 7.272 7.885 - 7.885 2.983 0.000 0.000 0.000 0.000 26.921

DE5: Decontamination (SDD)

- 15.399 7.989 16.954 - 16.954 9.729 5.074 9.793 9.317 Continuing Continuing

IP5: Individual Protection (SDD)

- 10.597 12.663 12.960 - 12.960 12.858 12.796 8.963 8.436 Continuing Continuing

IS5: Information Systems (SDD)

- 21.993 21.166 6.019 - 6.019 5.691 5.232 5.232 5.493 Continuing Continuing

MB5: Medical Biological Defense

(SDD)

- 127.933 130.074 86.460 - 86.460 56.868 45.226 68.593 83.282 Continuing Continuing

MC5: Medical Chemical Defense

(SDD)

- 43.648 60.220 54.392 - 54.392 52.813 31.441 15.215 15.019 Continuing Continuing

TE5: Test & Evaluation (SDD)

- 8.792 7.684 6.352 - 6.352 5.878 5.879 5.879 6.371 Continuing Continuing

A. Mission Description and Budget Item Justification

The projects in this program element (PE) support the development, build, and test of products to verify that all operational and derived requirements have been met,

and to support production or deployment decisions. The activities include mature system development, integration, and demonstration to support Milestone C decisions,

and conducting operational test and evaluation of production representative articles.

Individual projects include:

- Contamination Avoidance (CA5): system development of reconnaissance, detection, identification, and warning systems that minimize chemical, biological, and

radiological (CBR) contamination and prevent further cross-contamination during operations.

- Homeland Defense (CM5): system development of common analytical laboratory system capabilities to conduct on-site analysis of any unknown sample and test

potential life-threatening substances.

- Collective Protection. (CO5): system development of collectively protected systems that are smaller, lighter, less costly to produce and maintain, and more logistically

supportable enabling mission accomplishment in spaces safe from the effects of CBR contamination.

Volume 4 - 161

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 2 of 160 R-1 Line #126

Exhibit R-2, RDT&E Budget Item Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400: Research, Development, Test & Evaluation, Defense-Wide / BA 5:

System Development & Demonstration (SDD)

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL DEFENSE (EMD)

- Decontamination (DE5): system development of Contamination Mitigation (ConMit) systems utilizing solutions that will remove/eliminate and/or detoxify contaminated

material without damaging combat equipment, personnel, or the environment.

- Individual Protection (IP5): system development of the next generation protective ensembles (e.g., suits, boots, and gloves) and respiratory and ocular protection

equipment (e.g., protective masks) which enable the Joint Force to operate in a contaminated CBR environment with little or no degradation to his/her performance.

- Information Systems (IS5): system development of information architectures, applications, and cybersecurity hardening for shaping the battlespace against CBR

threats.

- Medical Biological Defense (MB5): product development of medical biological countermeasure platform technologies, medical biological countermeasures (vaccines

and therapeutics), reagents, assays, and diagnostic equipment to provide an effective capability for medical defense against biological warfare agent threats facing U.S.

Forces in the field.

- Medical Chemical Defense (MC5): product development of medical materiel and other medical equipment items (e.g., diagnostic equipment, prophylactic, pre-

treatment, and therapeutic drugs, and individual/casualty decontamination compounds) necessary to provide an effective capability for medical defense against chemical

warfare agent threats facing U.S. Forces in the field.

- Test and Evaluation (TE5): critical test capabilities, planning, and infrastructure improvements/modifications necessary to evaluate CBRN Defense systems in realistic

operating environments.

The projects in this PE support the engineering and manufacturing development phase of the Department of Defense (DoD) acquisition system and are therefore

correctly placed in Budget Activity 5.

B. Program Change Summary ($ in Millions)

FY 2019 FY 2020 FY 2021 Base FY 2021 OCO FY 2021 Total

Previous President's Budget 358.608 384.047 293.026 - 293.026

Current President's Budget 344.745 385.047 319.976 - 319.976

Total Adjustments -13.863 1.000 26.950 - 26.950

• Congressional General Reductions - -

• Congressional Directed Reductions 0.000 -10.000

• Congressional Rescissions - -

• Congressional Adds 0.000 11.000

• Congressional Directed Transfers 0.000 -

• Reprogrammings -4.750 -

• SBIR/STTR Transfer -9.113 -

• Other Adjustments 0.000 - 26.950 - 26.950

Volume 4 - 162

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 3 of 160 R-1 Line #126

Exhibit R-2, RDT&E Budget Item Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400: Research, Development, Test & Evaluation, Defense-Wide / BA 5:

System Development & Demonstration (SDD)

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL DEFENSE (EMD)

Change Summary Explanation

Funding: FY19 (-$4.750 Million): Reprogrammings to (-$2.750 Million) support CBDP Defense Finance and Accounting System transactions and Financial

Improvement & Audit Readiness and (-$2.000 Million) align filtration systems efforts to advanced technology development.

FY19 (-$9.113 Million): Transfer of funding to support Small Business Innovative Research/Small Business Technology Transfer efforts.

FY20 (+$11.000 Million): Congressional Add for Smallpox antiviral post-exposure prophylaxis.

FY20 (-$10.000 Million): Congressional Directed Reductions to the Mounted Manned Platform Radiological Detection System, the Common Analytical Laboratory

System, the Software Support Activity and other system development & demonstration programs.

FY21 (+$26.950 Million): The FY21 funding request was reduced during the Defense-Wide Review (DWR) to account for programs being terminated or

restructured (-$80.081 Million); Departmental economic adjustments (-$0.281 Million); and program increases to mitigate risk in the areas of detection, protection

and hazard mitigation; to chemical agent detection and biological detection programs, next generation diagnostic programs, and protection programs (+$107.312

Million).

Schedule: N/A

Technical: Provides for critical new start program Forward Area Mobility Spray - System (FAMS-S).

Volume 4 - 163

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 4 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

COST ($ in Millions)

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete

Total

Cost

CA5: Contamination Avoidance

(SDD)

- 102.827 127.833 128.954 - 128.954 64.217 32.247 28.065 29.730 Continuing Continuing

Quantity of RDT&E Articles - - - - - - - - - -

A. Mission Description and Budget Item Justification

This project supports Engineering and Manufacturing Development and Low Rate Initial Production (EMD/LRIP) of an array of reconnaissance, detection and

identification equipment, and warning systems.

Efforts included in this Project are:

(1) Mounted Manned Platform Radiological Detection System (MMPRDS)

(2) Mounted Enhanced Radiac Long Range Imaging Networkable (MERLIN)

(3) Aerosol & Vapor Chemical Agent Detector (AVCAD)

(4) Multi-Phase Chemical Agent Detector (MPCAD)

(5) Proximate Chemical Agent Detector (PCAD)

(6) CBRN Sensor Integration on Robotics Platforms (CSIRP)

(7) Enhanced Maritime Biological Detection (EMBD)

(8) the Global Biosurveillance Technology Initiatives (GBTI)

(9) Joint Biological Tactical Detection System (JBTDS)

(10) Joint Handheld Bio-Agent Identifier (JHBI)

(11) Joint Nuclear Biological Chemical Radiological System (JNBCRS) 1, also known as Stryker Nuclear Biological Chemical Reconnaissance Vehicle Sensor Suite

(NBCRV SS)

(12) Non-Traditional Agent (NTA) Defense Support, and

(13) the Reactive Chemistry Orthogonal Surface and Environmental Threat Ticket Array (ROSETTA)

The MMPRDS program includes two sets of mounted radiological and nuclear sensors: the MERLIN and the Vehicle Integrated Platform Enhanced Radiac (VIPER),

both of which originate with technology transitions from the Defense Threat Reduction Agency (DTRA). MMPRDS will sunset at the end of FY20. In FY21 and beyond,

the Defense-Wide Review (DWR) reduced this program for higher priorities, resulting in only the MERLIN program (Project Number CA5) being pursued.

MERLIN is a set of externally mounted sensors used in joint operations on the Stryker NBCRV Sensor Suite Upgrade with the potential for integration on other Army

platforms within the formation. The system supports manned and unmanned platform-mounted reconnaissance and surveillance of radiological and nuclear hazards at

standoff distances. It is the first and only standoff radiological and nuclear detection capability for the Army; all previously fielded detectors require platforms to travel

dangerously close to hazardous areas to detect radiological threats, which puts manned platform crews at risk of radiation exposure and presents contamination issues

for the vehicle (be it manned or unmanned). The MERLIN funding lines in FY21 and beyond support integration of the MERLIN system designed for the NBCRV.

Volume 4 - 164

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 5 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

AVCAD will fill critical gaps in current chemical sensor capabilities in the areas of aerosol Chemical Warfare Agent detection, and detection of specific advanced threat

agents/Non-Traditional Agents (NTAs). The AVCAD will also detect residual vapors to prevent/mitigate health effects associated with low concentration exposures. The

U.S. Military Departments view the AVCAD as a high-priority program and will use the system to support their missions, which include monitoring, collective protection,

base defense, decontamination, unmasking, reconnaissance, and shipboard and aviation platform chemical detection.

The MPCAD is two-man portable system that will conduct near real-time, near-laboratory grade analysis of solid, liquid, and vapor samples collected by the operator

in a presumptively contaminated area. The MPCAD results will support the Commander's tactical and operational decisions regarding maneuver, protection,

decontamination, and treatment measures. The Army and Marine Corp will employ MPCAD in Dismounted Reconnaissance and Site Assessment missions to

substantiate presumptive detector results. The Air Force will employ the MPCAD to support Post-Event Reconnaissance in support of Reconnaissance and Surveillance

missions by monitoring the environment at airbases after a chemical release. The Air Force will continuously monitor contaminated areas for chronic health effects levels

through analysis of samples from collectors deployed at the contamination site and brought back to the analyzer for identification and quantification. This information

will support commander decisions to determine Mission Oriented Protective Posture (MOPP) levels and eventual termination of cordon restrictions. In FY20, MPCAD is

continuing testing to support EMD development. In FY21, MPCAD will complete the EMD phase and prepare for Milestone C / LRIP decision in FY22.

The PCAD provides the Joint Services a handheld capability to locate and detect trace amounts of NTA liquids and a chemical capability for solid surface detection.

Efforts to mature technologies during Technology Maturation Risk Reduction (TMRR) phase resulted in systems that were too heavy and cumbersome to use.

Program office is working with users and JSTO to identify technologies to mature that may meet the users' needs for a hand held, non-contact, areal detection system.

Concurrently with the PCAD TMRR efforts, Combat Capabilities Development Command (CCDC) Chemical Biological Center (CBC) was exploring the use of adapting

the Joint Chemical Agent Detector (JCAD) to detect explosives. A JCAD is inserted into a cradle that has a heated inlet and modified library to detect explosives. The

effort was expanded for the system to detect NTAs, and Pharmaceutical Based Agents (PBAs) and is called JCAD Solid/Liquid Adapter (SLA). The JCAD SLA kit is

planned to be added to the M4A1 JCAD program as an Additional Authorized List (AAL) item. In FY20 the JCAD SLA will use the JCAD BA7 line.

CSIRP is a prototyping and fielding effort that will miniaturize and integrate modular CBRN sensors with Unmanned Air Systems (UAS) and Unmanned Ground

Vehicles (UGV) Programs of Record (PORs). CSIRP will provide situational awareness across the echelons of command in order to enable freedom of maneuver

and action on the battlefield. An integrated CSIRP capability will exploit advances in machine learning and autonomy. Additional capabilities include sensing and

communication, timely and accurate detection, warning and reporting of CBRN hazards. This reduces risk at tactical and operational echelons in mounted and

dismounted configurations. CSIRP gives the Joint Force an opportunity to enhance capabilities and maintain operational advantage in multi domain operations.

The EMBD is the Navy's automated biological point detection, collection and identification system. EMBD replaces/upgrades the 135 Joint Biological Point Detection

Systems (JBPDS) currently fielded to the Navy and provides 40 systems for new construction ships. EMBD improves detection sensitivity providing the Navy the

ability to "detect to inform" reducing the number of contaminated ships during a biological warfare agent attack and minimizing sailor casualties. EMBD reduces false

alarm rates, modernizes the computing architecture and increases reliability and sailors confidence in the system. These improvements decrease fleet O&S costs,

and reduces the obsolescence issues with current biological detection capability. The EMBD program will test, produce, integrate and field a lower cost biological point

Volume 4 - 165

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 6 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

detection system. In FY20, EMBD will complete EMD (Engineering and Manufacturing Development) DT/OT (Developmental Testing/Operational Testing) and move to

Milestone C.

GBTI will research and characterize laboratory networks and develop algorithms to identify key nodes, having the greatest potential to compress the time between

disease event initiation and the production of actionable data. In FY19, GBTI will close. The Targeted Acquisition of Reference Materials Augmenting Capabilities

(TARMAC) will track projects of mutual interest, formerly under GBTI, with the Chemical Biological Defense Program. The Targeted Acquisition of Reference Materials

Augmenting Capabilities (TARMAC) an initiative under Defense Biological Product Assurance Program (DBPAO) will leverage the investments made under GBTI. The

(TARMAC) effort will transition to the Defense Biological Products Assurance Program (DBPAP) project MB5 line in FY20.

The JBTDS is the first tactical lightweight, low-cost biological surveillance system to detect, collect, and identify Biological Warfare Agent (BWA) aerosols. JBTDS

components are man-portable, battery-operable and easy to employ by any military user. JBTDS provides notification of a hazard and enhances battle space

awareness to protect and preserve the forces and is capable of archiving a sample for follow up analysis. When networked, JBTDS augments existing biological

detection systems providing a theater-wide array capable of biological detection, identification and warning to support time sensitive force protection decisions. The

JBTDS provides surface sampling capability which interfaces with the JBTDS identifier to support sensitive site exploitation missions. In FY20, JBTDS will complete

development of components and deliver systems for record test and evaluation.

The JHBI program is a Joint Service Acquisition Category (ACAT) III program consisting of two increments to address an existing United States Special Operations

Command (USSOCOM) requirement for handheld, multiplexed, environmental, bio-agent identification. The JHBI program was initiated under the JBTDS program and

transitioned to its own funding line in FY18. JHBI will provide two different handheld bio-identification systems for the rapid and accurate identification of organisms at

the point of contact for multiple mission types. The proposed JHBI systems will be handheld, Polymerase Chain Reaction-based, multiplexed devices for the analysis

of powder or liquid environmental biological samples. JHBI capabilities will provide Special Operations Forces with timely and accurate identification of eight or more

bio-agents at the point of need. JHBI 1 is anticipated to serve as a supplemental capability to the BioFire RAZOR with JHBI 2 fielding the complete replacement of the

RAZOR by FY20.

The JNBCRS 1, including the Styker NBCRV SSU, provides maneuver formations the ability to conduct mounted reconnaissance and surveillance missions of CBRN

named areas of interest (NAIs). The NBCRV SSU will answer the commander's priority intelligence requirements (PIR), and facilitate proactive risk-based decisions to

ensure freedom of action and survivability. A modern and capable NBCRV SSU is a critical component for Joint Force success when operating in the complex CBRN

environment. Operating with combat vehicles fighting against increasingly capable and determined enemies requires like capability with regard to protection, mobility,

and lethality. The NBCRV SSU will accomplish this by integrating the capability for command and control of unmanned systems with CBRN payload. The NBCRV SSU

will provide a CBRN detection, tipping and queuing system to accomplish desired standoff distances to keep the warfighter out of harm's way and reduce sustainment

costs over the current system. A Chemical Surface Detector (CSD) will be developed to replace the Dual Wheel Sampling System to increase maneuver speed when

conducting NBC missions and increase reliability. This schedule was accelerated from the previous schedule based on the maturity of the sensor and guidance from the

Chief of Staff of the Army. In FY20, NBCRV SSU program will develop a prototype of integrated sensors for demonstration in Joint Warfighter Assessment 2020.

Volume 4 - 166

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 7 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

The NTA Defense program is the lead for DoD, Interagency, and international work pertaining to Pharmaceutical Based Agents (PBAs) and other emerging threats.

The NTA Defense program assesses existing and new portfolio capabilities against PBAs and other emerging threats to develop dedicated initiatives and projects

to transition information, technologies, and capabilities into acquisition programs across all non-medical commodity areas. System prototyping, modification, and

integration efforts serve to advance capabilities, reduce risk, and provide improved knowledge for decision making.

The ROSETTA is a modernization effort to provide a higher confidence chemical liquid hazard detection ticket in the currently fielded M256A2 kit for the Warfighter

to make timely decisions. These decisions will reduce casualties and improve the combat effectiveness of troops engaged in conflicts involving the use of chemical

warfare agents. ROSETTA is based on colorimetric technology and will be eye-readable and ease the Warfighter from current training and operational burden. In

addition, the ROSETTA ticket will provide improved hazard detection performance with reduced false alarm rate, potential for increased number of chemicals detected,

reduced detection time especially for certain compounds of interest, and potential for integration onto unmanned platforms. The ROSETTA funding will complete the

development and testing of the new ROSETTA ticket as well as update the currently fielded M256A2 technical data package via an engineering change proposal (ECP)

to create a new M256A3 kit that will be available to all Services. In FY20, ROSETTA will award contract(s) for technical data package testing.

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Title: 1) Mounted Manned Platform Radiological Detection System (MMPRDS)

Description: Capability Development (Vehicle Integrated Platform Enhanced Radiac (VIPER) and Mounted Enhanced Radiac

Long Range Imaging Networkable (MERLIN))

FY 2020 Plans:

Continue system development via industry/contracts with a focus on NBCRV integration. Conduct sensor-level production

qualification testing for VIPER and MERLIN, which covers: radiation detection performance, environmental survivability (MIL-

STD-810, -461, -464), CBRN survivability, cybersecurity, and human factors. For VIPER, execute operational assessment using

Stryker NBCRVs. Conduct production verification testing for both VIPER and MERLIN.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being restructured, resulting in only the MERLIN program being pursued under Project Number CA5. MMPRDS will

sunset at the end of FY20.

2.743 6.031 -

Title: 2) Mounted Enhanced Radiac Long Range Imaging Networkable (MERLIN)

Description: Risk reduction efforts for integration onto Army platforms.

FY 2021 Plans:

Release contract to begin design of an integration kit used to mount MERLIN onto Army platforms in the formation.

FY 2020 to FY 2021 Increase/Decrease Statement:

- - 1.294

Volume 4 - 167

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 8 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Program/project funding transferred from another funding line. MERLIN will transition from MMPRDS in FY21.

Title: 3) Aerosol & Vapor Chemical Agent Detector (AVCAD)

Description: Product Development

FY 2020 Plans:

Continue EMD development and support various EMD test events to include: Chemical Chamber, Explosive Atmosphere,

Maintenance Demonstration, shipboard false alarm, shipboard verification operation, platform integrations, ship shock and

vibration, rotary and fixed wing, battlefield contaminant, physical characteristics, MIL-STD 4061, Stryker on the move, coastal

operational service life and MIL-STD 810G.

FY 2021 Plans:

Continue EMD development contracts, Systems Engineering, and other IPTs for product development of AVCAD and award LRIP

long lead items.

FY 2020 to FY 2021 Increase/Decrease Statement:

Increase due to change in program/project technical parameters. Increase for contract support to complete EMD DT, OA and

purchase LRIP Long Leads in FY21

8.269 13.802 19.052

Title: 4) Aerosol & Vapor Chemical Agent Detector (AVCAD)

Description: Test and Evaluation

FY 2020 Plans:

Continue and complete testing for: chemical chamber, explosive atmosphere, maintenance demonstration, shipboard false alarm,

shipboard verification operations, platform integration, ship shock and vibration, rotatory and fixed wing integration, battlefield

contaminants, physical characteristics, MIL-STD 461. Initiate tests for: Stryker on the move, coastal operational service life, and

MIL-STD 810G.

FY 2021 Plans:

Complete chemical chamber testing, conduct multiple test requirements to support operational assessment in support of Milestone

C decision.

FY 2020 to FY 2021 Increase/Decrease Statement:

Increase due to change in program/project technical parameters. Increase to complete remainder of EMD Record DT, and

execute OA.

1.319 3.980 8.840

Title: 5) Aerosol & Vapor Chemical Agent Detector (AVCAD) 1.239 4.027 3.155

Volume 4 - 168

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 9 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Description: Program Management Support

FY 2020 Plans:

Continue Program Management including Government system engineering, program/financial management, costing, personnel

support, travel and overhead.

FY 2021 Plans:

Continue Program Management including program/financial management, costing, travel and overhead

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Decrease due to FY21 labor reallocation to appropriate cost category item

under Product Development.

Title: 6) Multi-Phase Chemical Agent Detector (MPCAD)

Description: Product Development

FY 2020 Plans:

Continue up to two EMD contract(s), Government and contracted Integrated Product Development team, systems engineering

and IPT Support. Incorporate fixes and purchase 26 test articles at $150 thousand each to conduct testing and operational

assessment to support Milestone C decision.

FY 2021 Plans:

Continue two EMD contract(s), Government and contracted Integrated Product Development team, systems engineering and

IPT Support. Conduct Milestone C / Low Rate Initial Production (LRIP) and purchase 15 test articles to conduct LRIP testing and

operational testing in FY22.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

18.359 17.477 18.525

Title: 7) Multi-Phase Chemical Agent Detector (MPCAD)

Description: Testing

FY 2020 Plans:

Complete Library Build and system verification. Initiate and conduct DT Interoperability Test, Cyber Security Vulnerability Test,

Chemical Biological Radiological Contamination Survivability (CBRCS) Test, DT Environmental (MIL-STD-810G) Test, DT

Explosive Atmosphere Test, DT False (Positive) Alarm Test, DT Natural Desert Environmental Storage Test, DT Electromagnetic

Survivability Test, DT/OT Chemicals Test, DT Chemical Chamber Test, DT Maintenance Demonstration, DT Post Field Test,

2.436 13.166 9.931

Volume 4 - 169

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 10 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

and OT Limited User Test. Continue Other Government Agency (OGA) support of development and testing of MPCAD systems

including development of logistics product, test plans, and conducting tradeoff discussions.

FY 2021 Plans:

Complete EMD testing started in FY20. Prepare for Milestone C / Low Rate Initial Production (LRIP) and purchase 15 test articles

to conduct LRIP testing and operational testing in FY22. Continue OGA support of development and testing of MPCAD systems

including development of logistics products, test plans, and reports.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. FY20 funds majority of EMD testing; with FY21 funding completion of testing.

Title: 8) Multi-Phase Chemical Agent Detector (MPCAD)

Description: Program Management Support

FY 2020 Plans:

Continue Program Management including Government system engineering, program/financial management, costing, personnel

support, travel and overhead.

FY 2021 Plans:

Continue Program Management including Government system engineering, program/financial management, costing, personnel

support, travel and overhead.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

2.119 5.189 5.501

Title: 9) Proximate Chemical Agent Detector (PCAD)

Description: EMD Contract & Test and Evaluation

8.296 - -

Title: 10) CBRN Sensor Integration onto Robotic Platforms (CSIRP)

Description: Product Development, Program Management, Support, Testing and Evaluation

FY 2021 Plans:

Continue multiple sensor integration efforts for unmanned ground and air platforms. Continue coordination of demonstrations

and test events for end users evaluating the capabilities of the integrated sensors onto the Unmanned Air Systems (UAS)

- - 11.251

Volume 4 - 170

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 11 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

and Unmanned Ground Vehicles (UGV). Program management including government system engineering, program/financial

management, costing, personnel support, travel and overheard. Initiate evaluation of capability and development of CONOPS.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project transitioned to Advanced Development.

Title: 11) EMBD

Description: Product Development

FY 2020 Plans:

Continue Government system engineering, program/financial management, and costing in support of the EMBD program.

Complete acquisition of systems support for contractor developmental testing (DT) and government DT/ Operational Assessment

(OA). Finalize Software (SW) support for test and OA, and finalize SW support and transition to Prime Contractor.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project transitioned to Production and Deployment Phase. EMD completes in FY20

10.452 5.947 -

Title: 12) EMBD

Description: Program management support and Test & Evaluation

FY 2020 Plans:

Continue combat developer, test community and service representation during EMD Phase. Continue program management

support including Government system engineering, program/financial management, costing, personnel support, travel and

overhead. Initiate and complete logistics demonstration and record testing. Initiate and complete Operation Assessment,

Cooperative Vulnerability and Penetration Assessment(CVPA) and Operational Testing. Initiate and complete whole system live

agent aerosol testing.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project transitioned to Production and Deployment Phase. OT is only being conducted in FY20

4.123 7.220 -

Title: 13) GBTI

Description: The Global Biosurveillance Technology Initiative (GBTI) will research and characterize laboratory networks and

develop algorithms to identify key nodes, having the greatest potential to compress the time between disease event initiation

and the production of actionable data. In FY19, GBTI will close. The Targeted Acquisition of Reference Materials Augmenting

Capabilities (TARMAC) will track projects of mutual interest, formerly under GBTI, with the Chemical Biological Defense Program.

The Targeted Acquisition of Reference Materials Augmenting Capabilities (TARMAC) an initiative under Defense Biological

1.100 - -

Volume 4 - 171

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 12 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Product Assurance Program (DBPAO) will leverage the investments made under GBTI. The (TARMAC) effort will transition to the

Defense Biological Products Assurance Program (DBPAP) project MB5 line in FY20

Title: 14) JBTDS: Product Development

Description: EMD Contract & Program Management

FY 2020 Plans:

Continue Government system engineering, program/financial management, and costing in support of the JBTDS program.

Complete EMD contract for product development, on-the-move capability testing and development, networking solution, program

management support, and product team support.

FY 2021 Plans:

Continue Government systems engineering, program/financial management, and costing in support of the JBTDS program.

Continue EMD contract to support testing events. Complete EMD testing and prepare for milestone C decision.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

9.820 6.319 6.610

Title: 15) JBTDS: Program Support

Description: Test & Evaluation

FY 2020 Plans:

Complete sensor calibration. Complete the verification and validation of military utility model/Chemical Biological Attack

Consequence Estimator (CBACE). Continue combat developer and test community support. Continue program management

support including Government system engineering, program/financial management, costing, personnel support, travel and

overhead. Complete production of Biological Warfare Agent (BWA) for testing. Complete live agent and collector characterization

developmental testing.

FY 2021 Plans:

Continue combat developer and test support. Complete EMD testing which include Detector/Collector aerosol agent testing, agent

identification testing, collector characterization, false alarm testing, Mil-STD, interoperability, outdoor simulant testing, logistics

demonstration, operational assessment, cyber adversarial assessment, and modeling and simulation. Continue updates to the

JBTDS Test & Evaluation Master Plan (TEMP) to prepare for milestone C decision.

FY 2020 to FY 2021 Increase/Decrease Statement:

8.069 8.033 7.452

Volume 4 - 172

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 13 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Minor change due to routine program adjustments.

Title: 16) JHBI

Description: JHBI three9-Integrated Sample Prep (ISP) system development, developmental testing, and operational

assessment.

1.632 - -

Title: 17) JNBCRS 1 (NBCRV SSU)

Description: CBRN Sensor Development and Integration

FY 2020 Plans:

Continue CBRN sensor and integrated sensor suite prototype development, maturation, and procurement. Continued government

strategic planning, systems engineering, logistics, training, test and evaluation, technical support, and the bulk of integration

product development for the acceleration of the program.

FY 2021 Plans:

Continue CBRN sensor and integrated sensor suite prototype development, maturation, and procurement. Continue government

strategic planning, systems engineering, logistics, training, test and evaluation, technical support, and the bulk of integration

product development for the acceleration of the program. Will also perform system level development testing.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

18.677 24.587 22.144

Title: 18) JNBCRS 1 (NBCRV SSU)

Description: Program Management Support

FY 2020 Plans:

Continue Program Management including Government system engineering, program/financial management, costing, personnel

support, travel and overhead.

FY 2021 Plans:

Continue Program Management including Government system engineering, program/financial management, costing, personnel

support, travel and overhead.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

1.374 4.340 4.718

Title: 19) NTA Defense 1.054 2.900 3.679

Volume 4 - 173

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 14 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Description: Non-Traditional Agent (NTA) Defense program provides assessment, modification, and testing of detection,

protection, and decontamination capabilities to protect the Joint Services against emerging threats, with current focus on

Pharmaceutical Based Agents (PBAs). Specific efforts include: purchase, test, and assessment of Commercial Off the Shelf/

Government Off the Shelf (COTS/GOTS) equipment; development of prototype equipment for rapid fielding to the Joint Services;

update detection equipment survey to include current devices and a web interface for information sharing; and survey equipment

and techniques to provide improved sample collection and decontamination of PBAs.

FY 2020 Plans:

Continue COTS detection market survey with new technologies and conduct user evaluation of web interface to provide improved

customer usability. Purchase, test, and assess emerging COTS detection equipment and protective equipment materials against

PBAs in many forms (solid/liquid/vapor/aerosol/dusty). Test prototype sampling device to allow users to safely handle and test

chemical compounds in the field. Modify and test lightweight prototype detector that meets detection requirements while reducing

burden on users.

FY 2021 Plans:

Continue purchase of detection prototypes for user assessment. Continue performance assessment of existing capabilities

against PBAs. Finalize development of prototype decontamination system.

FY 2020 to FY 2021 Increase/Decrease Statement:

Increase due to change in program/project technical parameters. FY21 program management funds reallocated within NTA

Defense CA5 to this line to align with the appropriate planned funds.

Title: 20) NTA Defense

Description: Government Integrated Product Team program management and IPT Support.

FY 2020 Plans:

Continue Program Management including Government system engineering, program/financial management, costing, personnel

support, travel and overhead.

FY 2020 to FY 2021 Increase/Decrease Statement:

Decrease due to change in program/project technical parameters. FY21 program management funds reallocated within NTA

Defense CA5 from this line to align with the appropriate planned funds.

- 0.751 -

Title: 21) ROSETTA

Description: Product Development

1.746 4.064 6.802

Volume 4 - 174

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 15 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

FY 2020 Plans:

Continue award of OTA to complete the development and testing of prototype effort.

FY 2021 Plans:

Continue OTA contract and complete testing of ROSETTA prototypes, support operational demonstrations of prototypes and

development of technical data package for transition to production.

FY 2020 to FY 2021 Increase/Decrease Statement:

Increase due to change in program/project schedule. ECP to existing M256A2 kit

Accomplishments/Planned Programs Subtotals

102.827 127.833 128.954

C. Other Program Funding Summary ($ in Millions)

Line Item FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete Total Cost

• CA4: Contamination

Avoidance (ACD&P)

30.879 19.074 10.326 - 10.326 9.853 17.868 14.727 14.294 Continuing Continuing

• JF0100: JOINT CHEMICAL

AGENT DETECTOR (JCAD)

1.698 2.246 0.000 - 0.000 0.000 0.000 0.000 0.000 0.000 3.944

• MC0100: JOINT NBC

RECONNAISSANCE

SYSTEM (JNBCRS)

0.000 0.300 0.000 - 0.000 0.000 0.000 0.000 0.000 0.000 0.300

• MC0101: CBRN DISMOUNTED

RECONNAISSANCE

SYSTEMS (CBRN DRS)

98.231 58.020 47.393 - 47.393 47.009 66.488 85.905 87.775 Continuing Continuing

• MX0001: JOINT BIO TACTICAL

DETECTION SYSTEM (JBTDS)

0.000 0.000 0.000 - 0.000 17.492 52.290 69.255 84.824 Continuing Continuing

Remarks

D. Acquisition Strategy

MOUNTED MANNED PLATFORM RADIOLOGICAL DETECTION SYSTEM (MMPRDS)

The MMPRDS program transitioned the VIPER and MERLIN radiological/nuclear sensor technologies from the Defense Threat Reduction Agency (DTRA), rapidly

mature the systems with industry, and begin fielding via modification work orders (MWOs) to directly replace legacy mounted capabilities for the Army. Sensor

development and testing will continue in FY19-20 using separate Countering Weapons of Mass Destruction (CWMD) Other Transaction Authority (OTA) for VIPER and

Volume 4 - 175

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 16 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

MERLIN. The program plans to award production contracts in FY20 to support production verification testing and initial/rapid fielding to the Joint Nuclear Biological and

Chemical Reconnaissance Systems (JNBCRS) sensor suite upgrade platform under conditional materiel release. MMPRDS will sunset at the end of FY20 and transition

to a separate line of effort for MERLIN. In FY21 and beyond, the Defense-Wide Review (DWR) reduced this program for higher priorities, resulting in only the MERLIN

program being pursued.

MOUNTED ENHANCED RADIAC LONG RANGE IMAGING NETWORKABLE (MMPRDS MERLIN)

The MERLIN BA5 line covers risk reduction efforts for the possible integration of the MERLIN system onto other Army platforms within the formation. The work will be

accomplished through competition using an Other Transaction Authority (OTA) utilizing the Countering Weapons of Mass Destruction (CWMD) OTA.

AEROSOL VAPOR CHEMICAL AGENT DETECTOR (AVCAD)

Aerosol & Vapor Chemical Agent Detector (AVCAD) awarded two MS B Engineering and Manufacturing Development (EMD) contracts with production options. The

AVCAD program is conducting risk reduction testing with prototypes prior to full EMD DT Record Testing in support of the Milestone C decision. The program intends to

conduct P&D phase testing with LRIP units from both vendors if supported by EMD Record Test Data, to promote FRP price competition.

MULTI-PHASE CHEMICAL AGENT DETECTOR (MPCAD)

The Multi-Phase Chemical Agent Detector (MPCAD) (formerly NGCD 3) is using a streamlined acquisition strategy. The MPCAD EMD contract(s) are utilizing the

Countering Weapons of Mass Destruction (CWMD) Other Transaction Authority (OTA) for EMD and LRIP items. The MPCAD will procure production items through a

follow-on CWMD OTA or Federal Acquisition Regulation based contract. The program will develop and validate the systems during EMD utilizing two contractors to

increase competition.

PROXIMATE CHEMICAL AGENT DETECTOR (PCAD)

The Proximate Chemical Agent Detector (PCAD) (formerly NGCD 2) Analysis of Alternatives (AoA) reassessed the PCAD Capability requirement with each of the Joint

Services and determined the state of technologies necessary to meet the user's capability needs are not yet mature. The program will transition back to S&T to further

mature technology via a competitive contract in FY21. In the interim, the program office will support the operational test of the JCAD SLA kit and complete the logistical

analysis to incorporate the JCAD SLA kit as an Additional Authorized List (AAL) item to the M4A1 JCAD.

CBRN SENSOR INTEGRATION ON ROBOTIC PLATFORMS (CSIRP)

CSIRP is a streamlined acquisition effort to rapidly prototype and field capabilities distinct from the traditional acquisition system. CSIRP will provide unmanned CBRN

payload prototypes in 2 year prototyping plan cycles based on service requirements. The prototyping plans will utilize a streamlined acquisition process in order to

keep pace with industry and the rapid advancement of technologies. The CSIRP strategy is to utilize the rapid prototyping process enabled by the Other Transactional

Volume 4 - 176

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 17 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Agreements (OTA) contract vehicle. Upon award, the awardees will have up to two years to produce prototype CBRN sensors that are integrated onto service chosen

(air and/or ground) platforms. These prototypes will be demonstrated, evaluated and tested by the services as well as laboratories and academia. The most successful

will be transitioned to the services for the next steps in acquisition, production and eventual fielding across the services. BA4 funding will provide market research to

support the refinement and the building of technologically mature prototypes. BA5 funding will provide demonstrations, testing and operational assessments to support

transition decisions to POR or sustained capability of the prototypes.

ENHANCED MARITIME BIOLOGICAL DETECTION (EMBD)

The Enhanced Maritime Biological Detection (EMBD) program uses a streamlined acquisition strategy and acquired a Milestone B decision in June 2018. EMBD

will replace/upgrade 135 Joint Biological Point Detection Systems (JBPDS) in the Navy and provide 40 systems for new construction ships. In July 2018 EMBD

awarded a contract through Joint Enterprise Research, Development, Acquisition and Production/Procurement (JE-RDAP) contract for Engineering and Manufacturing

Development (EMD) with options for Low Rate Initial Production (LRIP) in FY20.

GLOBAL BIO TECH INITIATIVE (GBTI)

The Global Biosurveillance Technology Initiative (GBTI) strategy establishes a robust data stream that directly supports existing programs of record in their development

of biological defense countermeasures through the characterization of laboratory networks and augmentation of key nodes within those networks. This will be

accomplished through the use of a University of Affiliated Research Center (Johns Hopkins University) to characterize laboratory networks and develop decision-making

tools for evaluating potential augmentation of key nodes prior to investment. The GBTI program is sun-setting. FY19 will be the last year of funding.

JOINT BIO TACTICAL DETECTION SYSTEM (JBTDS)

The Joint Biological Tactical Detection System (JBTDS) program awarded a full and open contract to Chemring Sensors and Electronic Systems (CSES) in the 3rd

Quarter of FY15 for Engineering and Manufacturing Development (EMD) with options for Low Rate Initial Production (LRIP) and Full Rate Production (FRP). Based

on the results at Biological Point System Assessment (BPSA), JBTDS will integrate TacBio II as the detector and Joint Handheld Biological Identifier (JHBI) as the

identification capability. These technologies will offer significant production and O&S cost savings.

JOINT HANDHELD BIO-AGENT IDENTIFIER (JHBI)

The JHBI program will pursue a collaborative accelerated acquisition strategy. JHBI will use commercial items to procure candidate systems from two vendors for

further development and fielding. The JHBI program acquired test-articles of a single commercial-off-the-shelf (COTS) platform with relevant assays for the JHBI

Combat Evaluation (CV), which served as the decision gate for the completion of the Technology Maturation and Risk Reduction (TMRR) phase. To mitigate risk,

additional technologies were identified and inserted into the JHBI program. JHBI transitioned to production in FY20.

JOINT NBC RECONNAISSANCE SYSTEM - STRYKER (JNBCRS)

Volume 4 - 177

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 18 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Joint Nuclear Biological Chemical Radiological System (JNBCRS), includes the Stryker Nuclear Biological Chemical Reconnaissance Vehicle Sensor Suite Upgrade

(NBCRV SSU). The acquisition strategy for the Stryker NBCRV SSU is to integrate mature sensors into the Stryker NBCRV to support Joint Warfighter Assessment

2020 and system level testing. Following the testing and demonstration, the hardware and software will be fixed and updated for government developmental and

operational testing. The Joint Warfighter Assessments will provide user feedback and operational data to support programmatic and technical decisions. An In Progress

Review will be held after Joint Warfighter Assessment 2020 and system testing to approve a Modification Work Order for fielding. This schedule was accelerated from

the previous schedule based on the maturity of the sensor and guidance from the Chief of Staff of the Army.

NON TRADITIONAL AGENT DEFENSE (NTA DEFENSE)

The NTA Defense program will transition information, technologies, and capabilities associated with Pharmaceutical Based Agents (PBAs) and other emerging threats

into existing and future acquisition programs utilizing a variety of contract mechanisms.

REACTIVE CHEMISTRY ORTHOGONAL SURFACE AND ENVIRONMENTAL THREAT TICKET ARRAY (ROSETTA)

ROSETTA will use a streamlined approach. This approach is based on technology that will transition from Science and Technology Efforts and industry. It will be

developed using the Countering Weapons of Mass Destruction (CWMD) OTA to award multiple development contracts. The M256A3 Production Contract will use Army

Working Capital Funds (AWCF) to purchase the new kits. The ROSETTA funding will complete the development and testing of the new ROSETTA ticket as well as

update the currently fielded M256A2 technical data package via an engineering change proposal (ECP) to create a new M256A3 kit that will be available to all Services.

The M256A3 kit will replace the M256A2 kit by attrition.

Volume 4 - 178

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 19 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

MMPRDS - HW C MERLIN

System Refinement

C/CPFF

H3D INC : Ann

Arbor, MI

0.000 0.793 Feb 2019 3.532 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

MMPRDS - HW C - VIPER

System Refinement

C/CPFF

Spectral Labs Inc. :

San Diego, CA

0.000 0.750 Oct 2018 0.826 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

MERLIN - HW C - Army

Platform Integration Kit

Development

C/CPFF TBD : N/A 0.000 0.000 0.000 1.087 Nov 2020 - 1.087 Continuing Continuing 0.000

AVCAD - HW S - Aerosol

& Vapor Chemical Agent

Detector EMD Contract

C/CPIF

Chemring Detection

Systems : Inc.,

Charlotte, NC

0.000 1.719 Jan 2019 6.901 Oct 2019 6.476 Jan 2021 - 6.476 Continuing Continuing 0.000

AVCAD - HW S - Aerosol

& Vapor Chemical Agent

Detector EMD Contract #2

C/CPIF

Smiths Detection :

Edgewood, MD

0.000 4.801 Jan 2019 6.901 Oct 2019 10.415 Jan 2021 - 10.415 Continuing Continuing 0.000

AVCAD - HW C -

Government SE &

Technical Management

Team

MIPR Various : Various 0.000 1.657 Jan 2019 0.000 2.759 Nov 2020 - 2.759 Continuing Continuing 0.000

AVCAD - HW C -

Verification & Validation of

RAM Model

MIPR

Army Materiel

Systems Analysis

Activity : Aberdeen

Proving Ground, MD

0.000 0.065 Jan 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

AVCAD - HW C - Chemical

Biological Radiological and

Nuclear Contamination

Survivability Assessment

(CBRCSA) Paper Study

MIPR

West Desert Test

Center : Dugway, UT

0.000 0.025 Feb 2019 0.000 0.100 Jan 2021 - 0.100 Continuing Continuing 0.000

AVCAD - HW C - Shipping

chemicals for V&V

MIPR

Combat Capabilities

Development

Command (CCDC)

Chemical Biological

Center : Aberdeen

Proving Ground, MD

0.000 0.002 Jan 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

MPCAD - HW S - EMD

Contract - FLIR

C/CPFF

FLIR Systems : Inc.,

West Lafayette, IN

0.000 4.678 Jan 2019 8.442 Mar 2020 7.868 Dec 2020 - 7.868 Continuing Continuing 0.000

Volume 4 - 179

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 20 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

MPCAD - PM/MS

S - Government SE

&Technical Management

Team

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.000 1.686 Dec 2018 3.041 Jan 2020 2.014 Nov 2020 - 2.014 Continuing Continuing 0.000

MPCAD - HW S - EMD

Contract - Sig Sci

C/CPFF

Signature Science :

Austin, TX

0.000 11.995 Dec 2018 5.994 Mar 2020 8.443 Dec 2020 - 8.443 Continuing Continuing 0.000

MPCAD - HW C - OPETS

Contract Support

C/FFP

Kalman & Company

Inc. : Virginia Beach,

0.000 0.000 0.000 0.200 Feb 2021 - 0.200 Continuing Continuing 0.000

PCAD - HW S - JCAD SLA

Kit finalization

SS/CPIF

Smiths Detection :

Edgewood, MD

0.000 4.492 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

PCAD - HW C - PM/MS

S - Government SE &

Technical Management

Team

MIPR

JPM NBC

Contamination

Avoidance (JPM

NBC CA) : JPEO,

Aberdeen Proving

Ground, MD

0.000 0.764 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

PCAD - HW C - Calibration

Implementation and JCAD

SLA Algorithms Expansion

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.000 0.635 Jan 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

CSIRP - HW C - Prototype

Integration

C/FFP TBD : N/A 0.000 0.000 0.000 0.500 Feb 2021 - 0.500 Continuing Continuing 0.000

CSIRP - HW C -

Government Matrix and

Core Labor

Various Various : Various 0.000 0.000 0.000 1.701 Mar 2021 - 1.701 Continuing Continuing 0.000

CSIRP - HW C - OTA

Funding for Prototype Plan

Various TBD : N/A 0.000 0.000 0.000 2.100 Nov 2020 - 2.100 Continuing Continuing 0.000

CSIRP - HW C - OTA

Funding for Prototype Plan

Various TBD : N/A 0.000 0.000 0.000 4.900 Feb 2021 - 4.900 Continuing Continuing 0.000

EMBD - Product

Development Support

MIPR Various : Various 1.680 1.277 Nov 2018 1.152 Mar 2020 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 180

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 21 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

EMBD - OPETS contractor

team

C/FFP

Patricio Enterprises :

Inc., Woodbridge, VA

0.081 0.135 Mar 2019 0.130 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

EMBD - Prototype

Development

SS/FFP

MA Institute of Tech

- Lincoln Labs (MIT-

LL) : Lexington, MA

1.780 1.200 Nov 2018 1.000 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

EMBD - HW - Prototype

Development and

Manufacturing

C/CPIF

Chemring Detection

Systems : Inc.,

Charlotte, NC

5.557 7.840 Feb 2019 3.665 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

JBTDS - HW SB -

Prototype Development

C/CPFF

ATI Solutions : Inc.,

Tysons Corner, VA

0.000 3.500 Mar 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

JBTDS - HW - EMD

Contract Award

C/CPIF

Chemring Detection

Systems : Inc.,

Charlotte, NC

28.739 2.875 Feb 2019 1.850 Nov 2019 2.360 Feb 2021 - 2.360 Continuing Continuing 0.000

JBTDS - Product Cotractor

Support Team

C/FFP

Patricio Enterprises :

Inc., Woodbridge, VA

1.198 0.254 Feb 2019 0.280 Feb 2020 0.308 Feb 2021 - 0.308 Continuing Continuing 0.000

JBTDS - Product

Contractor Cost Support

Team

C/FFP

Tecolote Research

Inc : Arlington, VA

0.616 0.008 Feb 2019 0.157 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

JBTDS - Product

Development Support -

Labor, Travel, & GPC

MIPR Various : Various 19.130 3.183 Nov 2018 4.032 Nov 2019 3.954 Nov 2020 - 3.954 Continuing Continuing 0.000

JHBI - HW S - JHBI

BIOMEME three9

Handheld Diagnostics

System

C/CPFF

Advanced

Technologies

International :

Summerville, SC

0.000 1.577 Feb 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

JNBCRS 1 - HW-Sensor

Suite Development

C/CPIF Various : Various 6.282 1.563 Mar 2019 12.075 Nov 2019 3.600 Nov 2020 - 3.600 Continuing Continuing 0.000

JNBCRS 1 - HW C -

Contractor and Product

Support

SS/CPFF Various : Various 0.000 0.000 0.000 1.322 Nov 2020 - 1.322 Continuing Continuing 0.000

JNBCRS 1 - HW C -

Platform

C/FFP

General Dynamics

Land Systems :

Detroit, MI

0.800 0.058 May 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 181

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 22 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

JNBCRS 1 - HW C -

VIPER / MERLIN

C/CPFF

Advanced

Technologies

International :

Summerville, SC

2.570 1.500 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

JNBCRS 1 - HW C -

Government Team Labor

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

1.592 0.904 Nov 2018 2.292 Nov 2019 1.869 Nov 2020 - 1.869 Continuing Continuing 0.000

JNBCRS 1 - HW C - CSD

Contract

C/CPFF

AGENTASE : LLC,

Elkridge, MD

1.978 2.096 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

JNBCRS 1 - HW C - CSD

Contract #2

C/CPFF

L-3

Communications :

Santa Rosa, CA

1.959 1.322 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

JNBCRS 1 - SW C

Integration

C/CPFF

FLIR Systems Inc. :

Elkridge, MD

0.000 7.957 Mar 2019 0.000 11.438 Nov 2020 - 11.438 Continuing Continuing 0.000

JNBCRS 1 - HW C - CSD

Contract #3

C/CPFF

Hamilton Sundstrand

Corp. : Pomona, CA

1.058 0.272 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

NTA DEFENSE - HW C -

Information Management/

Strategic Coordination

Various TBD : N/A 0.000 0.000 0.000 0.176 Dec 2020 - 0.176 Continuing Continuing 0.000

NTA DEFENSE - HW S -

Capabilities Assessments

C/CPFF

MRIGlobal : Kansas

City, MO

0.301 0.000 0.300 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

NTA DEFENSE - HW S -

Capabilities Assessments

C/CPFF

Battelle Memorial

Institute : Columbus,

0.000 0.000 0.400 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

NTA DEFENSE - HW S -

Capabilities Assessment

MIPR

Edgewood Chemical

Biological Center

(ECBC) : Aberdeen

Proving Ground, MD

0.047 0.095 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

NTA DEFENSE - HW S

- System Protoype and

Modification

C/CPFF Various : Various 0.000 0.000 1.500 Dec 2019 0.495 Dec 2020 - 0.495 Continuing Continuing 0.000

NTA DEFENSE - HW

S - Government SE &

MIPR

Edgewood Chemical

Biological Center

0.097 0.200 Apr 2019 0.197 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 182

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 23 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

Technical Management

Team

(ECBC) : Aberdeen

Proving Ground, MD

ROSETTA - HW C -

Government Team Labor

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.000 0.128 Jan 2019 0.000 0.700 Nov 2020 - 0.700 Continuing Continuing 0.000

ROSETTA - Technical

Manuals

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.000 0.000 0.400 Apr 2020 0.000 - 0.000 Continuing Continuing 0.000

ROSETTA - Technical

Data Package

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.000 0.000 0.400 Apr 2020 0.000 - 0.000 Continuing Continuing 0.000

ROSETTA - HW C-

Contract Award

C/FFP

ATI Solutions : Inc.,

Tysons Corner, VA

0.000 1.512 Jul 2019 0.400 Jul 2020 3.418 Dec 2020 - 3.418 Continuing Continuing 0.000

Subtotal

75.465 73.518 65.867 78.203 - 78.203 Continuing Continuing N/A

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

MMPRDS - ES C - SEPM

Support

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.000 0.387 Nov 2018 0.456 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

MERLIN - ES S - SEPM

support

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.000 0.000 0.000 0.100 Nov 2020 - 0.100 Continuing Continuing 0.000

AVCAD - Non-test OGA

support

MIPR Various : Various 0.000 0.000 4.027 Nov 2019 3.527 Jan 2021 - 3.527 Continuing Continuing 0.000

PCAD - ES C - OGA

Support PCAD - Test

Planning

MIPR

Naval Surface

Warfare Center

(NSWC) - Dahlgren

Center : Dahlgren,

0.000 0.050 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 183

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 24 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

PCAD - ES C - Test

Oversight Support for the

JCAD SLA

MIPR

Indian Head : Indian

Head, MD

0.000 0.026 Mar 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

EMBD - ES - OTA/OGA

USN Variant Support

MIPR Various : Various 0.000 0.000 0.025 Mar 2020 0.000 - 0.000 Continuing Continuing 0.000

EMBD - ES S - Test

Planning Support

MIPR

Dugway Proving

Ground (DPG) :

Dugway, UT

0.000 0.100 Mar 2019 0.100 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

EMBD - ES S - Software

support

MIPR

Armament

Research :

Development and

Engineering Center,

Piccatinny, NJ

0.093 0.075 Feb 2019 0.075 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

EMBD - ES S - Test

Planning Support #2

MIPR

Navy Operational

Test and Eval Force

(OPTEVFOR) :

Norfolk, VA

0.208 0.181 Nov 2018 0.200 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

EMBD - ILS S - Logistics

Support

MIPR

U.S. Army Tank-

automotive &

Armaments

Command

(TACOM) : Warren,

0.000 0.100 Feb 2019 0.100 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

EMBD - ES C - Navy

Service Support

MIPR

Naval Surface

Warfare Center

(NSWC) - Dahlgren

Center : Dahlgren,

0.859 0.662 Oct 2018 0.606 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

JBTDS - ES - CBC - DPG MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.000 0.594 Jan 2019 0.750 Nov 2019 0.682 Jan 2021 - 0.682 Continuing Continuing 0.000

JBTDS - ES - Engineering

Support

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

2.425 0.210 Jan 2019 0.170 Nov 2019 0.197 Jan 2021 - 0.197 Continuing Continuing 0.000

Volume 4 - 184

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 25 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

JBTDS - ES - Biosensor

Calibration Effort

MIPR

Naval Research Lab

(NRL) : Washington,

2.622 0.159 Jan 2019 0.150 Nov 2019 0.154 Mar 2021 - 0.154 Continuing Continuing 0.000

JBTDS - ES - OTA/OGA

Service Representation

MIPR Various : Various 9.038 2.111 Jan 2019 2.735 Nov 2019 2.078 Jan 2021 - 2.078 Continuing Continuing 0.000

JNBCRS 1 - ES -

Engineering Support

MIPR Various : Various 2.222 0.223 Nov 2018 2.750 Nov 2019 0.250 Nov 2020 - 0.250 Continuing Continuing 0.000

JNBCRS 1 - ILS C C/CPFF Various : Various 0.000 0.000 0.000 1.638 Nov 2020 - 1.638 Continuing Continuing 0.000

ROSETTA - ES C -

Engineering and technical

services for ROSETTA

MIPR Various : Various 0.000 0.000 0.000 0.500 Nov 2020 - 0.500 Continuing Continuing 0.000

Subtotal

17.467 4.878 12.144 9.126 - 9.126 Continuing Continuing N/A

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

MMPRDS - DTE -S -

MERLIN DTRA Design

Testing

MIPR

White Sands Missile

Range (WSMR) :

Mesa, AZ

0.000 0.223 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

MMPRDS - DTE S -

MERLIN Production

Qualification Testing

MIPR

White Sands Missile

Range (WSMR) :

Mesa, AZ

0.000 0.000 0.760 Mar 2020 0.000 - 0.000 Continuing Continuing 0.000

MMPRDS - DTE S -

VIPER - DTRA Design

Testing

MIPR

White Sands Missile

Range (WSMR) :

Mesa, AZ

0.000 0.167 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

MERLIN - PM Program

Management

MIPR

JPM Guardian :

Aberdeen Proving

Ground, MD

0.000 0.000 0.000 0.107 Nov 2020 - 0.107 Continuing Continuing 0.000

AVCAD - DTE C - Risk

Reduction Chamber

Testing

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.000 0.764 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 185

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 26 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

AVCAD - DTE C - T&E

support

MIPR Various : Various 0.000 0.555 Dec 2018 0.600 Nov 2020 1.395 Jan 2021 - 1.395 Continuing Continuing 0.000

AVCAD - DTE C -

Operational Assessment

MIPR TBD : N/A 0.000 0.000 0.000 0.797 Jan 2021 - 0.797 Continuing Continuing 0.000

AVCAD - DTE C - DT/

OT Chemical Chamber,

Post Field Chamber,

MOT&E, Environmental

(MIL-STD-810G)

MIPR Various : Various 0.000 0.000 1.118 Feb 2020 1.030 Mar 2021 - 1.030 Continuing Continuing 0.000

AVCAD - DTE C - DT/

OT Cyber Security

Vulnerability

MIPR

Armament

Research :

Development and

Engineering Center,

Piccatinny, NJ

0.000 0.000 0.400 May 2020 0.000 - 0.000 Continuing Continuing 0.000

AVCAD - DTE C - DT

False (Positive) Alarm,

Interoperability, Platform

Integration

MIPR Various : Various 0.000 0.000 0.790 Dec 2019 0.218 Jan 2021 - 0.218 Continuing Continuing 0.000

AVCAD - DTE C - DT

Coastal Operational

Service Life

MIPR

U.S. Naval Research

Lab (NRL) : Key

West, FL

0.000 0.000 0.210 Apr 2020 0.100 Jan 2021 - 0.100 Continuing Continuing 0.000

AVCAD - DTE C - DT

Explosive Atmosphere

Test

MIPR

Electronic Proving

Ground : Fort

Huachuca, AZ

0.000 0.000 0.053 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

AVCAD - DTE C - DT

Rotary Wing Compatibility

Test

MIPR

Naval Air Warfare

Center (Aircraft

Division) : Patuxent

River, MD

0.000 0.000 0.053 Jan 2020 0.028 Jan 2021 - 0.028 Continuing Continuing 0.000

AVCAD - DTE C - DT

Shipboard Operation

Verification

MIPR

Potomac Test

Range : Potomac

Mills, VA

0.000 0.000 0.315 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

AVCAD - DTE C - DT MIL-

STD 901D - Ship Shock;

MIL-STD 167-1 Vibration

MIPR

Naval Surface

Warfare Center

(NSWC) - Dahlgren

0.000 0.000 0.053 Feb 2020 0.025 Jan 2021 - 0.025 Continuing Continuing 0.000

Volume 4 - 186

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 27 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

Center : Dahlgren,

AVCAD - DTE C - DT

Battlefield Contaminant/

Maintenance Demo

MIPR

Aberdeen Test

Center (ATC) :

Aberdeen Proving

Ground, MD

0.000 0.000 0.183 Feb 2020 0.028 Jan 2021 - 0.028 Continuing Continuing 0.000

AVCAD - DTE C -

DT Electromagnetic

Survivability

MIPR

White Sands Missile

Range (WSMR) :

Mesa, AZ

0.000 0.000 0.180 Feb 2020 0.075 Mar 2021 - 0.075 Continuing Continuing 0.000

AVCAD - DTE C - DT

Fixed Wing Compatibility

MIPR

Edwards Air Force

Base : Lancaster, CA

0.000 0.000 0.025 Feb 2020 0.011 Jan 2021 - 0.011 Continuing Continuing 0.000

MPCAD - DTE C - OGA

Program Support

MIPR Various : Various 0.000 0.000 0.000 0.095 Dec 2020 - 0.095 Continuing Continuing 0.000

MPCAD - DTE C - OGA

Test Support

MIPR Various : Various 0.000 0.326 Dec 2018 0.797 Feb 2020 0.658 Jan 2021 - 0.658 Continuing Continuing 0.000

MPCAD - DTE C - DT

Interoperability

MIPR

Eglin AFB : Eglin Air

Force Base, FL

0.000 0.000 0.400 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

MPCAD - DTE C -

DT Cyber Security

Vulnerability

MIPR

Army Research Lab

(ARL) : Adelphi, MD

0.000 0.000 0.100 Feb 2020 0.100 Feb 2021 - 0.100 Continuing Continuing 0.000

MPCAD - DTE C -

Chemcial Biological

Radiological

Contamination Survivability

(CBRCS)

MIPR

West Desert Test

Center : Dugway, UT

0.000 0.000 0.000 0.175 Jan 2021 - 0.175 Continuing Continuing 0.000

MPCAD - DTE C -

Physical Characteristics

and Signature

MIPR

Dugway Proving

Ground (DPG) :

Dugway, UT

0.000 0.000 0.000 0.005 Dec 2020 - 0.005 Continuing Continuing 0.000

MPCAD - DTE C -

Environmental (MIL-

STD-810G)

MIPR

Aberdeen Test

Center (ATC) :

Aberdeen Proving

Ground, MD

0.000 0.000 0.000 0.755 Dec 2020 - 0.755 Continuing Continuing 0.000

MPCAD - DTE C - DT

Explosive Atmosphere

MIPR

Aberdeen Test

Center (ATC) :

0.000 0.000 0.050 Feb 2020 0.012 Feb 2021 - 0.012 Continuing Continuing 0.000

Volume 4 - 187

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 28 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

Aberdeen Proving

Ground, MD

MPCAD - DTE C - DT

False (Positive) Alarm, DT

Logistics Demonstration

MIPR

Aberdeen Test

Center (ATC) :

Aberdeen Proving

Ground, MD

0.000 0.000 0.300 Feb 2020 0.285 Feb 2021 - 0.285 Continuing Continuing 0.000

MPCAD - DTE C -

DT Natural Desert

Environmental Storage

MIPR

Yuma Proving

Ground : Yuma, AZ

0.000 0.000 0.100 Mar 2020 0.050 Jan 2021 - 0.050 Continuing Continuing 0.000

MPCAD - DTE C -

DT Electromagnetic

Survivability

MIPR

White Sands Missile

Range (WSMR) :

Mesa, AZ

0.000 0.000 0.400 Jan 2020 0.711 Jan 2021 - 0.711 Continuing Continuing 0.000

MPCAD - DTE C - DT/OT

Chemical Chamber Event

MIPR

West Desert Test

Center : Dugway, UT

0.000 0.000 0.000 3.892 Dec 2020 - 3.892 Continuing Continuing 0.000

MPCAD - DTE C - DT/OT

Post Field Chamber

MIPR

West Desert Test

Center : Dugway, UT

0.000 0.000 0.000 0.493 Jan 2021 - 0.493 Continuing Continuing 0.000

MPCAD - DTE C - OT

Limited Users Test

MIPR

Aberdeen Test

Center (ATC) :

Aberdeen Proving

Ground, MD

0.000 0.000 1.800 Jun 2020 2.700 Mar 2021 - 2.700 Continuing Continuing 0.000

MPCAD - DTE C -

Contractor Development

Testing

MIPR

West Desert Test

Center : Dugway, UT

0.000 1.374 Jan 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

MPCAD - DTE C -

Program Management

Evaluation for Solid/Liquid

Vapor Testing

MIPR

West Desert Test

Center : Dugway, UT

0.000 0.736 May 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

MPCAD - DTE - DT

Library Build and System

Verification

MIPR

West Desert Test

Center : Dugway, UT

0.000 0.000 9.219 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

PCAD - DTE C - JCAD

SLA Comparative PBA

Testing in COTS/GOTS

Testing

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.000 0.055 Apr 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 188

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 29 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

PCAD - DTE C - Sieve

Packs for JCAD

C/CPIF

Smiths Detection :

Watford

Hertfordshire, UK

0.000 0.037 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

PCAD - DTE S - Agent

Chamber Testing

C/CPFF

Battelle Memorial

Institute : Columbus,

0.000 0.722 Jun 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

PCAD - DTE C - MIL

Standard Testing Report

MIPR

West Desert Test

Center : Dugway, UT

0.000 0.020 Jan 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

PCAD - DTE C - Evaluate

JCAD SLA against EMI

MIPR

White Sands Missile

Range (WSMR) :

Mesa, AZ

0.000 0.075 Jul 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

PCAD - DTE C - Military

Standard Testing

MIPR

Army Test and

Evaluation

Command (ATEC) :

Aberdeen Proving

Ground, MD

0.000 0.175 Jul 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

PCAD - DTE C - Evaluate

FGA Library Response

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.000 0.036 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

CSIRP - Prototype Testing

and Evaluation

Various TBD : N/A 0.000 0.000 0.000 0.229 Feb 2021 - 0.229 Continuing Continuing 0.000

EMBD - DTE S - DT/OT

Live Agent Aerosol Testing

MIPR

Dugway Proving

Ground (DPG) :

Dugway, UT

0.000 0.000 1.000 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

EMBD - DTE S - DT LOG

DEMO

MIPR

Design West

Technologies : Inc,

Tustin, CA

0.000 0.000 0.050 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

EMBD - DTE C - DT/OT -

OA/CVPA/RAM

MIPR

Navy Operational

Test and Eval Force

(OPTEVFOR) :

Norfolk, VA

0.000 0.030 Aug 2019 0.720 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

EMBD - OTE S -

Operational Test &

MIPR

Naval Surface

Warfare Center

(NSWC) - Dahlgren

0.000 0.000 0.750 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 189

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 30 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

Evaluation & Adverserial

Assessment

Center : Dahlgren,

EMBD - OTE S - DT - MIL-

STD

MIPR

Aberdeen Test

Center (ATC) :

Aberdeen Proving

Ground, MD

0.000 0.000 0.250 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

EMBD - DTE - Live Agent

Testing

C/CPFF

Johns Hopkins

University - Applied

Physics Lab : Laurel,

0.323 0.520 May 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

EMBD - DTE -

Consumable Procurement

MIPR

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.163 0.367 Jan 2019 0.600 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

EMBD - DTE - DT Testing

- False Alarm

MIPR Various : Various 0.000 0.259 Jan 2019 0.350 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

JBTDS - DTE -

Developmental Testing

MIPR Various : Various 5.171 1.065 Jan 2019 0.675 Nov 2019 0.771 Jan 2021 - 0.771 Continuing Continuing 0.000

JBTDS - DTE - ARCA

Chamber and Record Test

Support

C/FFP

Battelle Memorial

Institute : Columbus,

0.000 0.877 Nov 2019 0.850 Nov 2019 0.863 Jan 2021 - 0.863 Continuing Continuing 0.000

JBTDS - DTE - V&V of

JBTDS Military Utility

Model

FFRDC

Institute for Defense

Analysis (IDA) :

Alexandria, VA

0.000 0.000 0.125 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

JBTDS - DTE -

Operational Assessment

MIPR Various : Various 0.000 0.592 Jan 2019 0.000 0.494 Jan 2021 - 0.494 Continuing Continuing 0.000

JBTDS - JHU SOLITUDE C/FFP

Johns Hopkins

University - Applied

Physics Lab : Laurel,

2.642 0.990 May 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

JHBI - DTE S - Test and

Evaluation Support

MIPR

Johns Hopkins

University - Applied

0.203 0.055 Jul 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 190

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 31 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

Physics Lab : Laurel,

JNBCRS 1 - DTE - Test

and Evaluation

MIPR Various : Various 1.174 2.849 Nov 2018 7.470 Nov 2019 2.000 Nov 2020 - 2.000 Continuing Continuing 0.000

NTA DEFENSE - DTE

C - Field-forward PBA

Detection

Various TBD : N/A 0.000 0.000 0.000 1.416 Nov 2020 - 1.416 Continuing Continuing 0.000

NTA DEFENSE - DTE

C - System Prototype

Development

Various TBD : N/A 0.000 0.000 0.000 1.000 Apr 2021 - 1.000 Continuing Continuing 0.000

NTA DEFENSE - DTE S -

Capability Assessments

MIPR Various : Various 0.602 0.759 Dec 2018 0.700 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

ROSETTA - DTE C -

Development Testing

MIPR Various : Various 0.000 0.000 2.300 Oct 2019 1.100 Nov 2020 - 1.100 Continuing Continuing 0.000

Subtotal

10.278 13.628 33.746 21.618 - 21.618 Continuing Continuing N/A

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

MMPRDS - Program

Management Support

MIPR

JPM NBC

Contamination

Avoidance (JPM

NBC CA) : JPEO,

Aberdeen Proving

Ground, MD

0.000 0.423 Nov 2018 0.457 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

AVCAD - PM/MS C -

Management Support

MIPR

JPM NBC

Contamination

Avoidance (JPM

NBC CA) : JPEO,

Aberdeen Proving

Ground, MD

0.000 1.239 Jan 2019 0.000 4.063 Jan 2021 - 4.063 Continuing Continuing 0.000

MPCAD - PM/MS S -

JPEO CBRN and JPM

MIPR

JPM NBC

Contamination

0.000 2.119 Nov 2018 5.189 Dec 2019 5.501 Dec 2020 - 5.501 Continuing Continuing 0.000

Volume 4 - 191

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 32 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

NBC CA Management

Support

Avoidance (JPM

NBC CA) : JPEO,

Aberdeen Proving

Ground, MD

PCAD - PM/MS S - JPEO

CBRN and JPM NBC CA

Management Support

MIPR

JPM NBC

Contamination

Avoidance (JPM

NBC CA) : JPEO,

Aberdeen Proving

Ground, MD

0.000 1.209 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

CSIRP - Project

Management

Various TBD : N/A 0.000 0.000 0.000 1.821 Jan 2021 - 1.821 Continuing Continuing 0.000

EMBD - JPEO Program

Support

MIPR

JPEO Chem/Bio

Defense (JPEO-

CBD) : Aberdeen

Proving Ground, MD

0.878 1.329 Feb 2019 1.659 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

EMBD - JPM CA Program

Support

MIPR

JPM NBC

Contamination

Avoidance (JPM

NBC CA) : JPEO,

Aberdeen Proving

Ground, MD

2.600 0.500 Oct 2018 0.735 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

GBTI - PM/MS C -

Program Management

Support

Allot

JPM Guardian :

Aberdeen Proving

Ground, MD

1.855 1.100 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

JBTDS - JPEO Program

Support

MIPR

JPEO Chem/Bio

Defense (JPEO-

CBD) : Aberdeen

Proving Ground, MD

14.217 0.756 Nov 2018 1.808 Nov 2019 1.282 Nov 2020 - 1.282 Continuing Continuing 0.000

JBTDS - JPM CA Program

Support & Core Labor

MIPR

JPM NBC

Contamination

Avoidance (JPM

NBC CA) : JPEO,

Aberdeen Proving

Ground, MD

3.326 0.715 Jan 2019 0.770 Jan 2020 0.919 Jan 2021 - 0.919 Continuing Continuing 0.000

Volume 4 - 192

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 33 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

JNBCRS 1 - PM - Program

Management

MIPR

JPM NBC

Contamination

Avoidance (JPM

NBC CA) : JPEO,

Aberdeen Proving

Ground, MD

3.273 1.307 Nov 2018 4.340 Nov 2019 4.745 Nov 2020 - 4.745 Continuing Continuing 0.000

NTA DEFENSE - PM/MS

S - IPT Support/Program

Management

MIPR

JPEO Chem : Bio,

Rad, and Nuc

Defense (JPEO-

CBRND)

6.263 0.000 0.554 Dec 2019 0.592 Nov 2020 - 0.592 Continuing Continuing 0.000

ROSETTA - PM/MS C -

Program Management

MIPR

JPM NBC

Contamination

Avoidance (JPM

NBC CA) : JPEO,

Aberdeen Proving

Ground, MD

0.000 0.106 Jan 2019 0.564 Oct 2019 1.084 Jan 2021 - 1.084 Continuing Continuing 0.000

Subtotal

32.412 10.803 16.076 20.007 - 20.007 Continuing Continuing N/A

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost To

Complete

Total

Cost

Target

Value of

Contract

Project Cost Totals

135.622 102.827 127.833 128.954 - 128.954 Continuing Continuing N/A

Remarks

Volume 4 - 193

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 34 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

MMPRDS - MERLIN (Standoff Detection) RFP

MMPRDS - MERLIN (Standoff Detection)

Production Ready Test Assets

MMPRDS - Testing MERLIN (Standoff

Detection)

MMPRDS - MERLIN (Standoff Detection) FRP

MMPRDS - VIPER (Point Detection)

Production Ready Test Assets

MMPRDS - VIPER (Point Detection) Testing

MMPRDS - VIPER (Point Detection)

MERLIN - Army Platform Integration OTA

MERLIN - Army Platform Full Materiel Release

MERLIN - Army Platform Integration

MERLIN - MERLIN (Standoff Detection) FRP

MERLIN - Army Platform Integration Milestone

AVCAD - EMD Contract (NGCD 1)

AVCAD - MS C

AVCAD - LRIP

AVCAD - FRP Decision

AVCAD - IOC

MPCAD - EMD Contract

MPCAD - MS C

MPCAD - LRIP

MPCAD - FRP

Volume 4 - 194

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 35 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

CSIRP - OTA Request For Information

CSIRP - Materiel Development Decision

CSIRP - Request for White Papers -

Prototyping Plan #1

CSIRP - OTA Award for Prototyping Plan #1

CSIRP - Test and Evaluation of Prototypes -

Prototyping Plan #1

CSIRP - Demonstration and Transition

Decision - Prototyping Plan #1

CSIRP - Request for White Papers -

Prototyping Plan #2

CSIRP - OTA Award for Prototyping Plan #2

CSIRP - Test and Evaluation of Prototypes -

Prototyping Plan #2

CSIRP - Demonstration and Transition

Decision - Prototyping Plan #2

CSIRP - Prototyping Plan #3

EMBD - Joint Requirements Oversight Council

Memorandum (JROCM)

EMBD - Test and Evaluation Master Plan

EMBD - Production Quality Test (PQT)

EMBD - Operational Assessment

EMBD - MS C

EMBD - LRIP Contract Award

EMBD - OT&E

EMBD - FRP Decision

EMBD - FRP Production

Volume 4 - 195

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 36 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

GBTI - Evaluate Transition Options

JBTDS - Developmental Testing

JBTDS - PQT

JBTDS - Milestone C

JBTDS - LRIP Contract Award

JBTDS - LRIP Production

JBTDS - PVT

JBTDS - MOT&E

JBTDS - FRP Decision

JBTDS - FRP Award

JBTDS - IOC

JHBI - three9 System MS C

JHBI - Developmental Testing - Integrated

Sample Prep

JNBCRS 1 - NBCRV Sensor Suite

Development

JNBCRS 1 - Joint Warfighter Assessment 2019

JNBCRS 1 - Design and Fabrication Phase 2

JNBCRS 1 - Component Test

JNBCRS 1 - System Level Test 1

JNBCRS 1 - Joint Warfighter Assessment 2020

JNBCRS 1 - Modification Work Order

Executing IPR

JNBCRS 1 - Production / Fielding

NTA DEFENSE - Capabilities Assessment

Volume 4 - 196

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 37 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

NTA DEFENSE - Strategic Coordination/

Information Management

NTA DEFENSE - Systems Prototyping and

Development

NTA DEFENSE - Field Forward PBA-Detection

ROSETTA - OTA Contract

ROSETTA - Testing & Demonstrations

ROSETTA - Update TDP and TMs

ROSETTA - Approve Engineering Change

Proposals

Volume 4 - 197

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 38 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Schedule Details

Start End

Events Quarter Year Quarter Year

MMPRDS - MERLIN (Standoff Detection) RFP 1 2019 1 2019

MMPRDS - MERLIN (Standoff Detection) Production Ready Test Assets 1 2019 2 2020

MMPRDS - Testing MERLIN (Standoff Detection) 2 2019 2 2020

MMPRDS - MERLIN (Standoff Detection) FRP 3 2020 4 2020

MMPRDS - VIPER (Point Detection) Production Ready Test Assets 1 2019 1 2020

MMPRDS - VIPER (Point Detection) Testing 2 2019 2 2020

MMPRDS - VIPER (Point Detection) 3 2020 4 2020

MERLIN - Army Platform Integration OTA 1 2021 1 2021

MERLIN - Army Platform Full Materiel Release 4 2022 4 2022

MERLIN - Army Platform Integration 1 2021 4 2022

MERLIN - MERLIN (Standoff Detection) FRP 1 2023 3 2025

MERLIN - Army Platform Integration Milestone C 1 2022 1 2022

AVCAD - EMD Contract (NGCD 1) 1 2019 4 2021

AVCAD - MS C 4 2021 4 2021

AVCAD - LRIP 4 2021 2 2023

AVCAD - FRP Decision 2 2023 2 2023

AVCAD - IOC 2 2024 4 2024

MPCAD - EMD Contract 1 2019 3 2022

MPCAD - MS C 3 2022 3 2022

MPCAD - LRIP 3 2022 1 2025

MPCAD - FRP 2 2025 4 2025

CSIRP - OTA Request For Information 1 2019 1 2019

Volume 4 - 198

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 39 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Start End

Events Quarter Year Quarter Year

CSIRP - Materiel Development Decision 3 2019 3 2019

CSIRP - Request for White Papers - Prototyping Plan #1 2 2019 2 2019

CSIRP - OTA Award for Prototyping Plan #1 4 2019 4 2019

CSIRP - Test and Evaluation of Prototypes - Prototyping Plan #1 2 2020 4 2021

CSIRP - Demonstration and Transition Decision - Prototyping Plan #1 4 2021 4 2021

CSIRP - Request for White Papers - Prototyping Plan #2 2 2020 2 2020

CSIRP - OTA Award for Prototyping Plan #2 2 2021 2 2021

CSIRP - Test and Evaluation of Prototypes - Prototyping Plan #2 3 2021 4 2022

CSIRP - Demonstration and Transition Decision - Prototyping Plan #2 1 2023 1 2023

CSIRP - Prototyping Plan #3 4 2022 4 2024

EMBD - Joint Requirements Oversight Council Memorandum (JROCM) 4 2019 4 2019

EMBD - Test and Evaluation Master Plan 4 2019 4 2019

EMBD - Production Quality Test (PQT) 4 2019 3 2020

EMBD - Operational Assessment 2 2020 2 2020

EMBD - MS C 3 2020 3 2020

EMBD - LRIP Contract Award 3 2020 3 2020

EMBD - OT&E 3 2020 4 2020

EMBD - FRP Decision 2 2021 2 2021

EMBD - FRP Production 2 2021 4 2025

GBTI - Evaluate Transition Options 1 2019 2 2019

JBTDS - Developmental Testing 4 2019 4 2020

JBTDS - PQT 4 2020 4 2021

JBTDS - Milestone C 1 2022 2 2022

JBTDS - LRIP Contract Award 3 2022 3 2022

JBTDS - LRIP Production 3 2022 3 2023

Volume 4 - 199

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 40 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CA5 / Contamination Avoidance (SDD)

Start End

Events Quarter Year Quarter Year

JBTDS - PVT 1 2023 3 2023

JBTDS - MOT&E 1 2023 2 2023

JBTDS - FRP Decision 2 2024 2 2024

JBTDS - FRP Award 2 2024 2 2024

JBTDS - IOC 3 2023 3 2023

JHBI - three9 System MS C 3 2020 3 2020

JHBI - Developmental Testing - Integrated Sample Prep 2 2019 3 2020

JNBCRS 1 - NBCRV Sensor Suite Development 1 2019 3 2019

JNBCRS 1 - Joint Warfighter Assessment 2019 3 2019 3 2019

JNBCRS 1 - Design and Fabrication Phase 2 2 2019 3 2021

JNBCRS 1 - Component Test 3 2021 3 2022

JNBCRS 1 - System Level Test 1 3 2021 3 2022

JNBCRS 1 - Joint Warfighter Assessment 2020 3 2020 3 2020

JNBCRS 1 - Modification Work Order Executing IPR 2 2022 2 2022

JNBCRS 1 - Production / Fielding 3 2022 4 2024

NTA DEFENSE - Capabilities Assessment 1 2019 4 2025

NTA DEFENSE - Strategic Coordination/Information Management 1 2019 4 2025

NTA DEFENSE - Systems Prototyping and Development 1 2019 4 2025

NTA DEFENSE - Field Forward PBA-Detection 4 2019 4 2021

ROSETTA - OTA Contract 4 2019 4 2019

ROSETTA - Testing & Demonstrations 4 2019 1 2022

ROSETTA - Update TDP and TMs 1 2020 4 2022

ROSETTA - Approve Engineering Change Proposals 2 2022 2 2022

Volume 4 - 200

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 41 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CM5 / Homeland Defense (SDD)

COST ($ in Millions)

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete

Total

Cost

CM5: Homeland Defense (SDD)

- 4.775 10.146 0.000 - 0.000 0.000 0.000 0.000 0.000 0.000 14.921

Quantity of RDT&E Articles - - - - - - - - - -

A. Mission Description and Budget Item Justification

This project supports Engineering and Manufacturing Development of common analytical laboratory system capabilities to conduct on-site analysis of any unknown

sample and test potential life-threatening substances.

The effort included in this project is:

(1) Common Analytical Laboratory System capability (CALS)

The CALS will provide common analytical capabilities packaged to meet the specific CONOPS and mission of the gaining unit to detect and identify Chemical Warfare

Agents (CWAs), Toxic Industrial Chemicals (TICs), Toxic Industrial Materials (TIMs) and Biological Warfare Agents (BWAs). Users of the system will include the National

Guard Bureau, the Army 20th Support Command, the Army Medical Laboratory, the Air Force, and the Navy. There will be two variants of CALS, the Theater Validation

Integrated System (TV-IS) and the Field Confirmatory Analytical Capability Sets (FC-ACS). TV-IS is currently in the EMD phase, with proto-types built and EMD testing

that began in February 2019 and concludes in 2QFY2020.

Theater Validation Integrated System (TV-IS) Variant - Army User - A lab with a high level of confidence in analytical results through the use of orthogonal

(complimentary) technologies and an expanded analytical suite that employs multiple standardized ISO containers, which will be integrated onto one Family of Medium

Tactical Vehicles (FMTV) and two trailers. TV-IS is currently in the EMD phase, with EMD testing that concludes in early FY2020. The TV-IS Milestone C decision is

currently scheduled for Mid FY2020 to enter into the Production & Deployment Phase.

Field Confirmatory Analytical Capability Sets (FC-ACS) Variant - Army, Navy, Air Force and NGB User - A transportable equipment subset that allows

them to be loaded into transport cases and palletized if required. FC-ACS is post Milestone C and is not a RDTE funded part of CALS, it is in the production phase.

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Title: 1) CALS

Description: Theater Validation Integrated System (TV-IS) Variant - Army User - A lab with a high level of confidence in analytical

results through the use of orthogonal (complimentary) technologies and an expanded analytical suite that employs multiple

standardized ISO containers, which will be integrated onto one Family of Medium Tactical Vehicles (FMTV) and two trailers.

FY 2020 Plans:

4.775 10.146 -

Volume 4 - 201

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 42 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CM5 / Homeland Defense (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Complete Operational Test and Logistics Demonstration for the theater validation variant. Develop Next Generation Diagnostic

System (NGDS) food and water assay panel associated with Bio Detection capability to include sample processing protocols.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project transitioned to Production and Deployment Phase.

Accomplishments/Planned Programs Subtotals

4.775 10.146 -

C. Other Program Funding Summary ($ in Millions)

Line Item FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete Total Cost

• JS0005: COMMON ANALYTICAL

LABORATORY SYSTEM (CALS)

48.317 4.293 37.173 - 37.173 27.370 33.556 34.930 28.769 Continuing Continuing

Remarks

D. Acquisition Strategy

COMMON ANALYTICAL LABORATORY SYSTEM (CALS)

The Common Analytical Laboratory System (CALS) will be developed leveraging both Commercial Off the Shelf (COTS) and Government Off the Shelf (GOTS)

analytical components to support the identification of Chemical, Biological, Radiological and Nuclear (CBRN) agent materials in environmental samples. CALS will

consist of (2) variants which will be fielded, in accordance with mission need, to components of the Air Force, Army, Marines, Navy and National Guard Bureau requiring

CBRN field confirmatory analytical detection capability. A theatre validation variant will be designed and built for a longer duration mission and for semi-permanent

applications. An analytical capability suite variant will be designed for shorter duration field confirmatory missions. JPdM CBRNE A&RS awarded one contract during

the EMD Phase. The contract was awarded to Battelle Memorial Institute (BMI) (prime) to develop, deliver, manage, and maintain a CALS Technical Data Package

(TDP) throughout the EMD Phase. The TDP to be delivered to the Government at the end of the EMD Phase is to include all product data required by the Production

Level specifications outlined in Military Standard (MIL-STD)-31000A, and will reflect the tested baseline configuration incorporating all approved changes. As part of the

common acquisition strategy, CALS is incorporating the NGDS platform to meet this threshold requirement; specifically to identify various bacterial and viral agents in the

CALS integrated systems. This platform provides the ability to analyze for bacterial and viral agents in various environmental, food, and water matrices (sample types).

Volume 4 - 202

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 43 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CM5 / Homeland Defense (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CALS - HW S Prototype

System Manufacturing

C/CPIF

Battelle Memorial

Institute : Columbus,

33.551 2.168 Nov 2018 0.000 0.000 - 0.000 0.000 35.719 0.000

CALS - HW S - NGDS

Tactical Variant Alpha

Prototype

SS/CPFF

BioFire Dx : Salt

Lake City, UT

1.855 0.000 1.396 Nov 2019 0.000 - 0.000 0.000 3.251 0.000

Subtotal

35.406 2.168 1.396 0.000 - 0.000 0.000 38.970 N/A

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CALS - ES S - Engineering

Support System

C/FFP Various : Various 13.229 0.000 1.221 Feb 2020 0.000 - 0.000 0.000 14.450 0.000

CALS - ES C - Other

Government Agencies

Services

MIPR Various : Various 0.946 0.237 Jan 2019 0.902 Jan 2020 0.000 - 0.000 0.000 2.085 0.000

CALS - TD/D S - Safety

Internal Review Board

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.282 0.100 Mar 2019 0.100 Mar 2020 0.000 - 0.000 0.000 0.482 0.000

Subtotal

14.457 0.337 2.223 0.000 - 0.000 0.000 17.017 N/A

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CALS - OTHT C -

Operation Test Agency

MIPR

Operational Test

Command (OTC) :

Ft. Hood, TX

0.000 0.000 1.808 Apr 2020 0.000 - 0.000 0.000 1.808 0.000

CALS - DTE C - Other

Government Agencies

MIPR Various : Various 0.000 0.000 2.361 Apr 2020 0.000 - 0.000 0.000 2.361 0.000

Volume 4 - 203

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 44 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CM5 / Homeland Defense (SDD)

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

(Test Support) PVT &

LOGDEMO

CALS - DTE C - BMI Test

Support

C/CPIF

Battelle Memorial

Institute : Columbus,

0.000 0.150 Jan 2019 0.802 Dec 2019 0.000 - 0.000 0.000 0.952 0.000

CALS - DTE S - System

DT/OT and LOGDEMO

MIPR

Dugway Proving

Ground (DPG) :

Dugway, UT

5.000 0.675 Jul 2019 0.000 0.000 - 0.000 0.000 5.675 0.000

Subtotal

5.000 0.825 4.971 0.000 - 0.000 0.000 10.796 N/A

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CALS - PM/MS HW -

Program Office - Planning

and Programming

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

8.910 1.445 Nov 2018 1.556 Nov 2019 0.000 - 0.000 0.000 11.911 0.000

Subtotal

8.910 1.445 1.556 0.000 - 0.000 0.000 11.911 N/A

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost To

Complete

Total

Cost

Target

Value of

Contract

Project Cost Totals

63.773 4.775 10.146 0.000 - 0.000 0.000 78.694 N/A

Remarks

Volume 4 - 204

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 45 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CM5 / Homeland Defense (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

CALS - Developmental Testing (DT) (TV IS)

CALS - Functional Configuration Audit (TV IS)

CALS - Milestone C (TV IS) Decision

CALS - Production Verification Test (TV IS)

CALS - Operational Test (TV IS)

CALS - Logistics Demonstration (TV IS)

Volume 4 - 205

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 46 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CM5 / Homeland Defense (SDD)

Schedule Details

Start End

Events Quarter Year Quarter Year

CALS - Developmental Testing (DT) (TV IS) 2 2019 1 2020

CALS - Functional Configuration Audit (TV IS) 2 2020 2 2020

CALS - Milestone C (TV IS) Decision 2 2020 2 2020

CALS - Production Verification Test (TV IS) 3 2020 4 2020

CALS - Operational Test (TV IS) 4 2020 2 2021

CALS - Logistics Demonstration (TV IS) 4 2020 4 2020

Volume 4 - 206

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 47 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CO5 / Collective Protection (SDD)

COST ($ in Millions)

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete

Total

Cost

CO5: Collective Protection

(SDD)

- 8.781 7.272 7.885 - 7.885 2.983 0.000 0.000 0.000 0.000 26.921

Quantity of RDT&E Articles - - - - - - - - - -

A. Mission Description and Budget Item Justification

This project supports Engineering and Manufacturing Development and Low Rate Initial Production of Joint Service Chemical, Biological, and Radiological (CBR)

Collective Protection (CP) systems that are smaller, lighter, less costly to produce and maintain, and more logistically supportable enabling mission accomplishment in

CBR environments. This allows for a more resilient force posture, sustaining Joint Force military advantages and building a more lethal Force, efforts that align with the

National Defense Strategy.

The systems included in this project are:

(1) Chemical Biological Aircraft Survivability Barrier (CASB)

(2) Joint Expeditionary Collective Protection (JECP) Family of Systems

The CASB will provide a lightweight, low-cost, expendable, negative-pressure enclosure that will protect the interior of DoD multi-service aircraft assets (MH-47, CV22,

MC-130) capable of airlifting/exfiltrating chemically or biologically contaminated personnel, equipment, and cargos while preserving the aircraft for continued unrestricted

operations without the need for extensive decontamination. CASB will field a capability that supports the overall intent of the Aircraft chemical, biological, radiological

and nuclear (CBRN) Contamination Survivability (ACCS) Initial Capabilities Development (ICD) in the areas of barriers, aircraft containment systems, modular Collective

Protection (ColPro) for aircraft interiors, and disposable ColPro. CASB is one member of a family of systems that will support the ICD. It will protect the interior from

incidental cross-contamination by chemical and biological (CB)-contaminated personnel and equipment and cargos under transport.

JECP provides the Joint Expeditionary Forces a collective protection capability that is lightweight, compact, modular, and affordable. JECP is a family of systems,

developed in two phases, that will allow the application of collective protection to transportable soft-side shelters, enclosed spaces of opportunity, and in remote austere

locations as a standalone resource. Phase 1 includes standalone collective protection systems and kits that provide existing host platforms and structures with CBRN

protection. Phase 2 includes kits that provide CBRN protection to other host platforms and structures that were not explicitly designed in Phase 1. JECP will be capable

of protecting personnel groups of varying size, unencumbered by Individual Protective Equipment (IPE), from the effects of CB agents, Toxic Industrial Materials (TIMs),

radiological particles, heat, dust, and sand. The employment of JECP will reduce the need for personnel and equipment decontamination and is a strategic deterrence

against state adversaries and non-state actors from using weapons of mass destruction, a National Defense Strategy objective.

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Title: 1) Chemical and Biological Aircraft Survivability Barrier (CASB)

Description: CASB prototype development and testing through the EMD Phase.

2.809 0.877 -

Volume 4 - 207

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 48 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CO5 / Collective Protection (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

FY 2020 Plans:

Complete testing and prepare all required documentation in support of MS C.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project transitioned to Production and Deployment Phase.

Title: 2) JECP

Description: Phase 2 system Development and Demonstration Events

FY 2020 Plans:

Continue updates/development of logistics products. Conduct Logistics Demonstration, provisioning conference and begin

logistics assessment. Complete Phase 2 test article manufacturing for Government developmental and operational testing (OT).

(Qty 4 - Tent Kit Single Skin, Qty 3 - Tent Kit 1, Qty 1 - Tent Kit 3, Qty 4 - Structure Kit Unimproved). Continue Government DT

and begin detailed planning for Multi Operational Test and Evaluation (MOT&E) event and Technical Manual verification. Conduct

physical configuration audit, manufacturing readiness and production readiness assessments.

FY 2021 Plans:

Complete DT testing and reporting. Complete LRIP manufacturing for OT (Qty 2 - Tent Kit Single Skin, Qty 3 - Tent Kit 1, Qty 1

- Tent Kit 3, Qty 1 - Structure Kit Unimproved). Conduct MOT&E, Logistics Demonstration and TM verification events. Finalize

technical data, logistics products and update/draft program acquisition documentation.

FY 2020 to FY 2021 Increase/Decrease Statement:

Increase due to change in program/project schedule. Increase is due to program plans. Program will be completing DT and

conducting OT in FY21.

5.972 6.395 7.885

Accomplishments/Planned Programs Subtotals

8.781 7.272 7.885

C. Other Program Funding Summary ($ in Millions)

Line Item FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete Total Cost

• JP1111: JOINT

EXPEDITIONARY COLLECTIVE

PROTECTION (JECP)

24.552 13.570 14.496 - 14.496 24.135 32.490 39.038 25.193 Continuing Continuing

Remarks

Volume 4 - 208

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 49 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CO5 / Collective Protection (SDD)

D. Acquisition Strategy

CHEMICAL BIOLOGICAL AIRCRAFT SURVIVABILITY BARRIER (CASB)

The Chemical Biological Aircraft Survivability Barrier (CASB) overall strategy is to utilize primary materials (air filtration and flexible barrier material) currently in use by

other programs in the CB defense portfolio. CASB reviewed existing materials and technology as well as designs, configurations, and test data from legacy systems

developed for ColPro applications. Using this information, systems are being developed to meet the broader range of airframes and airframe specific requirements,

chemical biological protection, and logistic supportability that are now required. Based on commonality between the requirements of the CASB and the requirements

of similar programs (i.e. Joint Expeditionary Collective Protection, TIS, and Aeromedical Biological Containment System), CASB initiated at MS B EMD phase to meet

these expanded requirements within the various airframes. CASB is leveraging an IDIQ contract to pursue a Commercial-of-the-Shelf (COTS) development strategy

using full and open competition for awards following MS C. During the EMD phase, CASB awarded a Cost Plus Incentive Fee (CPIF) delivery order for the development

and delivery of prototypes for airworthiness certification within two years.

JOINT EXPEDITIONARY COLLECTIVE PROTECTION (JECP)

JECP Family of Systems (FoS) (Phase 1 and Phase 2) involves multiple contract types throughout the Engineering and Manufacturing Development (EMD) and

Production and Deployment Phases of the program. Having achieved a Full Rate Production (FRP) decision for Phase 1 Systems in December 2016, the program

exercised Fixed Price Incentive (FPI) production options in FY17 & FY18 through the now expired contract with Leidos in support of Initial Operational Capability (IOC).

A competitive build-to print follow-on production delivery order contract was awarded June 2019 to Production Products Manufacturing and will support the remaining

production of Phase 1 Systems to meet Full Operational Capability (FOC). Phase 2 systems will be developed as engineering changes to the Phase 1 systems under a

separate competitive delivery order awarded March 2019 to Leidos and undergo limited developmental and operational testing in pursuit of a FRP decision. Production

options are included in the delivery order to meet FOC for Phase 2 systems. Additionally, BA7 funding will develop incremental improvements to fielded JECP FoS. BA7

efforts include a range of improvements intended to enhance filtration protection, provide a field leakage test capability and update various fielded Environmental Control

Unit (ECU) interface types for use with collective protection. These efforts involve development of designs and prototyping under the Other Transaction Authority (OTA)

through the Countering Weapons Mass Destruction (CWMD) Consortium contract as well as exploitation of commercial off-the-shelf items.

Volume 4 - 209

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 50 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CO5 / Collective Protection (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CASB - HW S - Prototype

Development, TRA, MRA

C/FFP

Integrated Solutions

for Systems (IS4S) :

Huntsville, AL

1.279 0.352 Feb 2019 0.000 0.000 - 0.000 0.000 1.631 0.000

JECP - HW S - Phase

2 System Product

Development/Phase 2

Prototype Manufacturing

C/FPIF

Leidos : Abingdon,

0.845 2.506 Mar 2019 2.590 Jan 2020 3.200 Dec 2020 - 3.200 0.000 9.141 0.000

Subtotal

2.124 2.858 2.590 3.200 - 3.200 0.000 10.772 N/A

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CASB - ES S - IPT and

Technical Support

MIPR Various : Various 0.584 0.781 Nov 2018 0.252 Jan 2020 0.000 - 0.000 0.000 1.617 0.000

JECP - ES S/ILS S -

Engineering, Logistics,

Technical, IPT Support

MIPR Various : Various 2.036 0.850 Nov 2018 1.188 Nov 2019 1.779 Dec 2020 - 1.779 0.000 5.853 0.000

Subtotal

2.620 1.631 1.440 1.779 - 1.779 0.000 7.470 N/A

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CASB - OTE S -

Operational Testing

MIPR Various : Various 0.000 0.315 Jan 2019 0.520 Apr 2020 0.000 - 0.000 0.000 0.835 0.000

CASB - DTE S -

Developmental Testing

MIPR Various : Various 0.552 0.738 Nov 2018 0.000 0.000 - 0.000 0.000 1.290 0.000

JECP - OTHT SB - Test

& Evaluation IPT/OTE S -

Operational Testing/DTE S

MIPR Various : Various 7.839 1.627 Nov 2018 1.309 Nov 2019 1.249 Dec 2020 - 1.249 0.000 12.024 0.000

Volume 4 - 210

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 51 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CO5 / Collective Protection (SDD)

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

- Phase 2 Developmental

testing

Subtotal

8.391 2.680 1.829 1.249 - 1.249 0.000 14.149 N/A

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CASB - PM/MS S -

Program Management

Support

MIPR Various : Various 0.335 0.623 Nov 2018 0.105 Nov 2019 0.000 - 0.000 0.000 1.063 0.000

JECP - PM/MS S -

Program Management

Support

MIPR Various : Various 11.820 0.989 Nov 2018 1.308 Nov 2019 1.657 Dec 2020 - 1.657 0.000 15.774 0.000

Subtotal

12.155 1.612 1.413 1.657 - 1.657 0.000 16.837 N/A

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost To

Complete

Total

Cost

Target

Value of

Contract

Project Cost Totals

25.290 8.781 7.272 7.885 - 7.885 0.000 49.228 N/A

Remarks

Volume 4 - 211

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 52 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CO5 / Collective Protection (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

CASB - Developmental Test and Evaluation

CASB - Capabilities Production Document

CASB - Operational Test

CASB - Milestone C

CASB - Production and Deployment

CASB - IOC

CASB - FOC

JECP - Acquisition Decision Memorandum

JECP - Phase 2 Engineering Changes

Development

JECP - Phase 2 Development Testing (DT)

JECP - Phase 2 Operational Testing (OT)

JECP - Phase 2 Full Rate Production Decision

(FRP)

JECP - Initial Operational Capability (IOC)

Volume 4 - 212

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 53 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

CO5 / Collective Protection (SDD)

Schedule Details

Start End

Events Quarter Year Quarter Year

CASB - Developmental Test and Evaluation 1 2019 1 2020

CASB - Capabilities Production Document 1 2019 1 2019

CASB - Operational Test 4 2019 2 2020

CASB - Milestone C 2 2020 2 2020

CASB - Production and Deployment 2 2020 3 2022

CASB - IOC 1 2021 1 2021

CASB - FOC 3 2022 3 2022

JECP - Acquisition Decision Memorandum 3 2019 3 2019

JECP - Phase 2 Engineering Changes Development 2 2019 4 2019

JECP - Phase 2 Development Testing (DT) 4 2019 2 2021

JECP - Phase 2 Operational Testing (OT) 3 2021 4 2021

JECP - Phase 2 Full Rate Production Decision (FRP) 2 2022 2 2022

JECP - Initial Operational Capability (IOC) 4 2022 4 2022

Volume 4 - 213

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 54 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

COST ($ in Millions)

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete

Total

Cost

DE5: Decontamination (SDD)

- 15.399 7.989 16.954 - 16.954 9.729 5.074 9.793 9.317 Continuing Continuing

Quantity of RDT&E Articles - - - - - - - - - -

A. Mission Description and Budget Item Justification

This project supports the development of Contamination Mitigation (ConMit) systems utilizing solutions that remove and/or detoxify contaminated material without

damaging combat equipment, personnel, or the environment, helping sustain a resilient force posture, one of the efforts outlined in the National Defense Strategy.

ConMit systems provide a force restoration capability for units that become contaminated. Development efforts will provide systems that reduce operational impact

and logistics burden, reduce sustainment costs, increase safety, and minimize environmental effects associated with decontamination and contamination mitigation

operations. Experimentation and demonstration will be used in this phase to reduce risk and inform supporting materiel solutions, Concept of Operations and Tactics,

Techniques & Procedures.

Efforts included in this Project are:

(1) Contaminated Human Remains System (CHRS)

(2) Decontamination Family of Systems (DFoS) Contamination Indicator Decontamination Assurance System (CIDAS)

(3) DFoS CIDAS Blister

(4) Forward Area Mobility Spray - System (FAMS-S)

(5) Major Defense Acquisition Program (MDAP)

(6) Mass Personnel Decontamination (MPD)

(7) Joint Biological Agent Decontamination System (JBADS)

The CHRS program will provide a Contaminated Human Remains Transfer Case (CHRT) packaging solution to safely return chemical, biological, or radiological

contaminated human remains to the Continental United States. The CHRT is a containment system that will protect personnel from the hazards associated with

transporting human remains that are potentially contaminated with chemical, biological or radiological agents and Toxic Industrial Materials (TIM) without posing

additional risk to the handlers or the environment in accordance with federal and international transportation standards. The program addresses capability gaps

identified within both the ConMit Initial Capabilities Document (ICD), dated March 2011, and the Mortuary Affairs ICD, dated October 2008.

Decontamination Family of Systems (DFoS) Contamination Indicator Decontamination Assurance System (CIDAS) is a contamination indicator and decontamination

assurance technology. The indicator will be sprayed on tactical vehicles, aircraft, ships, crew-served weapons, and individual weapons that may have been exposed to

traditional and non- traditional chemical contamination. DFoS CIDAS is a new capability for the Joint Forces that will reduce the logistics burden of decontamination by

indicating presence and location of traditional (Nerve and Blister) and non-traditional chemical agents on militarily relevant surfaces pre- and post-decontamination. This

helps sustain a resilient force posture, making the Joint Force more adaptable against the uncertainty in a changing global strategic environment, an effort listed in the

National Defense Strategy under building a more lethal force. It will consist of an indicator and an applicator, with three applicator configurations -- small-scale, tactical

large scale, and reusable large scale applicators -- and three indicator formulations -- nerve training, nerve and blister indicators.

Volume 4 - 214

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 55 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

Starting in FY21, the DFoS CIDAS program is being broken into separate CIDAS Nerve and CIDAS Blister programs as the capabilities are intended to fulfill distinct

solutions to meet Warfighter needs. The CIDAS Nerve program will address the visual disclosure of traditional and non-traditional nerve agents while the CIDAS Blister

program addresses traditional blister agents, two separate threat scenarios that require different materiel solutions, modernizing a key capability to help build a more

lethal force, as outlined in the National Defense Strategy.

DFoS CIDAS Blister is a contamination indicator and decontamination assurance technology. It will consist of a blister indicator and an applicator. The indicator will be

sprayed on tactical vehicles, aircraft, ships, crew-served weapons, and individual weapons that may have been exposed to blister agent chemical contamination. DFoS

CIDAS Blister is a new capability for the Joint Forces that will reduce the logistics burden of decontamination by indicating presence and location of blister chemical

agent on militarily relevant surfaces pre- and post-decontamination.

The FAMS-S program is a new start program in FY21 and transitioning an improved sprayable decontaminate prototype technology being developed under the NTA

Defense budget to a dedicated budget line in FY21. FAMS-S will provide Special Operations Forces (SOF) and SOF Task Forces (SOTFs) a man-portable and mobile

platform capable of rapidly decontaminating chemical and biological (CB) agents from the exterior of aircraft, helicopters, boats, vehicles, or support equipment to a level

that is clean enough for re-use without having to wear CB protective equipment in order to quickly re-equip the force -- maximizing tactical flexibility and fighting strength

while minimizing the logistical burden and the cost of conducting Countering Weapons of Mass Destruction (CWMD) and CB operations. FAMS-S system variants

envisioned are Large, Small, and Man-Portable configurations that will provide sufficient form factor to enable the SOF tactical forces to push decontamination capability

as "far forward as possible" to execute decontamination "as soon as possible" following the tenants of decontamination.

The MDAP Chemical Biological Radiological and Nuclear (CBRN) Survivability Initiative ensures weapon system programs at all Acquisition Category (ACAT) levels,

as well as non-DoD agency programs such as those programs at the Department of Homeland Security (DHS), meet their CBRN defense requirements. This effort

facilitates and coordinates the research, development, test and evaluation, procurement, delivery, and life cycle sustainment of affordable CBRN defense materiel

solutions for each program's documented CBRN requirements.

The Mass Personnel Decontamination (MPD) program will develop an array of rugged and reliable best-of-breed hardware in a manageably sized, easy-to-erect,

modular system that can be quickly tailored to different mass casualty events in order to support decontamination of ambulatory and non-ambulatory patients, and allow

for the processing of contaminated human remains. The program addresses capability gaps identified within the Consequence Management ICD dated 14 October

2010, the ConMit ICD dated 1 March 2011, and the Mortuary Affairs Operations ICD dated October 2008, modernizing a key capability under the National Defense

Strategy?s line of effort of building a more lethal force.

The Joint Biological Agent Decontamination System (JBADS) will provide the capability to conduct biological agent decontamination of the interior and exterior of the

C-130 aircraft. The JBADS is a capability set that will include a shelter to encapsulate an airframe, a decontamination delivery system (e.g., hot-humid air-blower),

environmental control and monitoring system(s), and other ancillary components required to ensure efficacious biological agent decontamination. It will provide the

capability to decontaminate biologically contaminated aircraft to safe levels and allow more rapid return to service, rebuilding military readiness and building a more

lethal Joint Force as outlined in the National Defense Strategy. Future capability may address biological decontamination of vehicles and additional aircraft.

Volume 4 - 215

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 56 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Title: 1) Contaminated Human Remains System (CHRS)

Description: Contaminated Human Remains Transfer Case (CHRT) Development and Support

FY 2020 Plans:

Complete Operational Test Agency Evaluation Report (OER), and Technology and Manufacturing Readiness Assessments in

support of Full Rate Production (FRP). Update Technical Manuals, if required based on Operational

Testing (OT) results. Update Life Cycle Sustainment Plan and other documentation in preparation for Milestone C/Full Rate

Production decision. Complete Physical Configuration Audit.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project transitioned to Production and Deployment Phase.

- 2.118 -

Title: 2) Decon Family of Sys (DFoS) Contam Indicator Decon Assurance Sys (CIDAS)

Description: Small Scale Applicators (SSA) - Nerve Indicator Kit

0.260 - -

Title: 3) DFoS CIDAS

Description: Small Scale Applicators (SSA) - Blister Indicator Kit

FY 2020 Plans:

Conduct Sustainment Cost Reduction efforts with prime contractor to reduce the sustainment unit cost of the blister indicator by

qualifying alternate sources of raw materials and changing manufacturing processes to increase efficiencies. Procure 62 Small

Scale Applicator - Blister indicator kits for Developmental Testing (DT) and associated Contract Data Requirements Lists (CDRLs)

for Contractor's Progress, Status and Management Report, Program Schedule, etc. Conduct DT to include level of indication (LOI)

testing, material and detector compatibility.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred to another funding line. (DFoS CIDAS Blister)

0.419 4.248 -

Title: 4) DFoS CIDAS

Description: Large Scale Applicators (LSA) (Nerve and Blister kits)

FY 2020 Plans:

Procure 50 LSAs- Blister Indicator kits for Developmental Testing (DT) and associated Contract Data Requirements Lists

(CDRLs). Conduct DT and prepare for LSA production decision and fielding.

FY 2020 to FY 2021 Increase/Decrease Statement:

3.367 0.378 -

Volume 4 - 216

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 57 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Program/project funding transferred to another funding line. (DFoS CIDAS Blister)

Title: 5) DFoS CIDAS BLISTER

Description: Blister Indicator Kits and Large Scale Applicators

FY 2021 Plans:

Award option on Blister contract to procure 1,500 Small Scale Applicator (SSA) Blister Kits, 250 Large Scale Applicator (LSA)

Blister Kits, and associated Contract Data Requirements Lists (CDRLs) to initiate and complete Product Qualification Testing

(PQT) (i.e. area of coverage, environmental factors, logistics demonstration), Developmental Testing (DT), and Operational

Testing (OT) in support of Full Rate Production (FRP).

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred from another funding line. (DFoS CIDAS)

- - 5.467

Title: 6) Forward Area Mobility Spray - System

Description: Prototype Development

FY 2021 Plans:

Award system development contract to begin prototype build, and initiate early developmental and operational test planning for

integration suitability and interoperability effectiveness.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project is new start effort in FY 2021. FAMS-S will utilize efforts conducted under NTA DEFENSE budget, RDT&E

Project Contamination Avoidance (CA), for an improved sprayable decontamination slurry, containment system, and delivery

mechanism.

- - 1.828

Title: 7) Major Defense Acquisition Program (MDAP)

Description: CBRN Survivability support

FY 2020 Plans:

Continue to ensure CBRN survivability requirements are met for MDAP's by cross-walking requirements documents with program

execution plans. Attend meetings to address integration needs and present CBRN system and hardware options. Provide

subject matter expertise in the execution of CBRN survivability requirements for both materiel and non-material solutions. Review

and assist in document preparation for milestones and programs reviews. Conduct CBRN survivability compliance reviews for

Optionally Manned Fighting Vehicle, Robotic Combat Vehicle, Future Long Range Assault Aircraft, Future Attack Reconnaissance

0.435 1.023 1.035

Volume 4 - 217

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 58 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Aircraft, Littoral Combat Ship, European Reassurance Initiative, and other CBRN survivability system integration in preparation for

various program acquisition milestones, system and subsystem test events, design reviews and low rate initial production reviews.

FY 2021 Plans:

Continue to ensure CBRN survivability requirements are met for MDAP's by cross-walking requirements documents with program

execution plans. Attend meetings to address integration needs and present CBRN system and hardware options. Provide

subject matter expertise in the execution of CBRN survivability requirements for both materiel and non-material solutions. Review

and assist in document preparation for milestones and programs reviews. Conduct CBRN survivability compliance reviews for

Optionally Manned Fighting Vehicle, Robotic Combat Vehicle, Future Long Range Assault Aircraft, Future Attack Reconnaissance

Aircraft, Synthetic Training Environment, Precision Navigation and Timing, multiple Soldier Lethality programs, and other CBRN

survivability system integration in preparation for various program acquisition milestones, system and subsystem test events,

design reviews and low rate initial production reviews.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

Title: 8) Mass Personnel Decontamination (MPD)

Description: Engineering and Manufacturing Development (EMD) activities and Product Development

FY 2021 Plans:

Award contract for DT systems and conduct DT.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project transitioned to Engineering and Manufacturing Development Phase.

- - 3.825

Title: 9) Joint Biological Agent Decontamination System (JBADS)

Description: Development and Testing

FY 2020 Plans:

Complete Contractor Specification Testing. Continue Future Capabilities Analysis.

FY 2021 Plans:

Initiate/Complete Initial Operational Test and Evaluation (IOT&E). Complete Future Capabilities Analysis.

FY 2020 to FY 2021 Increase/Decrease Statement:

Increase due to change in program/project technical parameters. (IOT&E being conducted)

10.918 0.222 4.799

Accomplishments/Planned Programs Subtotals

15.399 7.989 16.954

Volume 4 - 218

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 59 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

C. Other Program Funding Summary ($ in Millions)

Line Item FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete Total Cost

• JD0050: DECONTAMINATION

FAMILY OF SYSTEMS (DFoS)

16.384 17.050 10.804 - 10.804 9.022 11.644 16.748 36.588 Continuing Continuing

Remarks

D. Acquisition Strategy

CONTAMINATED HUMAN REMAINS SYSTEM (CHRS)

The CHRS program will leverage previous efforts under a Joint Urgent Operational Needs Statement (JUONS) which have accelerated the CHRT project. Additional

minor design modifications, developmental and operational testing is part of the overall acquisition strategy. Product development consists of the design and prototyping

of a CHRT. The contracting strategy will use the Countering Weapons of Mass Destruction Other Transaction Agreement (CWMD OTA) to procure prototype units,

followed by Developmental Testing (DT). Following DT completion, an In-Process Review will be conducted. A Logistics Demonstration (LD) and Operational Testing

(OT) will be conducted. An Operational Test Agency (OTA) Evaluation Report (OER) will be written, and technical reviews will be conducted, in preparation for a

Milestone C/Full Rate Production decision.

DFoS CONTAMINATION INDICATOR DECONTAMINATION ASSURANCE SYSTEM (DFoS CIDAS)

The DFoS CIDAS program will follow an evolutionary acquisition strategy in consonance with user developed capability documents. Following MS A in 2011, the

program office collaborated with external efforts, including the Hazard Mitigation, Materiel and Equipment Restoration (HaMMER) Advanced Technology Development

(ATD) Operational Demonstration and Extended User Evaluations, and conducted technology demonstrations on candidate indicator and applicator technologies to

mitigate risk and identify affordable mature technologies that meet requirements. The DFoS CIDAS program determined the need for and initiated Government designed

reusable and tactical large scale applicators to provide affordable solutions to meet specific User requirements. Following MS B in 2015, the program used full and open

competition to award a performance based indefinite quantity contract with fixed price incentive successive target contract line items, with options for Low Rate Initial

Production (LRIP) and Full Rate Production (FRP) for nerve indicator and small scale applicator systems. The program will integrate the Contractor and Government

designed indicator and applicators and conduct developmental and operational testing.

DFoS CONTAMINATION INDICATOR DECON ASSURANCE SPRAY BLISTER (DFoS CIDAS BLISTER)

The DFoS CIDAS Blister program will follow an evolutionary acquisition strategy. The program office coordinated with Science and Technology efforts to identify blister

technologies that met Service requirements. After further development, in 4QFY19 a sole-source performance based indefinite delivery indefinite quantity contract was

awarded to develop blister indicator and small scale applicator systems with options for Low Rate Initial Production (LRIP) and Full Rate Production (FRP). The program

will leverage the contract to procure blister indicator kits and conduct test and evaluation events for the EMD phase in preparation for Milestone C.

Volume 4 - 219

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 60 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

FORWARD AREA MOBILITY SPRAY SYSTEM (FAMS-S)

The FAMS-S will be developed using an incremental acquisition strategy as an enabling technology for future application to include additional tactical and strategic

platforms as determined by Special Operations Force (SOF). FAMS-S will reduce technological risk by reviewing existing materials and technology as well as designs,

configurations, and test data from legacy systems developed for decontamination applications, including the High Mobility Decontamination System (HMDS), the M26

Joint System Tactical Decontamination System - Small Scale (JSTDS-SS), and multiple commercial systems and components currently at Technology Readiness Level

(TRL) 8 and 9.

MAJOR DEFENSE ACQUISITION PROGRAM (MDAP)

The MDAP program provides assistance to non-CBD programs with meeting and or optimizing their Chemical, Biological, Radiological, and Nuclear (CBRN) survivability

and force protection capabilities. The MDAP also provides systems engineering analyses to develop CBRN specific operational and technical requirements, identifies

performance gaps between existing materiel and technical requirements, develops cost and schedule estimates, conducts preliminary CBRN T&E and logistics planning,

develops CBRN defense architectures products, and performs trade space analyses for a number of non-CBD programs.

MASS PERSONNEL DECON (MPD)

The MPD program will develop the equipment, processes and procedures for DoD-affiliated personnel contaminated by chemical, biological, and radiological agents to

achieve ambulatory and non-ambulatory throughput requirements as dictated by the needs of the Services, while considering various mission scenarios. As part of the

acquisition strategy, key product developmental efforts will begin with the program achieving a MS A in 1QFY20, and includes efforts for the reduction of current MPD

System costs by assessing existing Mass Casualty Decontamination (MCD) equipment and processes as well as new technology through the use of Requests

For Information (RFI's), Market Research Analyses and Technology Demonstrations. Data collected from prior equipment demonstrations as well as fieldings of

commercial MCD systems in support of two validated Operational Needs Statements will inform the program as well. A competitive/sole source contract for prototyping

and production units will be awarded, followed by Milestone B. Results of Prototyping will inform developmental and operational testing effort, followed by Milestone

C/Full Rate Production Approval. These efforts will additionally support the development of hazardous waste disposal and integration with a Contaminated Human

Remains capability.

JOINT BIOLOGICAL AGENT DECONTAMINATION SYSTEM (JBADS)

The JBADS acquisition approach is to leverage information and technology from the JBADS Joint Capability Technology Demonstration (JCTD) to support entry into

the Engineering and Manufacturing Development (EMD) phase of the acquisition cycle. Following testing, the JBADS will transition to Full Rate Production. The JBADS

will utilize Commercial-off-the-Shelf components for the shelter, the decontamination delivery system, the environmental control and monitoring system(s), and other

ancillary components with the award of a competitive delivery order to produce, operate, and sustain the system. The program as a whole utilizes the evolutionary

acquisition approach for future increments that may expand JBADS capabilities to include other platforms (aircraft and vehicles) as requirements dictate. The Future

Volume 4 - 220

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 61 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

Capabilities Analysis will conduct studies, analyses, and prototyping based on the current JBADS concept to improve its readiness to meet potential future requirements

with minimal impact to the JBADS program.

Volume 4 - 221

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 62 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

DFoS CIDAS - HW S -

SSA/LSA - Blister/Nerve

SS/FPIF

FLIR Systems : Inc.,

Stillwater, OK

0.000 0.847 Feb 2019 2.344 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

DFoS CIDAS BLISTER

- HW S - Small Scale

Applicators

SS/FPIF

FLIR Systems : Inc.,

Stillwater, OK

0.000 0.000 0.000 2.018 Dec 2020 - 2.018 Continuing Continuing 0.000

DFoS CIDAS BLISTER

- HW S - Large Scale

Applicators

MIPR Various : Various 0.000 0.000 0.000 0.600 Dec 2020 - 0.600 Continuing Continuing 0.000

FAMS-S - HW S -

System Development and

Prototype Refinement

C/CPIF TBD : N/A 0.000 0.000 0.000 1.000 Jan 2021 - 1.000 Continuing Continuing 0.000

MPD - HW S -

Developmental Testing

Assets

C/FFP TBD : N/A 0.000 0.000 0.000 1.526 Dec 2020 - 1.526 Continuing Continuing 0.000

JBADS - HW C - Aircraft

Decontamination Units and

Aircraft Enclosure

C/CPIF

AeroClave : LLC,

Winter Park, FL

0.000 1.381 Jan 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

Subtotal

0.000 2.228 2.344 5.144 - 5.144 Continuing Continuing N/A

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CHRS - TD/D S - IPT

CHRT Support and

Readiness Assessments

MIPR Various : Various 0.000 0.000 1.626 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

DFoS CIDAS - TD/D S -

Logistics, Engineering, and

IPT Support

MIPR Various : Various 4.621 0.292 Nov 2018 1.149 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

DFoS CIDAS BLISTER

- TD/D S - IPT and

Technical Support

MIPR Various : Various 0.000 0.000 0.000 0.950 Dec 2020 - 0.950 Continuing Continuing 0.000

Volume 4 - 222

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 63 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

FAMS-S - ES S - Systems

Engineer/Technical SME

Support

Various TBD : N/A 0.000 0.000 0.000 0.472 Jan 2021 - 0.472 Continuing Continuing 0.000

MDAP - TD/D SB - IPT

and Technical Support

MIPR Various : Various 0.475 0.326 Nov 2018 0.819 Nov 2019 0.831 Nov 2020 - 0.831 Continuing Continuing 0.000

MPD - ES SB S - Logistics,

Engineering, and IPT

Support

Various Various : Various 0.000 0.000 0.000 0.417 Jan 2021 - 0.417 Continuing Continuing 0.000

JBADS - TD/D S -

Logistics, Engineering, and

IPT Support

MIPR Various : Various 3.829 0.625 Dec 2018 0.000 0.308 Dec 2020 - 0.308 Continuing Continuing 0.000

Subtotal

8.925 1.243 3.594 2.978 - 2.978 Continuing Continuing N/A

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CHRS - DTE S IPT Test &

Evaluation Reporting

MIPR

Army Test and

Evaluation

Command (ATEC) :

Aberdeen Proving

Ground, MD

0.000 0.000 0.075 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

DFoS CIDAS - OTHT

S - Live Agent / Lab,

Developmental, and

Operational Testing

Various Various : Various 5.039 2.204 Nov 2018 0.169 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

DFoS CIDAS BLISTER -

OTHT S - PQT/DT/OT

MIPR Various : Various 0.000 0.000 0.000 0.750 Dec 2020 - 0.750 Continuing Continuing 0.000

FAMS-S - DTE SB - Decon

Solution Analysis

Various TBD : N/A 0.000 0.000 0.000 0.100 Jan 2021 - 0.100 Continuing Continuing 0.000

MPD - DTE SB -

Developmental Testing

Various TBD : N/A 0.000 0.000 0.000 1.080 Mar 2021 - 1.080 Continuing Continuing 0.000

Volume 4 - 223

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 64 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

JBADS - OTE S - Initial

Operational Test and

Evaluation

C/CPIF

AeroClave : LLC,

Winter Park, FL

0.000 0.000 0.000 3.183 Dec 2020 - 3.183 Continuing Continuing 0.000

JBADS - Future Capability

Analysis/MIL-STD 810-

G Test Planning/Testing/

other T&E activities

Various Various : Various 0.000 1.157 May 2019 0.078 Dec 2019 0.300 Dec 2020 - 0.300 Continuing Continuing 0.000

JBADS - Contractor

Specification Testing/MIL-

STD 810-G support

C/CPIF

AeroClave : LLC,

Winter Park, FL

0.000 4.998 Jan 2019 0.100 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

JBADS - OTHT S -

Prototype Testbed

Capability Development

C/CPFF

Advanced

Technologies

International :

Summerville, SC

0.000 1.381 Jul 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

Subtotal

5.039 9.740 0.422 5.413 - 5.413 Continuing Continuing N/A

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CHRS - PM/MS S -

Program Management and

Technical Support

MIPR Various : Various 0.000 0.000 0.417 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

DFoS CIDAS - PM/MS S

- Program Management

Support

MIPR Various : Various 2.360 0.703 Nov 2018 0.964 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

DFoS CIDAS BLISTER

- PM/MS S - Program

Management Support

MIPR Various : Various 0.000 0.000 0.000 1.149 Dec 2020 - 1.149 Continuing Continuing 0.000

FAMS-S - PM/MS S

- Indirect Program

Management

Various TBD : N/A 0.000 0.000 0.000 0.256 Jan 2021 - 0.256 Continuing Continuing 0.000

Volume 4 - 224

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 65 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

MDAP - PM/MS SB -

Program Management and

Technical Support

MIPR Various : Various 0.052 0.109 Nov 2018 0.204 Nov 2019 0.204 Nov 2020 - 0.204 Continuing Continuing 0.000

MPD - PM/MS S - Program

Management Support

MIPR Various : Various 0.000 0.000 0.000 0.802 Jan 2021 - 0.802 Continuing Continuing 0.000

JBADS - PM/MS S -

Program Management

Support

MIPR Various : Various 3.331 1.376 Dec 2018 0.044 Feb 2020 1.008 Dec 2020 - 1.008 Continuing Continuing 0.000

Subtotal

5.743 2.188 1.629 3.419 - 3.419 Continuing Continuing N/A

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost To

Complete

Total

Cost

Target

Value of

Contract

Project Cost Totals

19.707 15.399 7.989 16.954 - 16.954 Continuing Continuing N/A

Remarks

Volume 4 - 225

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 66 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

CHRS - Developmental Test (DT)

CHRS - Capability Development Document

(CDD) - CHRT

CHRS - Critical Design Review (CDR) - CHRT

CHRS - Operational Test (OT) - CHRT

CHRS - Joint Independent Logistics

Assessment (JILA) - CHRT

CHRS - Type Classification/Material Release -

CHRT

CHRS - MS C- CHRT

CHRS - Full Rate Production (FRP) - CHRT

CHRS - Initial Operational Capability (IOC) -

CHRT

CHRS - Full Operational Capability (FOC) -

CHRT

DFoS - CIDAS JILA - Joint Independent

Logistics Assessment (Nerve Indicator)

DFoS - CIDAS LSA DT

DFoS - CIDAS SSA-Blister DT

DFoS - CIDAS SSA-Nerve Milestone C

DFoS - CIDAS SSA-Nerve Full Rate

Production (FRP)

DFoS CIDAS BLISTER - PQT/DT/OT

DFoS CIDAS BLISTER - Milestone C

DFoS CIDAS BLISTER - Full Rate Production

(FRP)

Volume 4 - 226

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 67 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

DFoS CIDAS BLISTER - Initial Operational

Capability (IOC)

FAMS-S - System Development and Prototype

Refinement

FAMS-S - DT/OT

FAMS-S - MS C

FAMS-S - Low Rate Initial Production

FAMS-S - Full Rate Production

FAMS-S - IOC

MDAP - Armored Multi-Purpose Vehicle

(AMPV) LRIP

MDAP - European Reassurance Initiative (ERI)

CBRN equipment

MDAP - Armored Multi-Purpose Vehicle

(AMPV) FRP

MDAP - Optionally Manned Fighting Vehicle

(OMFV) RFP 1

MDAP - Optionally Manned Fighting Vehicle

(OMFV) RP Contract

MDAP - Optionally Manned Fighting Vehicle

(OMFV) RFP 2

MDAP - Optionally Manned Fighting Vehicle

(OMFV) LRIP

MDAP - Robotic Combat Vehicle Experimental

Prototype Build

MDAP - Future Long Range Assault Aircraft

(FLRAA)

Volume 4 - 227

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 68 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

MDAP - Future Attack Reconnaissance Aircraft

(FARA)

MPD - Systems Engineering Plan (SEP)

MPD - Life Cycle Sustainment Plan (LCSP)

MPD - MS A

MPD - Request for Proposal (RFP)

MPD - Contract Award

MPD - Prototype Testing

MPD - MS B

MPD - Acquisition Program Baseline (APB)

MPD - Test Evaluation Master Plan (TEMP)

MPD - Contract Option

MPD - Critical Design Review (CDR)

MPD - Development Test (DT)

MPD - In Process Review (IPR)

MPD - Operational Test (OT)

MPD - Initial Operational Test and Evaluation

(IOT&E)

MPD - MS C

MPD - Full Rate Production (FRP)

MPD - Initial Operational Capability (IOC)

JBADS - Contractor Specification Testing

JBADS - MIL-STD 810-G Testing

JBADS - First System Build

JBADS - Product Verification Testing (PVT)

Volume 4 - 228

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 69 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

JBADS - Initial Operational Test and Evaluation

(IOT&E)

JBADS - Full Rate Production (FRP)

JBADS - Initial Operational Capability (IOC)

JBADS - Milestone C

JBADS - Full Operational Capability

Volume 4 - 229

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 70 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

Schedule Details

Start End

Events Quarter Year Quarter Year

CHRS - Developmental Test (DT) 1 2019 1 2020

CHRS - Capability Development Document (CDD) - CHRT 2 2019 2 2019

CHRS - Critical Design Review (CDR) - CHRT 4 2019 4 2019

CHRS - Operational Test (OT) - CHRT 4 2019 4 2019

CHRS - Joint Independent Logistics Assessment (JILA) - CHRT 2 2020 3 2020

CHRS - Type Classification/Material Release - CHRT 3 2020 3 2020

CHRS - MS C- CHRT 3 2020 3 2020

CHRS - Full Rate Production (FRP) - CHRT 3 2020 3 2020

CHRS - Initial Operational Capability (IOC) - CHRT 3 2021 3 2021

CHRS - Full Operational Capability (FOC) - CHRT 3 2022 3 2022

DFoS - CIDAS JILA - Joint Independent Logistics Assessment (Nerve Indicator) 3 2019 4 2019

DFoS - CIDAS LSA DT 3 2019 4 2020

DFoS - CIDAS SSA-Blister DT 1 2020 4 2020

DFoS - CIDAS SSA-Nerve Milestone C 4 2020 4 2020

DFoS - CIDAS SSA-Nerve Full Rate Production (FRP) 4 2020 4 2020

DFoS CIDAS BLISTER - PQT/DT/OT 1 2021 4 2021

DFoS CIDAS BLISTER - Milestone C 2 2022 2 2022

DFoS CIDAS BLISTER - Full Rate Production (FRP) 2 2022 2 2022

DFoS CIDAS BLISTER - Initial Operational Capability (IOC) 1 2024 1 2024

FAMS-S - System Development and Prototype Refinement 2 2021 3 2022

FAMS-S - DT/OT 4 2021 4 2022

FAMS-S - MS C 1 2023 1 2023

Volume 4 - 230

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 71 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

Start End

Events Quarter Year Quarter Year

FAMS-S - Low Rate Initial Production 1 2023 3 2023

FAMS-S - Full Rate Production 4 2023 4 2025

FAMS-S - IOC 2 2025 2 2025

MDAP - Armored Multi-Purpose Vehicle (AMPV) LRIP 1 2019 4 2021

MDAP - European Reassurance Initiative (ERI) CBRN equipment 1 2019 2 2020

MDAP - Armored Multi-Purpose Vehicle (AMPV) FRP 3 2021 4 2023

MDAP - Optionally Manned Fighting Vehicle (OMFV) RFP 1 1 2019 2 2020

MDAP - Optionally Manned Fighting Vehicle (OMFV) RP Contract 2 2020 2 2022

MDAP - Optionally Manned Fighting Vehicle (OMFV) RFP 2 2 2022 3 2023

MDAP - Optionally Manned Fighting Vehicle (OMFV) LRIP 3 2023 4 2025

MDAP - Robotic Combat Vehicle Experimental Prototype Build 3 2019 3 2023

MDAP - Future Long Range Assault Aircraft (FLRAA) 1 2019 4 2025

MDAP - Future Attack Reconnaissance Aircraft (FARA) 1 2019 4 2025

MPD - Systems Engineering Plan (SEP) 4 2019 4 2019

MPD - Life Cycle Sustainment Plan (LCSP) 1 2020 1 2020

MPD - MS A 2 2020 2 2020

MPD - Request for Proposal (RFP) 2 2020 2 2020

MPD - Contract Award 2 2020 2 2020

MPD - Prototype Testing 3 2020 1 2021

MPD - MS B 1 2021 1 2021

MPD - Acquisition Program Baseline (APB) 1 2021 1 2021

MPD - Test Evaluation Master Plan (TEMP) 1 2021 1 2021

MPD - Contract Option 2 2021 2 2021

MPD - Critical Design Review (CDR) 2 2021 2 2021

MPD - Development Test (DT) 3 2021 1 2022

Volume 4 - 231

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 72 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

DE5 / Decontamination (SDD)

Start End

Events Quarter Year Quarter Year

MPD - In Process Review (IPR) 1 2023 1 2023

MPD - Operational Test (OT) 4 2022 2 2023

MPD - Initial Operational Test and Evaluation (IOT&E) 4 2022 2 2023

MPD - MS C 4 2023 4 2023

MPD - Full Rate Production (FRP) 4 2023 4 2023

MPD - Initial Operational Capability (IOC) 3 2024 3 2024

JBADS - Contractor Specification Testing 2 2019 1 2020

JBADS - MIL-STD 810-G Testing 4 2019 4 2019

JBADS - First System Build 1 2020 3 2020

JBADS - Product Verification Testing (PVT) 3 2020 4 2020

JBADS - Initial Operational Test and Evaluation (IOT&E) 3 2021 4 2021

JBADS - Full Rate Production (FRP) 2 2022 2 2022

JBADS - Initial Operational Capability (IOC) 2 2022 2 2022

JBADS - Milestone C 2 2022 2 2022

JBADS - Full Operational Capability 2 2024 2 2024

Volume 4 - 232

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 73 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

COST ($ in Millions)

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete

Total

Cost

IP5: Individual Protection (SDD)

- 10.597 12.663 12.960 - 12.960 12.858 12.796 8.963 8.436 Continuing Continuing

Quantity of RDT&E Articles - - - - - - - - - -

A. Mission Description and Budget Item Justification

This project provides Engineering & Manufacturing Development Phase and Low Rate Initial Production (EMD/LRIP) for individual protection equipment, with the goal of

providing equipment that allows the individual Soldier, Sailor, Airman, or Marine to operate in a contaminated Nuclear, Biological and Chemical (NBC) environment with

little or no degradation of his/her performance.

Efforts included in this project are:

(1) Special Purpose Unit Rapid Capability Development and Deployment (SPU RCDD)

(2) Uniform Integrated Protective Ensemble (UIPE) Family of Systems (FoS)

(3) UIPE FoS General Purpose (GP)

(4) Joint Service Aircrew Mask for Strategic Aircraft (JSAM SA)

(5) JSAM for Tactical Aircraft (JSAM TA)

SPU RCDD will facilitate rapid response to near-term and emergent chemical-biological defensive capability requirements from elements of the Joint Special Operations

Command (JSOC), select elements from across the Special Operations Force (SOF) Enterprise such as Combatant Commanders Response Forces (CRFs) and other

Joint Force enabling units such as the 20th Chemical, Biological, Radiological, Nuclear and Explosives Command. SPU RCDD mitigates risk across the Chemical

Biological Defense Program (CBDP) by creating a portfolio of operationally-relevant chemical and biological (CB) capabilities that can be quickly transitioned to needed

elements and formations of the joint force, in whole or part, in response to the articulated, emergent capability needs of the geographic combatant commanders. These

objectives are met by the early transitioning of promising science and technologies (S&T) from the Joint Science and Technology Office (JSTO) and the Defense

Advanced Research Projects Agency (DARPA) among others; the focused conduct of combat evaluations and mission-oriented operational assessments to assess

technological and mission suitability; and the active leveraging of existing Commercial-Off-The-Shelf (COTS) products along with novel redesign approaches to optimize

existing solutions to new challenges supported by "buy-try-decide-acquire" acquisition strategies. Projects being initiated or continued in FY21 include 1) modular and

micro Powered Air Purifying Respirators (PAPR) that will provide users an improved form-fit over the existing C420 PAPR configuration, be of smaller size and weight

than the C420, and extend the filter and battery life beyond current capability so users may continue operating in a CB-contaminated environment unencumbered, and 2)

CBRND protective equipment in response to new and emerging threats and opportunities.

UIPE FoS will develop a family of systems that will provide the broad spectrum of users with individual percutaneous protective equipment allowing the ability to operate

in a contaminated environment with no or minimal degradation in performance. UIPE FoS will provide protection from operationally relevant traditional and non-

traditional CBRN threats likely to be encountered during joint force operations.

Volume 4 - 233

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 74 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

In FY21, UIPE FoS transitions to UIPE FoS General Purpose (GP), UIPE FoS Air and UIPE FoS Gloves. In order to reflect the structure of the program, UIPE FoS will

meet Mission Area needs, not individual Service needs. The four Mission Areas are: Land, Air, Sea, and Homeland Defense. Each of the Mission Areas have unique

mission requirements that the UIPE FoS GP, Air and Gloves solutions will fulfill.

UIPE FoS GP will provide a family of systems that will give the Warfighter percutaneous protection from operationally relevant traditional, non-traditional, and advanced

CBRN/Toxic Industrial Material (TIM) threats likely to be encountered during joint force operations. The family of systems is being developed based on agreed upon

Service Mission Areas of which there are four: Land, Sea, Air, and Homeland Defense. Each of the Mission Areas have unique mission requirements that the combined

UIPE FoS solutions will fulfill. The overarching goal of each of the four Mission Areas is to minimize operational burden and provide improved form, fit, function, and

integration with the current Warfighter kits compared to legacy systems. The Tactical All-Hazards Threat Protective Ensemble (TATPE) will be a subset to the UIPE FoS

GP and capitalize on the protection factor of commercial Level A with design modifications to align with the necessary operational requirements. This suit serves as an

additional tool in the arsenal until technology matures to the point of delivering a similar capability applied against the range of military operations in all environments

under all conditions.

The JSAM SA and JSAM TA are Acquisition Category (ACAT) III programs developed to provide respiratory and ocular protection. The JSAM family is a lightweight

Chemical, Biological, Radiological and Nuclear (CBRN) protective mask for most United States Army (USA), Navy (USN), Air Force (USAF), and Marine Corps (USMC)

rotary wing and fixed wing aircrew. All JSAM variants will be compatible with most Below-The-Neck (BTN) CB protection ensembles and existing Aircrew Life Support

Equipment (ALSE). They will include a protective hood assembly, CB filter, blower assembly (except JSAM SA), and an intercom for ground communication. They will

also provide flame protection, demist/emergency demist (except JSAM SA), and anti-drowning features. The goal of the JSAM programs is to develop, manufacture,

field, and sustain an aircrew respirator system that, in conjunction with BTN clothing ensembles. These masks posture all aircrew to operate in an actual or perceived

CB domain as directed in the 2018 National Defense Strategy.

The JSAM SA mask components will be optimized to minimize their impact on the wearer's performance and maximize its ability to interface with aircrew protective

clothing. JSAM SA will provide pressure breathing for altitude for aircraft that do not require pressure breathing for gravity. JSAM SA will integrate with aircraft

subsystems which include aviation life support equipment, aircrew flight equipment, aircraft seating, portable aircrew systems, communications systems, and aircraft

oxygen systems. The JSAM SA mask will provide individual respiratory, ocular, and percutaneous protection of chemical and biological warfare agents, and select Toxic

Industrial Chemicals (TICs) for USAF (E-3, E-8, C-135s, C-17, C-145, C-146, C-130s, C-5), Aeromedical personnel (C-130s, KC-10, U-18, KC-135, C-12s, KC-46), USN

(P-8, E-6, C-40, C-12, C-20), USMC (C-9, C-12, C-20, UC-35), and USA (RC-7, C-12s, C-20, C-26, UC-35, C-37) strategic aircrew.

The JSAM TA will provide chemical biological protection for aircrew of high performance, ejection seat tactical aircraft. The mask components will be optimized to

minimize their impact on the wearer's performance and maximize its ability to interface with aircrew protective clothing. JSAM TA will be compatible with anti-G systems,

providing Chemical, Biological, Radiological (CBR) protection without degrading protection against Gravity Induced Loss of Consciousness (GLOC) up to 9 Gz. JSAM

TA will integrate with essential aircraft subsystems. The JSAM TA mask will provide individual respiratory, ocular, and percutaneous protection of chemical and biological

warfare agents, and select Toxic Industrial Chemicals (TICs) for USAF (F-22 A), USN (E-2 C/D, E/A-18G, F/A-18 A/C/E/F), and USMC (F/A-18 A/C/D, AV-8B, KC-130J

and MV-22) tactical aircrew members. The mask components will be optimized to minimize their impact on the wearer's performance and maximize its ability to

Volume 4 - 234

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 75 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

interface with aircrew protective clothing. JSAM TA will be compatible with anti-G systems, providing Chemical, Biological, Radiological (CBR) protection without

degrading protection against Gravity Induced Loss of Consciousness (GLOC) up to 9 Gz. JSAM TA will integrate with essential aircraft subsystems.

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Title: 1) Special Purpose Unit Rapid Capability Development & Deployment (SPU RCDD)

Description: Development of specialized equipment for agent specific threats.

FY 2020 Plans:

Initiate rapid development and acquisition initiatives utilizing emergent chemical-biological defensive capabilities, decision

support tools, and respiratory/ocular enhancements to support Special Operations Force (SOF) counter-proliferation efforts and

development of decontamination of SOF specialized equipment.

FY 2021 Plans:

Continue developing, prototyping, and maturing CBRND technologies to rapidly equip users with capabilities in response to new

and emerging threats and opportunities.

FY 2020 to FY 2021 Increase/Decrease Statement:

Increase due to change in program/project technical parameters.

- 3.399 4.537

Title: 2) Uniform Integrated Protective Ensemble (UIPE) Family of Systems (FoS)

Description: Engineering and Manufacturing Development (EMD)

FY 2020 Plans:

Receive Contract Award for production, receive USN/USMC Fielding Decision Point

Conduct Initial Operational Test and Evaluation (IOT&E) for the Navy/Marine Corps, receive Operational Test Agency Evaluation

Report (OER).

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred to another funding line. (UIPE FoS GP)

5.852 4.737 -

Title: 3) UIPE FoS

Description: System Development and Demonstration/Engineering and Manufacturing Development of Tactical All-Hazards

Threat Protective Ensemble (TATPE)

FY 2020 Plans:

1.100 3.400 -

Volume 4 - 235

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 76 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Continue prototype refinement based on user input/feedback, complete entrance criteria for a MS B decision, and initiate

combined DT/OT.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project transitioned to Advanced Development.

Title: 4) UIPE FoS General Purpose (GP)

Description: Development of the next generation protective ensembles (e.g., suits, boots, and gloves) and respiratory and ocular

protection equipment (e.g., protective masks)

FY 2021 Plans:

Achieve Milestone B and award a contract for the Engineering and Manufacturing Development (EMD) phase; conduct a

Manufacturing Readiness Assessment(MRA); and begin Developmental/Operational Testing (DT/OT).

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred from another funding line. (UIPE FoS)

- - 4.328

Title: 5) UIPE FoS Tactical All-Hazards Threat Protective Ensemble (TATPE)

Description: TATPE system development, developmental testing, and operational assessment.

FY 2021 Plans:

Complete EMD phase to include system level testing and user evaluations. Complete MS C documentation to include final

assessment, analysis and system documentation. Mission area focus includes: Land, Sea, and Homeland Defense.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred from another funding line. (UIPE FoS)

- - 2.950

Title: 6) Joint Service Aircrew Mask for Strategic Aircraft (JSAM SA)

Description: Operational Testing and Evaluation (OT&E)

FY 2020 Plans:

Continue Operational Testing (OT), Integration Testing and Safe-to-Fly on various Service aircraft. Continue engineering studies

to assess communication system adaptors and oxygen system adaptors for various Service aircraft. Continue updates to the

Technical Manual (TM) to include specialized procedures for the various aircraft tested.

FY 2021 Plans:

1.627 1.127 1.145

Volume 4 - 236

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 77 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Continue OT, Integration Testing and Safe-to-Fly on various Service aircraft. Continue updates to the TM to include specialized

procedures for the various aircraft based on testing results. Continue engineering studies to assess communication system

adaptors and oxygen system adaptors for remaining aircraft.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

Title: 7) Joint Service Aircrew Mask for Tactical Aircraft (JSAM TA)

Description: Integration Testing Events and Milestone C Preparation

2.018 - -

Accomplishments/Planned Programs Subtotals

10.597 12.663 12.960

C. Other Program Funding Summary ($ in Millions)

Line Item FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete Total Cost

• JI0002: JS AIRCREW

MASK (JSAM)

50.214 56.846 72.550 - 72.550 67.325 50.412 8.247 0.000 0.000 305.594

• MA0401: CBRN UNIFORM

INTEGRATED PROTECTION

ENSEMBLE (UIPE)

12.264 14.984 1.492 - 1.492 0.457 0.000 0.000 0.000 0.000 29.197

Remarks

D. Acquisition Strategy

SPU RAPID CAPABILITY DEVELOPMENT AND DEPLOYMENT (SPU RCDD)

Non-traditional projects will be executed for capabilities identified by Joint Special Operations Command (JSOC), select elements from across the Special Operations

Forces (SOF) Enterprise, and other Joint Force enabling units. The SPU RCDD BA5 acquisition strategy for developmental efforts will allow rapid prototyping and

testing of mission critical capabilities needed to enhance mission success. The SPU RCDD BA7 modernization effort will use technical and functional evaluations of

currently-fielded items to introduce and incorporate operationally-relevant system developments. Both efforts will be accomplished by awarding an agreement through

the Countering Weapons of Mass Destruction Other Transaction Authority (CWMD OTA) for the procurement of test assets. An OTA contracting approach will be used

to procure test prototypes and test articles of possible solutions. The OTA consists of a consortium of all potential industry, research institutions, and non-traditional

government that could be potential solvers for the program. Procurement will be through either the OTAs, a Small Business Innovative Research contract, or a more

traditional contracting vehicle.

CBRN UNIFORM INTEGRATED PROTECTION ENSEMBLE FAMILY OF SYSTEMS (UIPE FOS)

Volume 4 - 237

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 78 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

The UIPE FoS program will conduct market research through both Requests For Information (RFIs) and a call for White Papers through an Other Transaction Authority

(OTA) contracting approach. Candidate technologies will follow the same acquisition strategy employed for the suit: Early User Tests/Wear events and material and

system level testing to identify available capabilities followed by a Trade Space Analysis to determine the most suitable glove(s). The UIPE FoS GP program will monitor

S&T activities for possible technology transitions.

In FY21, UIPE FoS transitions to UIPE FoS GP, UIPE FoS Air and UIPE FoS Gloves. In order to reflect the structure of the program, UIPE FoS will meet Mission Area

needs, not individual Service needs. The four Mission Areas are: Land (i.e. GP), Air, Sea, and Homeland Defense. Each of the Mission Areas has unique mission

requirements that the UIPE FoS GP, Air and Gloves solutions will seek to fulfill.

UNIFORM INTEGRATED PROTECTIVE ENSEMBLE GENERAL PURPOSE (UIPE FOS GP)

The UIPE FoS GP program utilized an Other Transaction Authority (OTA) contracting approach to procure informational white papers during the Technology Maturation

and Risk Reduction (TMRR) phase, prototypes, and test articles of possible solutions. The OTA consists of a consortium of all potential Industry, research institutions,

and non-traditional government that could be potential solvers for the program. The OTA yielded several different prototypes that are undergoing material and system

level testing and Early User Tests. Along with the OTA prototypes, the program is exploring the feasibility of a layered concept designed by the government and a

manufacturing partner.

JOINT SERVICE AIRCREW MASK STRATEGIC AIRCRAFT (JSAM SA)

The JSAM SA acquisition approach involves modifying the fielded M53 ground mask design in order to add Pressure Breathing for Altitude (PBA), up to 40,000 feet

above sea-level, and middle ear equalization capabilities. The JSAM SA mask is intended to be fielded to the United States Air Force (USAF), United States Navy

(USN), United States Marine Corps (USMC), and United States Army (USA). The Research Development Test & Evaluation (RDT&E) contract was awarded via sole

source to Avon Protection Systems, Cadillac, Michigan to modify and field a commercially available mask (M53).

The overall acquisition strategy is to produce and field the JSAM SA masks incrementally. This approach allows the JSAM SA mask to be fielded to aircrew of the

most applicable aircrafts in the shortest amount of time. At the end of all increments, the Services will have achieved their Full Operating Capability (FOC). The first

increment will consist of fielding the JSAM SA mask to the USAF E-3 and USN P-8 aircrew. Based on technical difficulty and mission need, the JSAM SA program will

work with the Services to determine which aircraft will be addressed in subsequent increments.

The overall test strategy involves four major phases. The first test phase consists of Design Verification Testing (DVT) which will evaluate developmental prototype

masks prior to Critical Design Review (CDR). The second test phase is Developmental Testing (DT) to support Milestone C/LRIP. The third test phase is Operational

Testing (OT) of assets to support Initial Operating Capability (IOC) fielding to USAF, USN, and USA aircrew. The final test phase will consist of Integration and

Airworthiness Certification (I&AC) testing for all remaining aircraft.

Volume 4 - 238

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 79 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

The contract strategy consists of two sole-source contracts with Avon Protection Systems, the manufacturer of the fielded M53 mask. The first contract, which was

awarded on 31 July 2013, covers all activities during the Engineering and Manufacturing Development (EMD) phase to include all LRIP builds. The second contract,

which was awarded on 4 January 2019 to Avon Protection Systems, will cover the activities during the Production and Deployment (PD) phase including all Full Rate

Production (FRP) builds for the Services.

JOINT SERVICE AIRCREW MASK TACTICAL AIRCRAFT (JSAM TA)

The JSAM TA acquisition approach involves modifying the USN/USMC fielded A/P22P-14A series respirator design to meet aircraft integration requirements. The test

strategy involves integrated testing (combined DT/OT) completed prior to MS C/FRP. The contract strategy consists of two sole source Firm Fixed Price (FFP) contracts

with Cam Lock, Ltd., Aldershot Hampshire, United Kingdom. The first contract, awarded September 2016, covers all activities during the Engineering, Manufacturing,

and Development (EMD) phase. The second contract awarded, September 2019, is a sole source FFP Indefinite Delivery/Indefinite Quantity (ID/IQ) that covers the

activities during the Production and Deployment phase including Full Rate Production (FRP) builds. The JSAM TA mask is intended to be fielded to the USN and

USMC.

Volume 4 - 239

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 80 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

SPU RCDD - HW C -

Prototype Procurement

Various Various : Various 0.000 0.000 1.510 Dec 2019 2.016 Dec 2020 - 2.016 Continuing Continuing 0.000

UIPE FOS - HW S

- TATPE system

development, fabrication,

and swatch and system

level technical testing

C/CPFF

Battelle Memorial

Institute : Columbus,

0.000 0.621 Jan 2019 1.640 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

UIPE FOS - HW S -

UIPE FoS Prototype

Development

Various Various : Various 0.000 0.000 1.795 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

UIPE FOS GP - HW

S - TATPE System

Development

C/CPFF

Battelle Memorial

Institute : Columbus,

0.000 0.000 0.000 2.050 Nov 2020 - 2.050 Continuing Continuing 0.000

UIPE FOS GP - HW C -

Prototype Development

MIPR TBD : N/A 0.000 0.000 0.000 0.025 Dec 2020 - 0.025 Continuing Continuing 0.000

Subtotal

0.000 0.621 4.945 4.091 - 4.091 Continuing Continuing N/A

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

SPU RCDD - TD/D C -

Technical Support

Various Various : Various 0.000 0.000 0.342 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

SPU RCDD - ES C -

Engineering Support

Various Various : Various 0.000 0.000 0.335 Dec 2019 0.458 Dec 2020 - 0.458 Continuing Continuing 0.000

UIPE FOS - ES S -

Logistics, Engineering and

IPT Support

Various Various : Various 0.000 1.889 Apr 2019 1.773 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

UIPE FOS - ES S -

TATPE Integrated Product

Team (IPT) Program,

Engineering and Technical

Support

MIPR Various : Various 0.000 0.279 Jan 2019 0.685 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 240

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 81 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

UIPE FOS GP - ES S -

TATPE Engineering &

Technical IPT Support /

SME Support

Various Various : Various 0.000 0.000 0.000 0.300 Nov 2020 - 0.300 Continuing Continuing 0.000

UIPE FOS GP - ES C -

Engineering & Technical

IPT Support / SME

Support

Various Various : Various 0.000 0.000 0.000 1.280 Dec 2020 - 1.280 Continuing Continuing 0.000

JSAM SA - TD/D S -

Logistics, Engineering, and

IPT Support

MIPR Various : Various 0.116 0.674 Dec 2018 0.120 Feb 2020 0.130 Dec 2020 - 0.130 Continuing Continuing 0.000

JSAM TA - ES S -

Logistics, Engineering and

IPT Support

MIPR Various : Various 6.252 1.524 Jan 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

Subtotal

6.368 4.366 3.255 2.168 - 2.168 Continuing Continuing N/A

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

SPU RCDD - OTE S -

Operational Assessment

MIPR

National Assessment

Group : Kirkland, NM

0.000 0.000 0.000 0.500 Dec 2020 - 0.500 Continuing Continuing 0.000

SPU RCDD - DTE C -

Testing and Evaluation

MIPR

Combat Capabilities

Development

Command (CCDC)

Chemical Biological

Center : Aberdeen

Proving Ground, MD

0.000 0.000 0.665 Dec 2019 0.435 Dec 2020 - 0.435 Continuing Continuing 0.000

UIPE FOS - DTE S -

System Level Testing

Various Various : Various 0.000 3.155 Dec 2018 0.257 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

UIPE FOS - OTHT S

- TATPE Testing for

chemical warfare agent

and toxic industrial

MIPR

CCDC CBC :

Aberdeen Proving

Ground, MD

0.000 0.200 Jan 2019 1.075 Apr 2020 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 241

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 82 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

chemical swatch level

testing

UIPE FOS GP - DTE C -

DT/OT

Various Various : Various 0.000 0.000 0.000 1.499 Dec 2020 - 1.499 Continuing Continuing 0.000

UIPE FOS GP - OTE S -

TATPE User Evaluation

Various Various : Various 0.000 0.000 0.000 0.400 Nov 2020 - 0.400 Continuing Continuing 0.000

UIPE FOS GP - DTE S -

TATPE Technical Testing

Various Various : Various 0.000 0.000 0.000 0.200 Nov 2020 - 0.200 Continuing Continuing 0.000

JSAM SA - DTE S - DT/OT MIPR Various : Various 2.193 0.513 Nov 2018 0.770 Nov 2019 0.774 Dec 2020 - 0.774 Continuing Continuing 0.000

JSAM TA - DTE S -Testing

and Integration

MIPR Various : Various 4.179 0.127 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

Subtotal

6.372 3.995 2.767 3.808 - 3.808 Continuing Continuing N/A

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

SPU RCDD - PM/MS C

- Program Management

Support

Various Various : Various 0.000 0.000 0.547 Nov 2019 1.128 Nov 2020 - 1.128 Continuing Continuing 0.000

UIPE FOS - MS S -

PM/SME Program

Management Support

MIPR Various : Various 0.000 0.808 Dec 2018 0.912 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

UIPE FOS GP - PM/MS C

- Program Management

Support

Various Various : Various 0.000 0.000 0.000 1.524 Dec 2020 - 1.524 Continuing Continuing 0.000

JSAM SA - PM/MS S -

Program Management

Support

MIPR Various : Various 0.974 0.440 Nov 2018 0.237 Feb 2020 0.241 Dec 2020 - 0.241 Continuing Continuing 0.000

JSAM TA - PM/MS S -

Program Management

Support

MIPR Various : Various 2.073 0.367 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 242

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 83 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

Subtotal

3.047 1.615 1.696 2.893 - 2.893 Continuing Continuing N/A

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost To

Complete

Total

Cost

Target

Value of

Contract

Project Cost Totals

15.787 10.597 12.663 12.960 - 12.960 Continuing Continuing N/A

Remarks

Volume 4 - 243

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 84 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

SPU RCDD - Development Efforts

UIPE FOS - Air Material Testing

UIPE FOS - Air Design Reviews

UIPE FOS - Air System Testing

UIPE FOS - Air Worthiness Certification

UIPE FOS - Air System Verification Review

UIPE FOS - Air Capability Development

Document (CDD)

UIPE FOS - Air RFP

UIPE FOS - Air MRA

UIPE FOS - Air MS C

UIPE FOS - Air LRIP/USAF Fielding Decision

UIPE FOS - Air USN/USMC Initial OT&E

UIPE FOS - Air Production Award

UIPE FOS - Air Operational Test Agency

Evaluation Report (OER)

UIPE FOS - Air PRR

UIPE FOS - TATPE Technical Evaluation

UIPE FOS - TATPE Concept System

Refinement and Fabrication

UIPE FOS - TATPE CDD

UIPE FOS - TATPE DT/OT

UIPE FOS - TATPE Milestone B

UIPE FOS - TATPE User Evaluation

Volume 4 - 244

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 85 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

UIPE FOS GP - Capability Development

Document (CDD)

UIPE FOS GP - Test & Evaluation Master Plan

(TEMP) Update

UIPE FOS GP - Milestone B

UIPE FOS GP - Manufacturing Readiness

Assessment (MRA)

UIPE FOS GP - EMD Phase Contract

UIPE FOS GP - Make or Buy Decision

UIPE FOS GP - DT/OT

UIPE FOS GP - CDD Update

UIPE FOS GP - Milestone C

UIPE FOS GP - LRIP

UIPE FOS GP - Initial Operational Capability

(IOC)

UIPE FOS GP - FRP

UIPE FOS GP - Full Operational Capability

(FOC)

UIPE FOS GP - TATPE User Evaluation

UIPE FOS GP - TATPE Technical Testing

UIPE FOS GP - TATPE Milestone C

UIPE FOS GP - TATPE IOC

UIPE FOS GP - TATPE FOC

JSAM SA - DT/OT (Capability, Integration,

Airworthiness Certification)

JSAM SA - Initial Operational Capability (IOC)

JSAM SA - Full Operational Capability (FOC)

Volume 4 - 245

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 86 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

JSAM TA - AP22P (A) Safe to Fly Certification

JSAM TA - Integrated (Developmental/

Operational) Testing (DT/OT)

JSAM TA - AP22P (A) ECP Integration

JSAM TA - Capabililty Develoment Document

Update (CDD)

JSAM TA - MS C

JSAM TA - Full Rate Production (FRP)

JSAM TA - Initial Operational Capability(IOC)

JSAM TA - USN/USMC Full Operational

Capability (FOC)

Volume 4 - 246

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 87 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

Schedule Details

Start End

Events Quarter Year Quarter Year

SPU RCDD - Development Efforts 1 2020 4 2025

UIPE FOS - Air Material Testing 1 2019 4 2020

UIPE FOS - Air Design Reviews 1 2019 3 2020

UIPE FOS - Air System Testing 1 2019 1 2020

UIPE FOS - Air Worthiness Certification 1 2019 4 2019

UIPE FOS - Air System Verification Review 3 2019 3 2019

UIPE FOS - Air Capability Development Document (CDD) 3 2019 3 2019

UIPE FOS - Air RFP 2 2020 2 2020

UIPE FOS - Air MRA 2 2020 2 2020

UIPE FOS - Air MS C 2 2020 2 2020

UIPE FOS - Air LRIP/USAF Fielding Decision 2 2020 2 2020

UIPE FOS - Air USN/USMC Initial OT&E 2 2020 2 2020

UIPE FOS - Air Production Award 3 2020 3 2020

UIPE FOS - Air Operational Test Agency Evaluation Report (OER) 4 2020 4 2020

UIPE FOS - Air PRR 4 2020 4 2020

UIPE FOS - TATPE Technical Evaluation 1 2019 1 2019

UIPE FOS - TATPE Concept System Refinement and Fabrication 2 2019 4 2019

UIPE FOS - TATPE CDD 4 2019 4 2019

UIPE FOS - TATPE DT/OT 4 2019 1 2021

UIPE FOS - TATPE Milestone B 2 2020 2 2020

UIPE FOS - TATPE User Evaluation 4 2020 4 2020

UIPE FOS GP - Capability Development Document (CDD) 2 2021 2 2021

Volume 4 - 247

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 88 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

Start End

Events Quarter Year Quarter Year

UIPE FOS GP - Test & Evaluation Master Plan (TEMP) Update 2 2021 2 2021

UIPE FOS GP - Milestone B 2 2021 2 2021

UIPE FOS GP - Manufacturing Readiness Assessment (MRA) 3 2021 3 2021

UIPE FOS GP - EMD Phase Contract 3 2021 3 2021

UIPE FOS GP - Make or Buy Decision 3 2021 3 2021

UIPE FOS GP - DT/OT 4 2021 3 2022

UIPE FOS GP - CDD Update 4 2022 4 2022

UIPE FOS GP - Milestone C 1 2023 1 2023

UIPE FOS GP - LRIP 1 2023 1 2023

UIPE FOS GP - Initial Operational Capability (IOC) 4 2023 4 2023

UIPE FOS GP - FRP 4 2023 4 2023

UIPE FOS GP - Full Operational Capability (FOC) 4 2024 4 2024

UIPE FOS GP - TATPE User Evaluation 1 2021 1 2021

UIPE FOS GP - TATPE Technical Testing 1 2021 1 2021

UIPE FOS GP - TATPE Milestone C 2 2021 2 2021

UIPE FOS GP - TATPE IOC 4 2021 4 2021

UIPE FOS GP - TATPE FOC 4 2024 4 2024

JSAM SA - DT/OT (Capability, Integration, Airworthiness Certification) 1 2019 1 2022

JSAM SA - Initial Operational Capability (IOC) 4 2020 4 2020

JSAM SA - Full Operational Capability (FOC) 2 2025 2 2025

JSAM TA - AP22P (A) Safe to Fly Certification 1 2019 3 2020

JSAM TA - Integrated (Developmental/Operational) Testing (DT/OT) 1 2019 2 2019

JSAM TA - AP22P (A) ECP Integration 1 2019 1 2019

JSAM TA - Capabililty Develoment Document Update (CDD) 3 2019 3 2019

JSAM TA - MS C 4 2019 4 2019

Volume 4 - 248

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 89 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IP5 / Individual Protection (SDD)

Start End

Events Quarter Year Quarter Year

JSAM TA - Full Rate Production (FRP) 4 2019 4 2019

JSAM TA - Initial Operational Capability(IOC) 2 2021 2 2021

JSAM TA - USN/USMC Full Operational Capability (FOC) 4 2024 4 2024

Volume 4 - 249

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 90 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

COST ($ in Millions)

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete

Total

Cost

IS5: Information Systems (SDD)

- 21.993 21.166 6.019 - 6.019 5.691 5.232 5.232 5.493 Continuing Continuing

Quantity of RDT&E Articles - - - - - - - - - -

A. Mission Description and Budget Item Justification

This project supports Engineering and Manufacturing Development and Low Rate Initial Production (EMD/LRIP). Experimentation and demonstration will be used in this

phase to reduce risk and inform supporting materiel solutions, CONOPS and TTPs.

Efforts included in this project are:

(1) Global Biosurveillance Portal (Global-BSP)

(2) Chemical Biological Radiological and Nuclear Information Systems (CBRN IS)

(3) Joint Effects Model 2 (JEM 2)

(4) Joint Warning and Reporting Network 2 (JWARN 2), and

(5) Software Support Activity (SSA).

The Global-BSP is an unclassified, web-based computer and mobile application which facilitates collaboration, communication, and information sharing in support of

the preparedness, detection, management, and mitigation of CBRN, as well as all hazard events. These capabilities enable the use of data visualization, real-time

messaging and file sharing, and DoD and USG cooperation to expedite the timely identification and detection of CBRN events in order to minimize operational impacts to

the local and global populations.

CBRN IS provides a collaborative Cloud hosted environment that allows users to collect and disseminate CBRN warning and reporting data, provide detailed CBRN

hazard predictions, aid in decision support, and make relevant CBRN defense information available in near-real time. CBRN IS provides an environment that supports

the implementation of Integrated Early Warning (IEW) capabilities that allow users to access netted sensor information, data fusion, disease modeling, biosurveillance

data, source term estimation data, incident management tools, and planning and analysis capabilities. The CBRN IS enterprise makes CBRN decision aids readily

accessible from any desktop through a web browser simplifying interoperability, reducing integration and deployment costs and increases cybersecurity protection.

The JEM 2 is a software application that provides the Department of Defense (DoD) with the only operationally tested and accredited tool to model and simulate the

effects of Chemical, Biological, Radiological and Nuclear (CBRN) weapon strikes and incidents. JEM 2 applies advanced physics using weather, terrain, and agent

characteristics to predict the time-phased impact of CBRN and Toxic Industrial Chemical/Material (TIC/TIM). JEM 2 displays hazard information on the Common

Operational Picture (COP) and allows commanders to assess risk and take steps mitigate the effects of Weapons of Mass Destruction (WMD) on operational forces.

The JWARN 2 is a software application that provides the Department of Defense warning and reporting system that enables an immediate and integrated response

to threats of contamination by WMD, CBRN and TIM incidents. JWARN 2 provides a digital display of CBRN reports on the COP, presented through Service provided

Volume 4 - 250

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 91 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

Command and Control systems resident at all echelons of command. Commanders will be provided with enhanced situational battlespace awareness and support

warfighter battle management and continuity of operations in a contaminated environment.

The SSA provides for enterprise services in the areas of software development, network architecture, cybersecurity, technology transition, and information assurance

standards and policies to support programs in conducting network architecture integration, technology transition insertion, and continued cybersecurity risk management

framework efforts throughout the CBRND portfolio within the EMD/LRIP phase.

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Title: 1) Global Biosurveillance Portal (Global-BSP)

Description: Product Development

FY 2020 Plans:

Finalize development of FVEY(Five Eyes - US/UK/Canada/Australia/New Zealand)/NATO role-based access capability.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

4.116 3.047 -

Title: 2) Global-BSP

Description: Developmental Test and Evaluation

FY 2020 Plans:

Conduct Developmental and Operational T&E events on new FVEY and NATO role-based access capabilities, as well as conduct

Final Operational Test in preparation for Full Operational Capability Fielding Decision.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

0.358 0.295 -

Title: 3) Global-BSP

Description: Program Management Support

FY 2020 Plans:

Manage and conduct oversight of all aspects of Global-BSP program development and testing. Tasks include planning, budgeting,

execution oversight, risk management, test and user feedback coordination, scheduling, training and administration.

FY 2020 to FY 2021 Increase/Decrease Statement:

0.793 0.466 -

Volume 4 - 251

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 92 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

Title: 4) Global-BSP

Description: Operational Testing and Evaluation

FY 2020 Plans:

Conduct Final Operational Test & Evaluation (FOT&E) associated with Full Operational Capability. Conduct Operational Testing

of Global-BSP with one Production Capability Drop End-to-End test to validate capabilities prior to delivery to the Warfighter.

Support will consist of test, engineering, and operational personnel support. Conduct multiple User Feedback Events (UFEs).

UFEs provide a crucial link between the Program Managers, Engineers, and Operators.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

0.928 0.655 -

Title: 5) Global-BSP

Description: Training and Logistics Support

FY 2020 Plans:

Perform Training Development, Integrated Logistic Support, and Configuration Management.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

- 0.199 -

Title: 6) Chemical Biological Radiological and Nuclear Information Systems (CBRN IS)

Description: Technical Guidance

FY 2020 Plans:

Provide the management and systems engineering for Integrated Early Warning, Decision Support/ Consequence and Incident

Management, Data Analytics and other situational understanding and awareness tools. Ensure adherence to the Joint Operational

Environment standards and Cyber Security requirements. Provide strategy for integration of future capabilities and emerging

requirements including advanced technology demonstrations (ATDs) and experimental capability demonstrations (ECDs).

FY 2020 to FY 2021 Increase/Decrease Statement:

0.226 0.217 -

Volume 4 - 252

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 93 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Minor change due to routine program adjustments. Bullets with similar activities spanning multiple fiscal years were consolidated.

Title: 7) CBRN IS

Description: Standardization

FY 2020 Plans:

Provide guidance and direction to ensure new capabilities meet industry and program standards for integration. Ensure

development and integration efforts are compliant and compatible with the Joint Information Environment (JIE) and Service

common operational and common computing environments. Comply with DoD and Service specified Cybersecurity and Net

Ready Key Performance Parameters.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Bullets with similar activities spanning multiple fiscal years were consolidated.

0.362 0.575 -

Title: 8) CBRN IS

Description: Cybersecurity / Information Assurance

FY 2020 Plans:

Continue the implementation of ongoing cybersecurity requirements and policies and DoD information assurance vulnerability

alerts (IAVAs) to mitigate system vulnerabilities. Continue adversarial and cooperative vulnerability testing.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Bullets with similar activities spanning multiple fiscal years were consolidated.

0.210 0.203 -

Title: 9) CBRN IS

Description: Product Development

FY 2020 Plans:

Continue to develop additional capabilities, applications and implementations to support the National Defense priorities for

combating weapons of mass destruction. Continue to integrate CBRND products into a family-of-systems (FOS) framework.

Continue to refine sensor connectivity prototype.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Bullets with similar activities spanning multiple fiscal years were consolidated.

1.059 1.025 -

Title: 10) CBRN IS

Description: Operational Assessments

0.620 0.480 -

Volume 4 - 253

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 94 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

FY 2020 Plans:

Continue operational test and evaluations and user feedback events in accordance with product and application test plans to

assess and validate capabilities prior to implementing in the production enterprise environment. Tests will assess accessibility,

bandwidth/throughput, and reliability to meet program KPPs and KSAs. Continue cyber security and vulnerability testing.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Bullets with similar activities spanning multiple fiscal years were consolidated.

Title: 11) CBRN IS

Description: Product Development, Operational Assessments, Management, Engineering, and Cybersecurity Support

FY 2021 Plans:

Continue operational test and user feedback events to assess and validate capabilities prior to implementing in the production

environment. Continue operational test and evaluations in order to meet Key Performance Parameters (KPP) and Key System

Attributes (KSA). Provide management and system engineering oversight and integration of future capabilities and emerging

requirements including advanced technology demonstrations (ATDs) and experimental capability demonstrations (ECDs). Ensure

development and integration efforts are compliant and compatible with the Joint Information Environment (JIE) and Service

common operational and common computing environments. Continue the implementation of ongoing cybersecurity requirements

and policies and DoD information assurance vulnerability alerts (IAVAs) to mitigate system vulnerabilities. Continue adversarial

and cooperative vulnerability testing.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Bullets with similar activities spanning multiple fiscal years were consolidated.

- - 3.131

Title: 12) Joint Effects Model 2 (JEM 2)

Description: Developmental Test and Evaluation

FY 2020 Plans:

Continue Government Development Test of software deliveries in preparation for Initial Operational Test & Evaluation (IOT&E)

for development to C2 systems. Continue to perform VV&A of new hazard prediction models provided by the S&T community as

defined in RDP-4.

FY 2020 to FY 2021 Increase/Decrease Statement:

0.150 0.420 -

Volume 4 - 254

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 95 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

Title: 13) JEM 2

Description: Product Development

FY 2020 Plans:

Continue development of JEM 2 software and perform integration into C2 systems. Integrate new hazard prediction models

provided by the S&T community into the JEM 2 baseline software and develop/transition new S&T capabilities as defined in

Requirements Definition Package RDP-4.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

1.530 1.443 -

Title: 14) JEM 2

Description: Program Management

FY 2020 Plans:

Continue to perform program/financial management, costing, contracting, scheduling and acquisition oversight support for JEM 2.

Continue development and execution of JEM 2 while working within the agile development process, to include performing a Joint

Integrated Logistics Assessment (JILA) and Logistics Demonstration (LOG DEMO) in order to deploy JEM 2 to the services and to

the Science and Technology Community.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

0.198 0.521 -

Title: 15) JEM 2

Description: Operational Test and Evaluation

FY 2020 Plans:

Develop operational test plans and conduct lab based OT and limited scope service specific IOT&E to support fielding decisions

for the JEM 2 software which will allow for additional CDs with added JEM capabilities and functionality to be deployed to the

services.

FY 2020 to FY 2021 Increase/Decrease Statement:

0.430 0.782 -

Volume 4 - 255

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 96 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

Title: 16) JEM 2

Description: Training and Logistics Support

FY 2020 Plans:

Perform Training Development, Integrated Logistics Support and Configuration Management for upgraded fielded capabilities.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

0.242 0.842 -

Title: 17) Joint Warning and Reporting Network 2 (JWARN 2)

Description: Management Support

FY 2020 Plans:

Provide program/financial management, costing, contracting, scheduling, acquisition and deployment oversight for JWARN.

Continue software development, integration, and deployment of JWARN capabilities in the milCloud CBRN IS enterprise

environment and Services Command and Control systems.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

0.821 0.834 -

Title: 18) JWARN 2

Description: Product Development

FY 2020 Plans:

Continue JWARN 2 software development and perform integration into Command and Control and integration of CBRN sensor/

detector data/input with JWARN software baseline. Transition False Sensor Alert Reduction prototyping into JWARN software

development. Continue Information Assurance Certification and accreditation to support cybersecurity deployment of JWARN 2

in the milCloud CBRN IS enterprise environment and Service Command and Control systems. Continue software development in

preparation for Operational Test and Evaluation (OT&E) for USMC and Navy systems.

FY 2020 to FY 2021 Increase/Decrease Statement:

4.415 5.002 -

Volume 4 - 256

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 97 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

Title: 19) JWARN 2

Description: Developmental Test and Evaluation

FY 2020 Plans:

Continue Government development test and evaluation of software deliveries in preparation for annual Multiservice Operational

Test and Evaluation (MOT&E) which will allow for Initial Operational Capability of JWARN 2 to be deployed to the services.

Conduct development test and evaluation of JWARN 2 in preparation for OT&E for development to COE v3.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

0.300 0.567 -

Title: 20) JWARN 2

Description: Operational Test and Evaluation

FY 2020 Plans:

Conduct Multiservice Operational Test & Evaluation (MOT&E), which will allow for additional capability drops (CDs) with added

JWARN capabilities and functionality to be deployed to the services. Conduct IOT&E of JWARN in preparation for deployment to

Navy and Marine Corps C2 systems.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

0.625 0.850 -

Title: 21) JWARN 2

Description: Training and Logistics Support

FY 2020 Plans:

Provide New Equipment Training to operational users in US Army, Air Force, Navy, and Marine Corps in accordance with

Services' Fielding and Training Plans, as JWARN approaches Full Operational Capability across all services. Continue to

coordinate with operational forces for User Feedback Events, improving user interface and creating more efficient operational

experience.

FY 2020 to FY 2021 Increase/Decrease Statement:

1.604 1.084 -

Volume 4 - 257

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 98 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

Title: 22) Software Support Activity (SSA)

Description: Policies, Standards and Guidelines

FY 2020 Plans:

Provide standards, formats, templates, training and best practices to support practical compliance with laws, regulations, and

policy for acquisition, certification, and sustainment of net-centric, interoperable, and spectrum dependent systems and devices.

Help programs achieve a mandated net-centric environment by providing enabling tools for data management.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Bullets with similar activities spanning multiple fiscal years were consolidated.

0.313 0.064 -

Title: 23) SSA

Description: Integrated Architecture

FY 2020 Plans:

Continue to create, implement, validate, maintain, and continually shape a set of standard, enterprise-wide integrated CBRN

Family of Systems architectures. Assists in development of acquisition program documents by providing early architecture

products for inclusion and assists in the analysis and management of acquisition programs by producing architectural products

that visualize system and program interdependencies, which help to expose gaps and requirements.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Bullets with similar activities spanning multiple fiscal years were consolidated.

0.373 0.075 -

Title: 24) SSA

Description: Enterprise Support and Services

FY 2020 Plans:

Provide technical expertise in managing information-related risks in enterprise architectures, acquisition strategies, testing and

evaluation, and in achieving cybersecurity certification and accreditation. SSA cybersecurity SMEs assist with the development of

cybersecurity strategies, project plans and required documentation.

FY 2021 Plans:

Support the CBRND enterprise through continuous engagement to assist with the development of acquisition products during

the Engineering and Manufacturing Development and Low Rate Initial Production (EMD/LRIP) phase to reduce risk; assist with

0.257 0.221 2.888

Volume 4 - 258

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 99 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

technology transitions, and logistics; plan and execute new equipment training, and program management. Provide subject

matter expertise in the areas of software development, network architecture, cybersecurity, technology transition, and information

assurance standards and policies.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. In FY21, bullets with similar activities spanning multiple fiscal years were

consolidated.

Title: 25) SSA

Description: Chemical, Biological, Radiological, Nuclear (CBRN) Data Model

FY 2020 Plans:

Assist programs and vendors in interpreting and implementing the CCSI standard. This XML-based specification enables

standardized and repeatable integration and interoperability between CBRN sensors, network, and C2 systems.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Bullets with similar activities spanning multiple fiscal years were consolidated.

0.323 0.446 -

Title: 26) SSA

Description: Cybersecurity / Information Assurance

FY 2020 Plans:

Employ Information Systems Security Engineering (Cybersecurity) efforts to develop or modify the CS/IA component of a system

architecture to ensure it is in compliance with the IA component of the Global Information Grid architecture, and makes maximum

use of enterprise CS/IA capabilities and services.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Bullets with similar activities spanning multiple fiscal years were consolidated.

0.743 0.442 -

Title: 27) SSA

Description: Policy and Standards Repository

FY 2020 Plans:

0.578 0.127 -

Volume 4 - 259

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 100 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Provide standards, formats, templates, training and best practices to support practical compliance with laws, regulations, and

policy for acquisition, certification, and sustainment of net-centric, interoperable, and spectrum dependent systems and devices.

Help programs achieve a mandated net-centric environment by providing enabling tools for data management.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Bullets with similar activities spanning multiple fiscal years were consolidated.

Title: 28) SSA

Description: Technology Transition Support

FY 2020 Plans:

Provide innovation, management and implementation of science and technology initiatives in support of CBRND systems across

the enterprise to improve warfighter capability.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Bullets with similar activities spanning multiple fiscal years were consolidated.

0.419 0.284 -

Accomplishments/Planned Programs Subtotals

21.993 21.166 6.019

C. Other Program Funding Summary ($ in Millions)

Line Item FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete Total Cost

• IS7: Information

Systems (Op Sys Dev)

14.039 16.111 3.234 - 3.234 3.554 15.381 15.383 16.154 Continuing Continuing

• G47101: JOINT WARNING &

REPORTING NETWORK (JWARN)

0.502 0.442 0.000 - 0.000 0.000 0.000 0.000 0.000 0.000 0.944

• JC0208: JOINT

EFFECTS MODEL (JEM)

0.911 0.689 0.000 - 0.000 0.000 0.000 0.000 0.000 0.000 1.600

• JS5230: SOFTWARE

SUPPORT ACTIVITY (SSA)

0.094 0.081 0.074 - 0.074 0.070 1.187 1.187 1.247 Continuing Continuing

Remarks

D. Acquisition Strategy

BIOSURVEILLANCE PORTAL (BSP)

Volume 4 - 260

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 101 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

The Global-BSP program is using the SOFCIDS (Special Operations Capabilities Integration and Development System) requirements approach and the JROC's "IT

Box" acquisition construct which allows fielding of operational capabilities while continued R&D matures technology required for follow-on versions. IT Box enables

programs to tailor the incrementally fielded software program model in the DODI 5000.02 to conduct multiple iterative fielding events in lieu of a single fielding event, and

field products to the warfighter utilizing an incremental delivery approach. The Global-BSP will achieve Full Operational Capability, complete resourced capabilities, and

commence an orderly transition to sustainment in 2020. In FY21 and beyond, the Defense-Wide Review (DWR) reduced this program for higher priorities.

CBRN INFORMATION SYSTEMS

CBRN IS acquisition strategy utilizes a Family-of-Systems (FoS) approach to align multiple capabilities to the CBRN-IS architecture and operational environment. CBRN

IS leverages the concepts of CBRN Hazard Awareness and Understanding and DISA Enterprise Services to integrate current CBRN capabilities, and other information

and intelligence services, applications, and systems to provide increased situational awareness and decision support to commanders for CBRN defense. The strategy

supports the implementation of integrated early warning capabilities by incorporating mature science and technology products and emerging technologies from existing

advanced technology demonstrations (ATD) and experimental capability demonstrations (ECD). CBRN IS utilizes the Agile software development process to provide for

the spiral development and fielding of modular capability packages.

JOINT EFFECTS MODEL (JEM)

The JEM 2 acquisition strategy utilizes Agile software development practices, employing the incrementally fielded software program model in the DODI 5000.02 to

conduct multiple, more frequent fieldings in lieu of a single fielding event. As part of the strategy, an over-arching Milestone B and Build Decision for Requirements

Definition Package 1 (RDP-1) were approved by the Milestone Decision Authority (MDA) in 4QFY14. Subsequent RDPs have been approved along with Capability

Drops (CD) that define capability sets to be developed, tested, and fielded operationally. JEM will prioritize and complete resourced CD's for RDP 1 and 2 to transition

into sustainment. In FY21 and beyond, the Defense-Wide Review (DWR) reduced this program for higher priorities.

JOINT WARNING & REPORTING NETWORK (JWARN)

JWARN 2 acquisition utilizes Agile software development practices, employing the incrementally fielded software program model in the DODI 5000.02 to conduct

multiple, more frequent fieldings in lieu of a single fielding event. As part of the strategy, an over-arching MS B and Build Decision for Requirements Definition Package

1 (RDP-1) were approved by the Milestone Decision Authority (MDA) in 4QFY14. Subsequent RDPs have been approved along with Capability Drops (CD) that define

capability sets to be developed, tested, and fielded operationally. JWARN will prioritize and complete resourced CD's for RDP 1 and 2 to transition into sustainment. In

FY21 and beyond, the Defense-Wide Review (DWR) reduced this program for higher priorities.

SOFTWARE SUPPORT ACTIVITY (SSA)

Software Support Activity (SSA) is a non-acquisition, service organization that provides professional subject matter expertise support throughout the CBDP Enterprise.

These services are provided by government and contract personnel with expertise in software development, network architecture, cybersecurity, technology transitions,

Volume 4 - 261

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 102 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

information assurance, and standards and policies compliance, and are provided throughout the lifecycle of programs within the CBDP portfolio. These efforts facilitate

the efficient development, transition, fielding, modernization, and sustainment of interoperable and integrated CBRN capabilities.

Volume 4 - 262

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 103 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

BSP - SW S - software

-Global-BSP software

development

FFRDC

Johns Hopkins

University - Applied

Physics Lab : Laurel,

20.700 4.169 Dec 2018 2.797 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

CBRN IS - SW S -

software - integration with

BSP, JEM, JWARN

MIPR Various : Various 1.878 1.059 Dec 2018 1.025 Dec 2019 1.339 Dec 2020 - 1.339 Continuing Continuing 0.000

JEM - SW SB -2 -

Hazard Prediction

Model Development and

Integration

C/CPAF

General Dynamics

Information

Technologies :

Fairfax, VA

13.796 1.530 Jan 2019 1.964 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

JWARN - SW S - Product

Dev, Various

Various Various : Various 0.000 1.315 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

JWARN - 2- SW S - Soft

Dev Follow-On

C/CPAF

DCS Corps :

Alexandria, VA

0.000 3.100 Dec 2018 5.002 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

SSA - SW S - CBRN Data

Model

C/CPAF Various : Various 8.253 0.781 Feb 2019 0.446 Feb 2020 0.778 Feb 2020 - 0.778 Continuing Continuing 0.000

Subtotal

44.627 11.954 11.234 2.117 - 2.117 Continuing Continuing N/A

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CBRN IS - ES S - Support

Costs - Cybersecurity and

IA updates, architecture

documentation

MIPR

Space and Naval

Warfare (SPAWAR)

Systems Center :

San Diego, CA

1.885 0.565 Dec 2018 0.672 Dec 2019 0.715 Dec 2020 - 0.715 Continuing Continuing 0.000

JEM - ILS C - Training and

Logistics Support

Various Various : Various 0.000 0.242 Dec 2018 0.321 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

JWARN - ILS C - Training

and Logistics Support

Various Various : Various 0.000 1.604 Apr 2019 1.084 Apr 2020 0.000 - 0.000 Continuing Continuing 0.000

SSA - ES S - Support

Costs

MIPR

Space and Naval

Warfare (SPAWAR)

9.604 2.105 Feb 2019 1.149 Feb 2020 2.000 Feb 2021 - 2.000 Continuing Continuing 0.000

Volume 4 - 263

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 104 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

Systems Center :

San Diego, CA

Subtotal

11.489 4.516 3.226 2.715 - 2.715 Continuing Continuing N/A

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

BSP - DTE S - Software MIPR Various : Various 3.225 0.636 Dec 2018 0.488 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

BSP - OTE S - Software -

MOT&E

MIPR Various : Various 3.744 0.597 Dec 2018 0.911 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

CBRN IS - OTE S -

Operational Test - service-

specific testing, joint test

MIPR Various : Various 1.304 0.620 Dec 2018 0.675 Dec 2019 0.786 Dec 2020 - 0.786 Continuing Continuing 0.000

JEM - Test & Evaluation MIPR Various : Various 3.653 0.580 Dec 2018 1.202 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

JWARN - 2- DTE S -

Completed Development

Test and Evaluation of

JWARN 2 in support of

JWARN 2 IOT&E

MIPR Various : Various 1.505 0.300 Dec 2018 0.567 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

JWARN - 2 - OTE S -

Multi-service Operational

Test and Evaluation of

JWARN 2 software

MIPR Various : Various 3.074 0.625 Dec 2018 0.850 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

Subtotal

16.505 3.358 4.693 0.786 - 0.786 Continuing Continuing N/A

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

BSP - PM/MS S - Program

Management

Various Various : Various 2.920 0.793 Dec 2018 0.466 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 264

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 105 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CBRN IS - PM/MS S -

Program Management -

Planning, Programming,

and Budgeting

MIPR Various : Various 0.549 0.233 Dec 2018 0.128 Dec 2019 0.291 Dec 2020 - 0.291 Continuing Continuing 0.000

JEM - PM/MS S - Program

Office - Planning and

Programming

Various Various : Various 8.722 0.198 Dec 2018 0.521 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

JWARN - 2- PM/MS C -

Program Management

Support

MIPR

Space and Naval

Warfare (SPAWAR)

Systems Center :

San Diego, CA

2.030 0.821 Dec 2018 0.834 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

SSA - PM/MS S -

Management Services

MIPR

Space and Naval

Warfare (SPAWAR)

Systems Center :

San Diego, CA

3.353 0.120 Dec 2018 0.064 Dec 2019 0.110 Dec 2020 - 0.110 Continuing Continuing 0.000

Subtotal

17.574 2.165 2.013 0.401 - 0.401 Continuing Continuing N/A

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost To

Complete

Total

Cost

Target

Value of

Contract

Project Cost Totals

90.195 21.993 21.166 6.019 - 6.019 Continuing Continuing N/A

Remarks

Volume 4 - 265

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 106 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

BSP - RDP-1

BSP - CSG BD 9, 10

BSP - Final Operational Test and Evaluation -

RDP 1

BSP - FOC

CBRN IS - Product Development

CBRN IS - Operational Assessments

CBRN IS - Developmental Test

CBRN IS - Total Package Fielding

JEM Increment 2 - RDP 4

JEM Increment 2 - FD 3

JEM Increment 2 - FD 4

JEM Increment 2 - Govt DT / OT / V&V

JEM Increment 2 - BD 4

JEM Increment 2 - BD 5

JEM Increment 2 - FOC Standalone

JEM Increment 2 - IOC Emerging Capabilities

JWARN Increment 2 - Govt DT / OT / UFEs /

OAs / FOTs

JWARN Increment 2 - Modernization and

Update

JWARN Increment 2 - Product Development

SSA - Provide Integration and Test, M&S,

VV&A Certification and Accreditation

Volume 4 - 266

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 107 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

SSA - Provide Information Assurance

Certification/Acceptance products/services,

including compliance testing

SSA - Provide Modeling, Simulation, VV&A,

Integration/Test support and interoperability

demonstrations.

SSA - Provide Net-Centric Assessment and

assist programs with implementation of policy

SSA - Develop and provide CBRN Data Model

implementation guidance, including reference

implementations

SSA - Provide CBRN Interface Standards,

including reference implementations, e.g.

Common CBRN Sensor Interface

Volume 4 - 267

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 108 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

Schedule Details

Start End

Events Quarter Year Quarter Year

BSP - RDP-1 1 2019 4 2020

BSP - CSG BD 9, 10 2 2019 2 2019

BSP - Final Operational Test and Evaluation - RDP 1 3 2020 4 2020

BSP - FOC 4 2020 4 2020

CBRN IS - Product Development 1 2019 4 2025

CBRN IS - Operational Assessments 1 2019 4 2025

CBRN IS - Developmental Test 4 2019 4 2025

CBRN IS - Total Package Fielding 1 2019 4 2022

JEM Increment 2 - RDP 4 3 2019 4 2019

JEM Increment 2 - FD 3 3 2019 3 2019

JEM Increment 2 - FD 4 3 2020 3 2020

JEM Increment 2 - Govt DT / OT / V&V 1 2019 4 2020

JEM Increment 2 - BD 4 1 2019 1 2019

JEM Increment 2 - BD 5 3 2019 3 2019

JEM Increment 2 - FOC Standalone 2 2019 2 2019

JEM Increment 2 - IOC Emerging Capabilities 4 2019 4 2019

JWARN Increment 2 - Govt DT / OT / UFEs / OAs / FOTs 1 2020 4 2020

JWARN Increment 2 - Modernization and Update 1 2020 4 2020

JWARN Increment 2 - Product Development 1 2020 3 2020

SSA - Provide Integration and Test, M&S, VV&A Certification and Accreditation 1 2019 4 2025

SSA - Provide Information Assurance Certification/Acceptance products/services,

including compliance testing

1 2019 4 2025

Volume 4 - 268

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 109 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

IS5 / Information Systems (SDD)

Start End

Events Quarter Year Quarter Year

SSA - Provide Modeling, Simulation, VV&A, Integration/Test support and interoperability

demonstrations.

1 2019 4 2025

SSA - Provide Net-Centric Assessment and assist programs with implementation of

policy

1 2019 4 2025

SSA - Develop and provide CBRN Data Model implementation guidance, including

reference implementations

1 2019 4 2025

SSA - Provide CBRN Interface Standards, including reference implementations, e.g.

Common CBRN Sensor Interface

1 2019 4 2025

Volume 4 - 269

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 110 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

COST ($ in Millions)

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete

Total

Cost

MB5: Medical Biological Defense

(SDD)

- 127.933 130.074 86.460 - 86.460 56.868 45.226 68.593 83.282 Continuing Continuing

Quantity of RDT&E Articles - - - - - - - - - -

A. Mission Description and Budget Item Justification

This project supports Engineering and Manufacturing Development and Low Rate Initial Production (EMD/LRIP) of medical countermeasures, development of reagents,

assays, diagnostic equipment, biosurveillance and supporting efforts.

Efforts included in this project are:

(1) Botulinum Monoclonal Antibodies (BOT MAB)

(2) Chem Bio Incident Preparedness and Response - Advanced Development and Manufacturing (CBIPR - ADM)

(3) Countermeasures for Multi-Drug Resistance-Bacterial (CMDR-B)

(4) Medical Countermeasure Platform Technologies (MCMPT)

(5) Next Generation Diagnostic System 2 (NGDS 2)

(6) NGDS 2 Chemical Diagnostic (NGDS 2 CHEMDX)

(7) NGDS 2 Man Portable Diagnostic System (NGDS 2 MPDS)

(8) Defense Biological Products Assurance Program (DBPAP)

(9) Antiviral Therapeutics Program (AV TX)

(10) Joint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC)

(11) Botulinum Vaccine (VAC BOT)

(12) Antiviral Prophylaxis Studies (Congressional Interest Item)

(13) Plague Vaccine (VAC PLG)

(14) Special Immunizations Program (VAC SIP)

Initiated by the Medical Countermeasure Platform Technologies (MCMPT), the goal of Botulinum Monoclonal Antibodies (BOT MAB) advanced development effort is

to counter exposure to BOT A & B toxins. This capability is complementary to botulinum vaccine and therapeutics and will provide a continuum of protection against

botulinum toxins. BoNT Advanced Development and Manufacturing of Antibody Technology (ADAMANT) leverages the advanced platform technology developed

within the DoD's Advanced Development Manufacturing (ADM) facility. Efforts will focus on the evaluation of efficacy in pivotal animal studies to satisfy Food and

Drug Administration (FDA) requirements for the animal rule, as well as the preparation for and execution of consistency lots to support phase 2/3 clinical trials. A

Biologics License Application (BLA) will be submitted to the FDA including all clinical, non-clinical and manufacturing data. The FDA grants licensure to products that are

determined to be safe and efficacious.

Volume 4 - 270

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 111 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

The capability building effort at the DoD ADM will establish and enhance proven biopharmaceutical and vaccine manufacturing technologies to accelerate the delivery

of medical countermeasures as part of a medical integrated layered defense. The return on investment is an increased level of preparedness and responsiveness to

counter current and emerging chemical and biological threats. By establishing and enhancing proven enabling technologies, the DoD ADM will accelerate development

of MCMs at all stages of development, enhance preparedness for existing threats, and accelerate response to emerging threats. MCMs impacted by these efforts

include: Vaccines for Viral Agents, Vaccines for Bacterial Agents and Toxins, Monoclonal antibodies, antibody fragments, and antibody conjugates for therapeutic and

prophylactic use across all agent classes, and Adjuvants. Funds to support the state of readiness were previously provided through individual product development and

manufacturing funding lines.

The CMDR-B program develops medical countermeasures (MCMs) for Service members for protection against MDR bacteria, including Biological Warfare Agents

(BWAs) and organisms that are genetically modified to be MDR and resulting bio-toxins. The resulting product(s) will be US Food and Drug Administration (FDA)-

approved to prevent or minimize effects of MDR bacterial exposures. The candidate drug was approved by the FDA in Oct 18 for Community Acquired Bacterial

Pneumonia (CABP) that was required as part of the acquisition strategy for the antibiotic repurposing program from S&T to advanced development.

MCMPT is establishing enabling technologies and pre positioning platform systems at the DoD's Advanced Development Manufacturing (ADM) facility using

standardized discovery, design, manufacturing, and testing processes to reduce the medical countermeasure (MCM) development risks. Efforts will center on leveraging

the ADM's facility and developing robust manufacturing processes. MCMPT will leverage platform technologies to streamline and accelerate the MCM delivery to the

Force by reducing developmental risk. A subset of these technologies will be adapted to deliver a rapid response capability to novel and emerging threats. Through the

Advanced Development and Manufacturing Antibody Technologies (ADAMANT) and Rapid Response platforms, MCMPT will deliver an enduring capability from which

future candidates can be manufactured. The Agile Medical Paradigm (AMP) is the CBDP's strategic framework to accelerate the delivery of MCMs. To achieve this goal

the DOD is establishing a medical countermeasures platform technology (MCMPT) capability.

The NGDS is a family of systems providing increments of diagnostic capabilities over time that address varied CBR threats across the different echelons of the Combat

Health Support System. The mission of the NGDS is to provide CBR threat and infectious disease identification and FDA-cleared diagnostics to inform individual patient

treatment and CBR situational awareness and disease surveillance. NGDS Increment 1 improves diagnostic capabilities in deployable and laboratory-based combat

health support units. NGDS Increment 1 offers improved operational suitability and affordability over legacy systems by developing FDA cleared BWA and infectious

disease IVD assays on an existing commercial diagnostic device with a well established FDA regulatory history and pipeline of commercial non-BWA infectious disease

diagnostic tests. NGDS 2 will complement NGDS Increment 1 by developing diagnostics for unmet biological pathogen and toxin threats, chemical and radiological

exposures, and to provide capability to lower echelons of care. NGDS 2 will provide additional capability for diagnosis of CBR-induced diseases, suitable for use in

far forward environments, by developing lightweight, portable, and simple-to-use instruments and test kits. In FY21, NGDS 2 has been broken out into two separate

programs; NGDS 2 MPDS Program and NGDS 2 CHEMDX Program. NGDS 2 MPDS will complement NGDS Increment 1 by providing a lightweight, portable, and

simple-to-use diagnostic capability to end-users in non-laboratory, far-forward environments. NGDS 2 CHEMDX will provide a lightweight, portable, and simple-to-use

diagnostic capability to end-users in non-laboratory, far-forward environments.

The DBPAP strategy establishes a core research and development capability by developing biological threat agent reference materials (strains, antigens, antibodies and

nucleic acids) and detection/diagnostic assays for biothreat agent detection. These reagents/assays are leveraged across multiple programs to meet the requirements

Volume 4 - 271

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 112 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

of the Warfighter and Joint biological defense systems and support the biological defense community. Through the Targeted Acquisition of Reference Materials

Augmenting Capabilities (TARMAC) initiative, the DBPAP will use a systematic approach to the introduction of new materials and information into MCM development.

This includes advanced platform technologies within the DoD's ADM facility.

The AV TX will develop and deliver FDA approved antiviral therapeutics for the warfighter. Initial drug product will be developed targeting Ebola Virus Disease with

Marburg and Sudan to follow for approval of a PanFilo therapeutic to the warfighter. Development of models to provide a therapeutic for alphavirus are being developed

through JSTO Research & Development. Other pathogens on the biological warfare threat lists, including viruses of interest from Filoviridae, Arenaviridae, Bunyaviridae,

and Flaviviridae, are targets of future interest. Developed antiviral therapeutics will be employed after suspected or confirmed exposure to the relevant threat agents and

AV TX MCMs will ameliorate the effect of threat agents to the warfighter. In the event of a natural occurring outbreak, antiviral therapeutics can be provided to ensure

freedom of operation.

The JMEDICC is a collaboration between United States and Ugandan research and outbreak response entities intended to enable clinical trials for filovirus (Ebola and

Marburg) therapeutics during an outbreak. The JMEDICC effort provides a platform of advanced supportive care, scientific rigor, laboratory and logistical capacity,

mobility, and rapid response to test new therapeutics or MCM in a filovirus outbreak setting. The JMEDICC effort is a project whose resulting capability offers a

mechanism to greatly accelerate the development of life-saving products for future outbreaks. The performer received approval of an emergency access protocol for the

use of the Remdesivir drug in the country of Uganda. JMEDICC effort was funded by the AV TX Program in FY19.

The DoD provides for the development of vaccines that are directed against validated biological warfare (BW) weapons to include bacteria, viruses, and toxins of

biological origin. Effective medical countermeasures are urgently needed to negate the threat of these BW agents. Vaccines have been identified as the most efficient

countermeasure against the validated threat of BW weapons. Products under development in this budget item include Recombinant Botulinum A/B and Plague

vaccines. Efforts to be conducted during the Engineering Manufacturing Development (EMD) Phase include the development of large scale manufacturing process and

validation of that process, nonclinical studies, demonstration of manufacturing consistency, and expanded clinical human safety studies. The results of these efforts,

and those conducted during the EMD phase, will be used to submit a BLA to the FDA for product licensure. To evaluate vaccine effectiveness, pivotal animal studies will

be conducted concurrently with the Phase 3 clinical trial to satisfy the requirements of the FDA's "Animal Rule". The Recombinant Botulinum A/B and Plague vaccine

programs are no longer seeking FDA licensure.

IND vaccines will be used to provide additional levels of protection to laboratory workers in the SIP conducting research on these diseases. DoD has the mission to

maintain Investigational New Drug (IND) vaccines in Good Manufacturing Practice (GMP) storage and to conduct the periodic potency and stability testing of these

materials to support submissions to the FDA.

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Title: 1) Botulinum Monoclonal Antibodies (BOT MAB)

Description: Manufacturing

FY 2021 Plans:

- - 21.211

Volume 4 - 272

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 113 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Initiate Botulinum monoclonal antibody platform development.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred from another funding line. Platform technology transitions from Medical Countermeasure

Platform Technologies (MCMPT).

Title: 2) Chem Bio Incident Preparedness and Response - Adv Dev Mfg (CBIPR - ADM)

Description: ADM Infrastructure

FY 2020 Plans:

Continue activities to maintain the DoD ADM's capabilities in a state of readiness to support Medical Countermeasure (MCM)

development and manufacturing.

FY 2021 Plans:

Continue activities to maintain the DoD ADM's capabilities in a state of readiness to support Medical Countermeasure (MCM)

development and manufacturing.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

- 10.000 10.157

Title: 3) Countermeasures for Multi-Drug Resistance-Bacterial (CMDR-B)

Description: Animal Efficacy Studies.

FY 2020 Plans:

Execute advanced development contract for mature drug products.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

- 8.385 -

Title: 4) Medical Countermeasure Platform Technologies (MCMPT)

Description: Advanced Development and Manufacturing Antibody Technologies (ADAMANT) BOT A/B

FY 2020 Plans:

Complete establishment phase of the ADAMANT platform capability.

FY 2020 to FY 2021 Increase/Decrease Statement:

4.702 0.199 -

Volume 4 - 273

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 114 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Program/project funding transferred to another funding line. Platform technology transitions to BOT MAB.

Title: 5) Next Generation Diagnostic System 2 (NGDS 2)

Description: Man Portable Diagnostic System (MPDS)

FY 2020 Plans:

Continue Engineering & Manufacturing Development, conduct test activities and initiate clinical trials for MPDS.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred to another funding line. NGDS 2 MPDS funding was split out from the NGDS 2 funding line in

FY21.

13.108 10.368 -

Title: 6) NGDS 2

Description: Chemical Diagnostic (CHEMDX)

FY 2020 Plans:

Begin Engineering & Manufacturing Development for the Chemical Diagnostic (CHEMDX).

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred to another funding line. NGDS 2 CHEMDX funding was split out from the NGDS 2 funding

line in FY21.

- 2.697 -

Title: 7) NGDS 2 Chemical Diagnostic (NGDS 2 CHEMDX)

Description: Chemical Diagnostic System (CHEMDX)

FY 2021 Plans:

Begin Engineering & Manufacturing Development for the Chemical Diagnostic System.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred from another funding line. Program/project funding transferred from NGDS 2.

- - 2.089

Title: 8) NGDS 2 Man Portable Diagnostic System (NGDS 2 MPDS)

Description: Man Portable Diagnostic System (MPDS) Product Development

FY 2021 Plans:

Conduct Hardware, software and assay development; system integration, and two clinical trials.

FY 2020 to FY 2021 Increase/Decrease Statement:

- - 20.283

Volume 4 - 274

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 115 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Program/project funding transferred from another funding line. Program/project funding transferred from NGDS 2.

Title: 9) NGDS 2 MPDS

Description: Man Portable Diagnostic System (MPDS) Program Management and Support

FY 2021 Plans:

Conduct program management, developmental testing, and operational assessments.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred from another funding line. Program/project funding transferred from NGDS 2.

- - 9.141

Title: 10) Defense Biological Products Assurance Program (DBPAP)

Description: Development

FY 2020 Plans:

Continue development/expansion of biological threat agents reference materials to known and emerging threats. Continue

development of assays and nucleic acid based genomic assays to support fielded and developmental systems. Continue QA/

QC testing to encompass the transition and fielding of biological detection assays. Continue to maintain yearly accreditation

audits such as ISO 9001, 17025, and Guide 34 certifications. Continue quality actions throughout to maintain the quality managed

systems. Continue development of prototypes/information for strains contained in Unified Culture Collection.

FY 2021 Plans:

Continue development/expansion of biological threat agents reference materials to known and emerging threats. Continue

development of assays and nucleic acid based genomic assays to support fielded and developmental systems. Continue QA/

QC testing to encompass the transition and fielding of biological detection assays. Continue to maintain yearly accreditation

audits such as ISO 9001, 17025, and Guide 34 certifications. Continue quality actions throughout to maintain the quality

managed systems. Continue development of prototypes/information for strains contained in Unified Culture Collection. Supports

establishment of a Common Reference Repository - a single source for well-characterized, traceable test articles and vital

information for biological defense, effective verification of proficiency testing, improved acquisition of emerging technologies, all at

a decreased cost for the individual organizations.

FY 2020 to FY 2021 Increase/Decrease Statement:

Increase due to accelerated development effort.

7.699 6.712 8.872

Title: 11) Antiviral Therapeutics Program (AV TX)

Description: Enabling Technologies

7.447 7.095 11.831

Volume 4 - 275

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 116 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

FY 2020 Plans:

Non-clinical: Continue efficacy studies with Non-Human Primates infected with Ebola virus.

FY 2021 Plans:

Complete efficacy studies with Non-Human Primates infected with Ebola virus. Start efficacy studies with Non-Human Primates

infected with Marburg virus.

FY 2020 to FY 2021 Increase/Decrease Statement:

Increase due to accelerated development effort.

Title: 12) AV TX - JMEDICC

Description: Enabling Technologies

1.987 - -

Title: 13) Joint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC)

Description: Enabling Technologies

FY 2020 Plans:

Continue & complete readiness activities for OCONUS clinical capabilities.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

- 3.398 -

Title: 14) VAC BOT - Recombinant Botulinum Vaccine

Description: Manufacturing

FY 2020 Plans:

Activities to terminate pursuit of Food and Drug Administration (FDA) licensure.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

29.758 18.500 -

Title: 15) VAC BOT - Recombinant Botulinum Vaccine

Description: Non Clinical and Clinical

FY 2020 Plans:

4.891 21.999 -

Volume 4 - 276

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 117 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Activities to terminate pursuit of FDA licensure.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

Title: 16) Cong #230

Description: Antiviral prophylaxis studies.

FY 2020 Plans:

Complete phase 3 clinical trials for extended period of safety.

FY 2020 to FY 2021 Increase/Decrease Statement:

Congressional Increase.

12.000 11.000 -

Title: 17) VAC PLG

Description: Nonclinical and Clinical

FY 2020 Plans:

Activities to terminate pursuit of FDA licensure.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

26.008 17.149 -

Title: 18) VAC PLG

Description: Manufacturing

FY 2020 Plans:

Activities to terminate pursuit of FDA licensure.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being terminated.

17.488 9.807 -

Title: 19) VAC SIP

Description: Storage, Distribution, Potency Testing

2.845 2.765 2.876

Volume 4 - 277

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 118 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

FY 2020 Plans:

Continue storage, distribution, potency testing, and biosurety compliance activities in support of the Special Immunization

Program.

FY 2021 Plans:

Continue storage, distribution, potency testing, and biosurety compliance activities in support of the Special Immunization

Program.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

Accomplishments/Planned Programs Subtotals

127.933 130.074 86.460

C. Other Program Funding Summary ($ in Millions)

Line Item FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete Total Cost

• MB7: Medical Biological

Defense (Op Sys Dev)

8.602 3.231 2.308 - 2.308 2.012 2.305 5.975 9.188 Continuing Continuing

• JM8788: NEXT GENERATION

DIAGNOSTICS SYSTEM (NGDS)

6.563 4.905 0.970 - 0.970 0.000 0.000 0.000 0.000 0.000 12.438

• JX0005: DOD

BIOLOGICAL VACCINE

PROCUREMENT (VACCINES)

0.183 0.173 0.000 - 0.000 0.000 0.000 0.000 0.000 0.000 0.356

• JX0210: DEFENSE BIOLOGICAL

PRODUCTS ASSURANCE

PROGRAM (DBPAP)

0.975 2.961 2.845 - 2.845 2.760 2.736 2.736 2.736 Continuing Continuing

Remarks

D. Acquisition Strategy

BOTULINUM MONOCLONAL ANTIBODIES (BOT MAB)

The goal of the BOT MABs advanced development effort is to counter exposure to BOT A & B toxins. A contract will be awarded to a prime performer responsible

for executing efforts in the EMD phase to focus on the evaluation of efficacy in pivotal animal studies to satisfy FDA requirements for the animal rule, as well as the

preparation for, and execution of, consistency lots to support phase 2/3 clinical trials. A Biologics License Application (BLA) will be submitted to the FDA including all

non-clinical, clinical and manufacturing data. The FDA grants licensure to products that are determined to be safe and efficacious.

Volume 4 - 278

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 119 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

CHEM BIO INCIDENT PREPAREDNESS AND RESPONSE - ADM

A contract was awarded to Ology Bioservices on 20 March 2013 (then Nanotherapeutics, Inc.) to establish a Department of Defense (DoD) ADM Facility to rapidly

develop, approve (through FDA approval), and manufacture MCMs. The contract was structured to be executed in two (2) phases:

Phase 1-Establish, commission and validate (facility(ies)/ equipment) for two (2) advanced development and manufacturing suites that use agile, flexible (single use,

disposable), modular and multi-product technologies for MCM advanced development and manufacturing. Both suites must meet Biological Safety Level-3 (BSL-3)

standards. Phase 1 was completed on 31 March 2017.

Phase 2-Support and maintain that capability in a state of readiness to support MCM development (under the animal rule as applicable) and manufacturing and assist in

training personnel in its use. This includes transition and integration of new technologies, from Pre-Investigational New Drug Application phase with readiness to support

simultaneous operations, through FDA licensure. The first sustainment option (POP 2 years) was completed in 2QFY19; the subsequent sustainment option began

thereafter and is scheduled for completion in 4QFY20, but can be extended until 2QFY21 if needed.

COUNTERMEASURES FOR DRUG RESISTANT BACTERIA (CMDR-B)

The CMDR-B program develops MCMs for Service members for protection against MDR bacteria, including Biological Warfare Agents (BWAs) and organisms that

are genetically modified to be MDR and resulting bio-toxins. The resulting product(s) will be US Food and Drug Administration (FDA)-approved to prevent or minimize

effects of MDR bacterial exposures. The candidate is a transitional product from S&T that showed efficacy against plague, anthrax, and other BW agents. The regulatory

approach of the program is to pursue development of products to FDA approval under the Animal Rule. The program will conduct non-human primate studies to confirm

efficacy. The performer will develop and submit an IFC package to FDA for emergency use to support the warfighter preparedness against MDR. The performer

will submit Supplemental New Drug Application for the therapeutic during the EMD Phase. In FY18 PK study on non-human primates was completed for the plague

indication and results were analyzed against threat indication. Continued coordination with FDA for supplemental indication of anthrax based on threat level to the

warfighter. In FY21 and beyond, the Defense-Wide Review reduced this program for higher priorities.

MCM PLATFORM TECHNOLOGIES (MCMPT)

The goal of the MCMPT is to rapidly counter a broad-spectrum of threat agents using standardized discovery, design, manufacturing, and testing processes to reduce

the MCM development risks. Efforts will focus on establishing advanced platform technologies within the DoD's Advanced Development Manufacturing (ADM) facility

and evaluating that capability through nonclinical and clinical testing. A subset of these technologies will be adapted to deliver a rapid response capability to novel and

emerging threats. Once established, future programs will be able to leverage these platforms for the development of future medical countermeasures. It is anticipated

that these efforts will leverage the Other Transactions Authority (OTA) through the medical OTA consortium.

NEXT GENERATION DIAGNOSTICS SYSTEM (NGDS)

Volume 4 - 279

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 120 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

The NGDS 1 program was a MS A to MS C - acquisition strategy, with MS C approval granted in Dec 2016 for limited production and fielding. NGDS 1 is replacing the

legacy Joint Biological Agent Identification and Diagnostic System (JBAIDS) beginning in FY17. NGDS 1 Full Rate Production was approved in Aug 2018.

NGDS 2 will employ a family of systems approach to bridge identified capability gaps for man-portable diagnostics, immunoassay diagnostics, and chemical diagnostics

systems. NGDS 2 continued the technology maturation and risk reduction of a man-portable diagnostic capability in FY18 and transitioned to engineering and

manufacturing development phase in FY19. NGDS 2 initiated prototyping of a chemical diagnostic capability in FY18. Separate decisions will be utilized to proceed with

further development and production for each capability, based on individual determinations of technology maturity to meet user requirements. Development efforts are

cost-plus awards using Other Transactions Authority (OTA) agreements to take advantage of nontraditional Defense contractor offerings. NGDS 2 is broken out into

NGDS 2 CHEMDx and NGDS 2 MPDS starting in FY21.

NEXT GEN DIAG 2 CHEMICAL DIAGNOSTICS (NGDS 2 CHEMDX)

NGDS Increment 2 will employ a family of systems approach to bridge identified capability gaps for man-portable diagnostics, immunoassay diagnostics, and chemical

diagnostics systems. NGDS 2 CHEMDX will provide a lightweight, portable, and simple-to-use diagnostic capability against chemical threat agents to end-users in

non-laboratory, far-forward environments. NGDS 2 CHEMDX initiated prototyping in FY18 and will conclude prototyping in FY21. NGDS 2 CHEMDX is using an Other

Transactions Authority (OTA) agreement to take advantage of nontraditional Defense contractor offerings. NGDS 2 CHEMDX program is broken out from the NGDS

Increment 2 program starting in FY21.

NEXT GEN DIAG 2 MAN PORTABLE DIAGNOSTIC SYSTEM (NGDS 2 MPDS)

NGDS Increment 2 will employ a family of systems approach to bridge identified capability gaps for man-portable diagnostics, immunoassay diagnostics, and chemical

diagnostics systems. NGDS 2 Man Portable Diagnostic System (MPDS) will complement NGDS Increment 1 by providing a lightweight, portable, and simple-to-use

diagnostic capability to end-users in non-laboratory, far-forward environments. NGDS 2 MPDS concluded prototyping in FY19 and is continuing with engineering and

manufacturing development. MPDS is using Other Transactions Authority (OTA) agreements to take advantage of nontraditional Defense contractor offerings. The

NGDS 2 MPDS program is broken out from the NGDS Increment 2 program starting in FY21.

DEFENSE BIOLOGICAL PRODUCTS ASSURANCE PROGRAM (DBPAP)

The Defense Biological Products Assurance Program's (DBPAP) strategy establishes a core research and development capability to develop biological threat agent

reference materials (antigens, nucleic acids, and antibodies) as well as detection and diagnostic assays for biothreat agent detection that shall be used across multiple

detection and diagnostic platforms. In addition, this strategy includes a formal, validated advanced development process for transitioning new assays into production

and subsequent integration with the appropriate detection/diagnostic platform.

ANTI-VIRAL THERAPEUTICS (AV TX)

Volume 4 - 280

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 121 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

The Anti-viral Therapeutics program acquisition strategy supports the development of multiple therapeutics through the Engineering, Manufacturing and Development

(EMD) phase against the Ebola (Zaire), Marburg and Sudan bio warfare threats. The initial therapeutic candidate is for the Ebola Zaire that completed a Milestone B

decision review in 2QFY19. The overall regulatory approach of the program remains to pursue development of products to FDA approval under the Animal Rule that

was approved as the path, by the FDA in 1QFY19. The program completed a Natural History study as well as a dose ranging study that are part of the pivotal animal

studies for FDA approval planned. There are 3 more pivotal animal studies for FDA approval. The acquisition strategy for Marburg and Sudan indications will have the

performer submitting amended New Drug applications for the therapeutics during the Engineering, Manufacturing and Development (EMD) phase.

JOINT MOBILE EMERGING DISEASE INTERVENTION CLINICAL CAPABILITY (JMEDICC)

The Joint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC) is a collaboration between United States and Ugandan research and outbreak response

entities. It currently is a joint effort with The United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and The Naval Medical Research Center

(NMRC) to enable clinical trials for filovirus (i.e., Ebola and Marburg) therapeutics during an outbreak. JMEDICC effort was funded by the Antiviral Therapeutics (AV

TX) Program (MB5) in FY19. A new funding line was added in FY20 to support this effort. The JMEDICC effort is currently focused on filovirus, but is an adaptable

capability that can incorporate multiple different medical countermeasures (MCM) in parallel and accommodate multiple site activities. This will maximize JMEDICC's

current response capability and infrastructure by expanding as the endemic situation warrants. A cost sharing plan is currently being explored with other government

and nongovernment agencies to determine interest and relevance levels. In FY21 and beyond, the Defense-Wide Review reduced this program for higher priorities.

BOTULINUM VACCINE (VAC BOT)

The Prime System Contractor (Dynport Vaccine Company/DVC LLC, Frederick MD) will function as the FDA regulatory sponsor and will perform all ancillary, regulatory,

quality assurance, and data management as required by the FDA. The current budget supports development through FDA licensure of a recombinant bivalent (A and

B) botulinum vaccine. Other serotypes will be developed through an evolutionary approach, as funding becomes available. The Advanced Component Development

and Prototypes (ACD&P) phase included the manufacture of candidate current Good Manufacturing Practices (cGMP) lots, animal safety testing, and initial clinical

trials. During this phase, the vaccine was evaluated for safety and immunogenicity in a small human clinical trial (Phase 1). During the Engineering Manufacturing

Development (EMD) Phase, the prime contractor stabilized the vaccine formulation, validated the manufacturing process and testing protocols, optimized the delivery

systems and manufactured consistency lots. Phase 2 clinical trials were performed and provided additional safety data. The evaluation of efficacy in pivotal animal

studies to satisfy FDA requirements for the Animal Rule has been completed. The remaining efforts to be conducted during the EMD phase include the Phase 3 clinical

trial to demonstrate safety in an expanded volunteer population. In FY21 and beyond, the Defense-Wide Review (DWR) reduced this program for higher priorities.

CONGRESSIONAL INTEREST ITEMS

CONGRESSIONAL INTEREST ITEM #230

Assay development and validation for monkeypox performed in FY19 that informs approval from the FDA for post-exposure prophylaxis (PEP) indication for smallpox.

Antiviral prophylaxis studies are being performed. Contract awarded to performer to complete animal rule studies for FDA approval.

Volume 4 - 281

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 122 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

PLAGUE VACCINE (VAC PLG)

The Advanced Component Development and Prototypes (ACD&P) phase included the manufacture of candidate current Good Manufacturing Practices (cGMP) lots,

animal safety testing, and initial clinical trials. During this phase, the vaccine was evaluated for safety and immunogenicity in a small human clinical trial (Phase 1). In

order to reduce technical program risk in the Plague vaccine program, the program office conducted competitive prototyping between a US vaccine candidate and a

United Kingdom vaccine candidate. During the 2008 Resource Allocation Decision, the US Plague Vaccine candidate was selected for development through licensure

under a Prime System Contract. The Prime System Contractor (Dynport Vaccine Company/DVC LLC, Frederick MD) currently functions as the FDA regulatory sponsor

and performs all ancillary, regulatory, quality assurance, and data management as required by the FDA. A Project Arrangement is in place with the United Kingdom

and Canada. During the Engineering Manufacturing Development (EMD) Phase, the prime contractor stabilized the vaccine formulation, validated the manufacturing

process and testing protocols, optimized the delivery systems and manufactured consistency lots. Phase 2 clinical trials were performed and provided additional safety

data. The remaining efforts to be conducted during the EMD phase include the Phase 3 clinical trial to demonstrate safety in an expanded volunteer population and

evaluation of efficacy and duration of protection in pivotal animal studies to satisfy FDA requirements for the Animal Rule. In FY21 and beyond, the Defense-Wide

Review (DWR) reduced this program for higher priorities.

SPECIAL IMMUNIZATION PROGRAM (VAC SIP)

The SIP effort continually manages, updates, and executes the INDs of selected prophylaxis, treatments and diagnostics development products which provide additional

protection to individuals that are at high risk of exposure to CBRN agents. Efforts span Good Manufacturing Practices (GMP), Good Laboratory Practices guidelines

necessary to conduct storage and periodic potency testing, as well as clinical administration or products in accordance with the FDA regulated Investigational New Drug

(IND) requirements. This Department of Defense program supports the Federal interagency with this effort, as well as academic and industry partners.

Volume 4 - 282

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 123 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CMDR-B - Advanced

Development Contract

C/CPIF TBD : N/A 0.000 0.000 5.439 Oct 2019 0.000 - 0.000 Continuing Continuing 0.000

MCMPT - HW S -

ADAMANT BOT A/B

establishment

C/CPFF Ology : Alachua, FL 9.573 3.930 Jan 2019 0.175 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

NGDS - HW C - Man

Portable Diagnostic

System

C/CPFF

Cepheid : Sunnyvale,

7.165 10.951 Nov 2018 6.662 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

NGDS - HW C - Chemical

Diagnostic (CHEMDX)

C/CPFF

MRIGlobal : Palm

Bay, FL

0.000 0.000 1.076 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

NGDS - HW C - Man

Portable Diagnostic

System #2

C/CPFF

MRIGlobal : Palm

Bay, FL

10.679 0.500 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

NGDS 2 CHEMDX - HW

C - Chemical Diagostic

System (CHEMDX)

C/CPFF

MRIGlobal : Palm

Bay, FL

0.000 0.000 0.000 0.774 Dec 2020 - 0.774 Continuing Continuing 0.000

NGDS 2 CHEMDX - HW

C - Develop and mature

Assays for Chemical Agent

Diagnostics

MIPR

US Army Medical

Research Institute of

Chemical Defense :

Fort Detrick, MD

0.000 0.000 0.000 0.034 Dec 2020 - 0.034 Continuing Continuing 0.000

NGDS 2 MPDS - HW C -

Man Portable Diagnostic

System (MPDS)

C/CPFF

Cepheid : Sunnyvale,

0.000 0.000 0.000 20.258 Dec 2020 - 20.258 Continuing Continuing 0.000

DBPAP - HW C -

Development of Select

Biological Threat Agent

Reference Materials and

Assays

MIPR Various : Various 1.826 1.662 Jun 2019 1.400 Mar 2020 1.873 Mar 2021 - 1.873 Continuing Continuing 0.000

AV TX - Joint Mobile

Emerging Disease

Intervention OCONUS

Clinical Capability

(JMEDICC)

MIPR

US Army Medical

Research Institute of

Infectious Disease

(USAMRIID) : Fort

Detrick, MD

0.804 0.539 Jan 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 283

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 124 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

AV TX - Joint Mobile

Emerging Disease

Intervention OCONUS

Clinical Capability

(JMEDICC) - OTA

C/FP

Henry M. Jackson

Foundation for the

Advancement of

Military Medicine :

Bethesda, MD

0.000 1.448 Jun 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

AV TX - Clinical Trials -

OTA (Ebola)

C/FP

Gilead Sciences :

San Francisco, CA

0.000 7.433 Jan 2019 4.946 Nov 2019 6.561 Nov 2020 - 6.561 Continuing Continuing 0.000

JMEDICC - Clinical Trial

Conduct Support

MIPR

US Army Medical

Research Institute of

Infectious Disease

(USAMRIID) : Fort

Detrick, MD

0.000 0.000 0.500 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

JMEDICC - OCONUS

Clinical Capabilities - OTA

C/FP

Henry M. Jackson

Foundation for the

Advancement of

Military Medicine :

Bethesda, MD

0.000 0.000 2.115 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

VAC BOT - Manufacturing,

Validation and Consistency

Lot Production

C/CPAF

DynPort Vaccine

Company (DVC)

LLC. : Frederick, MD

71.218 26.684 Dec 2018 30.394 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

CONG - Clinical Trials -

OTA

C/FP

SIGA Technologies :

Inc., New York, NY

2.213 10.754 Jul 2019 9.857 Jul 2020 0.000 - 0.000 Continuing Continuing 0.000

VAC PLG - HW S -

Manufacturing, Validation,

and Consistency Lot

Production

C/CPAF

DynPort Vaccine

Company (DVC)

LLC. : Frederick, MD

30.671 26.181 Nov 2018 17.549 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

VAC PLG - HW S - -

Manufacturing Validation

MIPR

Battelle Memorial

Institute : Columbus,

2.770 0.890 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

Subtotal

136.919 90.972 80.113 29.500 - 29.500 Continuing Continuing N/A

Volume 4 - 284

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 125 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CBIPR-ADM -

Infrastructure

C/CPFF Ology : Alachua, FL 0.000 0.000 8.383 Dec 2019 9.225 Dec 2020 - 9.225 Continuing Continuing 0.000

NGDS - ES C - Studies

and WIPT Support

C/CPFF

John Hopkins

University : Laurel,

0.000 0.145 Aug 2019 0.302 Oct 2019 0.000 - 0.000 Continuing Continuing 0.000

DBPAP - ES C - Select

Biological Threat Agent

Reference Material

Support

MIPR Various : Various 1.620 1.920 Jun 2019 1.500 Mar 2020 1.911 Mar 2021 - 1.911 Continuing Continuing 0.000

DBPAP - ES C - Select

Biological Threat Agent

Reference Material

Regulatory/Quality

Assurance (QA) Support

MIPR

Edgewood Chemical

Biological Center

(ECBC) : Aberdeen

Proving Ground, MD

1.580 1.361 Jun 2019 1.482 Mar 2020 1.927 Mar 2021 - 1.927 Continuing Continuing 0.000

VAC BOT - Regulatory

Integration (Environmental

and FDA Documentation)

and Delivery System

C/CPAF

DynPort Vaccine

Company (DVC)

LLC. : Frederick, MD

33.198 5.136 Dec 2018 1.310 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

VAC SIP - Storage and

Distribution of Vaccines

SS/FP

Fisher BioServices :

Rockville, MD

1.790 0.437 Feb 2019 0.453 Jan 2020 0.469 Jan 2021 - 0.469 Continuing Continuing 0.000

Subtotal

38.188 8.999 13.430 13.532 - 13.532 Continuing Continuing N/A

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

BOT MAB - DTE C - BOT

MONO

C/CPFF TBD : N/A 0.000 0.000 0.000 15.132 Dec 2020 - 15.132 Continuing Continuing 0.000

NGDS - OTHT C - Test

and evaluate interagency

MIPR Various : Various 0.360 0.020 Aug 2019 0.500 Oct 2019 0.000 - 0.000 Continuing Continuing 0.000

NGDS - DTE C - Virus

Strain Production &

Testing

MIPR Various : Various 0.432 0.417 Nov 2018 0.500 Oct 2019 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 285

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 126 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

NGDS 2 CHEMDX - DTE

S - Chemical Diagnostic

(CHEMDX) Testing

MIPR Various : Various 0.000 0.000 0.000 0.400 Dec 2020 - 0.400 Continuing Continuing 0.000

NGDS 2 MPDS - OTHT S -

BSL4 Testing

MIPR Various : Various 0.000 0.000 0.000 0.365 Dec 2020 - 0.365 Continuing Continuing 0.000

NGDS 2 MPDS - DTE S

- MPDS SystemTest &

Evaluation

MIPR Various : Various 0.000 0.000 0.000 0.889 Dec 2020 - 0.889 Continuing Continuing 0.000

VAC BOT - DTE C -

Nonclinical Studies

C/CPAF

DynPort Vaccine

Company (DVC)

LLC. : Frederick, MD

81.485 1.000 Dec 2018 8.795 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

VAC BOT - DTE C -

Battelle

Allot

Battelle Memorial

Institute : Columbus,

0.900 1.480 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

VAC PLG - DTE C -

Clinical Trials/Non-Clinical

Studies

C/CPAF

DynPort Vaccine

Company (DVC)

LLC. : Frederick, MD

91.814 3.920 Dec 2018 9.407 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

VAC SIP - OTHT C

- Potency Testing of

Vaccines

MIPR

US Army Medical

Research Institute of

Infectious Disease

(USAMRIID) : Fort

Detrick, MD

12.103 2.118 Dec 2018 2.170 Jan 2020 2.081 Jan 2021 - 2.081 Continuing Continuing 0.000

Subtotal

187.094 8.955 21.372 18.867 - 18.867 Continuing Continuing N/A

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

BOT MAB - PM/MS C -

BOT MONO

Various

JPEO Chem : Bio,

Rad, and Nuc

Defense (JPEO-

CBRND)

0.000 0.000 0.000 2.409 Dec 2020 - 2.409 Continuing Continuing 0.000

Volume 4 - 286

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 127 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

BOT MAB - PM/MS C -

BOT MONO #2

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 0.000 1.468 Dec 2020 - 1.468 Continuing Continuing 0.000

BOT MAB - PM/MS C -

JPdM Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 0.000 2.202 Dec 2020 - 2.202 Continuing Continuing 0.000

CBIPR-ADM - PM/MS C

- Program Management

Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Belvoir,

0.000 0.000 0.917 Dec 2019 0.932 Dec 2020 - 0.932 Continuing Continuing 0.000

CBIPR-ADM - PM/MS C

- Program Management

Support #2

Various

JPEO Chem/Bio

Defense (JPEO-

CBD) : Aberdeen

Proving Ground, MD

0.000 0.000 0.700 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

CMDR-B - PM/MS SB -

Program Management

(Biological Therapeutics)

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 1.055 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

CMDR-B - PM/MS S -

Program Management

(OPETS)

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 1.891 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

MCMPT - PM/MS C -

Program Management

Various

JPEO Chem : Bio,

Rad, and Nuc

Defense (JPEO-

CBRND)

0.000 0.273 Dec 2018 0.024 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

MCMPT - PM/MS C -

ADMC Support

C/CPFF Ology : Alachua, FL 0.000 0.499 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 287

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 128 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

NGDS - PM/MS C -

Program Management

(Dx) Support

MIPR

Edgewood Chemical

Biological Center

(ECBC) : Aberdeen

Proving Ground, MD

0.000 0.230 Nov 2018 0.329 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

NGDS - PM/MS S -

Program Management

(JPEO) Support

Various

JPEO Chem/Bio

Defense (JPEO-

CBD) : Aberdeen

Proving Ground, MD

8.885 0.000 Dec 2018 0.947 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

NGDS - PM/MS S -

Program Management

(Dx) Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

3.006 0.845 Nov 2018 1.887 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

NGDS - PM/MS SB -

Product Management

Systems Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

3.436 0.000 0.862 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

NGDS 2 CHEMDX -

PM/MS S - Program

Management (JPM)

Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 0.000 0.186 Dec 2020 - 0.186 Continuing Continuing 0.000

NGDS 2 CHEMDX -

PM/MS S - Program

Management (JPEO)

Various

JPEO Chem : Bio,

Rad, and Nuc

Defense (JPEO-

CBRND)

0.000 0.000 0.000 0.199 Dec 2020 - 0.199 Continuing Continuing 0.000

NGDS 2 CHEMDX -

PM/MS S - Program

Management (CHEMDX)

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 0.000 0.496 Dec 2020 - 0.496 Continuing Continuing 0.000

NGDS 2 MPDS - PM/MS

S - Program Management

(JPM) Support

Various

JPM Medical

Countermeasure

Systems (JPM

0.000 0.000 0.000 2.061 Dec 2020 - 2.061 Continuing Continuing 0.000

Volume 4 - 288

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 129 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

MCS) : Fort Detrick,

NGDS 2 MPDS - PM/MS

S - Program Management

(JPEO)

Various

JPEO Chem : Bio,

Rad, and Nuc

Defense (JPEO-

CBRND)

0.000 0.000 0.000 2.700 Dec 2020 - 2.700 Continuing Continuing 0.000

NGDS 2 MPDS - PM/MS

S - Program Management

(MPDS)

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 0.000 1.121 Dec 2020 - 1.121 Continuing Continuing 0.000

NGDS 2 MPDS - PM/MS

S - Product Management

Support

MIPR

Combat Capabilities

Development

Command (CCDC)

Chemical Biological

Center : Aberdeen

Proving Ground, MD

0.000 0.000 0.000 0.486 Dec 2020 - 0.486 Continuing Continuing 0.000

NGDS 2 MPDS - PM/MS

S - Program Management

(OPETS)

C/FFP Various : Various 0.000 0.000 0.000 1.544 Dec 2020 - 1.544 Continuing Continuing 0.000

DBPAP - PM/MS C -

Product Management

Contractor Support

SS/FFP Various : Various 1.123 0.849 Feb 2019 0.860 Feb 2020 1.075 Feb 2021 - 1.075 Continuing Continuing 0.000

DBPAP - PM/MS C -

Product Management

Support

Allot

JPM Guardian :

Aberdeen Proving

Ground, MD

2.621 1.907 Jan 2019 1.470 Jan 2020 2.086 Jan 2020 - 2.086 Continuing Continuing 0.000

AV TX - PM/MS - SB -

Program Management

(JPEO)

Various

JPEO Chem : Bio,

Rad, and Nuc

Defense (JPEO-

CBRND)

8.983 0.000 0.514 Jan 2020 0.974 Jan 2021 - 0.974 Continuing Continuing 0.000

AV TX - PM/MS S -

Program Management

(OPETS)

C/FFP Various : Various 0.000 0.000 0.000 2.035 Jan 2021 - 2.035 Continuing Continuing 0.000

Volume 4 - 289

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 130 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

AV TX - PM/MS - SB -

Management Support

(Biological Therapeutics)

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

2.804 0.014 Dec 2018 0.468 Jan 2020 0.991 Jan 2021 - 0.991 Continuing Continuing 0.000

AV TX - PM/MS - SB -

Management Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Belvoir,

0.304 0.000 0.395 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

AV TX - PM/MS - SB -

Management Support

(JPM) Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

3.438 0.000 0.772 Jan 2020 1.270 Jan 2021 - 1.270 Continuing Continuing 0.000

JMEDICC - PM/MS SB

- Program Management

(Biological Therapeutics)

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 0.224 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

JMEDICC - PM/MS S -

Program Management

(OPETS)

C/FFP Various : Various 0.000 0.000 0.370 Feb 2020 0.000 - 0.000 Continuing Continuing 0.000

JMEDICC - PM/MS SB

- Program Management

(JPM) Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 0.189 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

VAC BOT - Program

Management (JPM)

Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.349 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 290

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 131 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CONG - PM/MS SB -

Program Management

(Biological Therapeutics)

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.220 Dec 2018 0.202 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

CONG - PM/MS S -

Program Management

(OPETS)

C/FFP Various : Various 0.000 1.026 Nov 2018 0.941 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

VAC PLG - Program

Management (JPM)

Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

25.786 1.547 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

VAC PLG - Program

Management (JPEO)

Support

Various

JPEO Chem/Bio

Defense (JPEO-

CBD) : Aberdeen

Proving Ground, MD

42.933 4.417 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

VAC PLG - ADMC

Sustainment

C/CPFF Ology : Alachua, FL 1.800 6.541 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

VAC SIP - PM/MS C -

Program Management

Support

MIPR

Edgewood Chemical

Biological Center

(ECBC) : Aberdeen

Proving Ground, MD

2.746 0.290 Mar 2019 0.142 Mar 2020 0.326 Mar 2021 - 0.326 Continuing Continuing 0.000

Subtotal

107.865 19.007 15.159 24.561 - 24.561 Continuing Continuing N/A

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost To

Complete

Total

Cost

Target

Value of

Contract

Project Cost Totals

470.066 127.933 130.074 86.460 - 86.460 Continuing Continuing N/A

Remarks

Volume 4 - 291

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 132 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

BOT MAB - Platform development

CBIPR-ADM - MCM Enabling Manufacturing

Technologies

CBIPR-ADM - MCM Development and

Manufacturing Support

CMDR-B - Pharmacokinetic Studies

CMDR-B - Bacterial Therapeutics Core

Program Evaluation of BAXDELA

CMDR-B - Animal Efficacy Studies

MCMPT - ADAMANT

NGDS Increment 2 - Man Portable Dx System

(MPDS) Prototype Development

NGDS Increment 2 - Man Portable Dx System

MS B

NGDS Increment 2 - Man Portable Dx System

EMD

NGDS 2 CHEMDX - ChemDx MS B

NGDS 2 CHEMDX - ChemDx EMD

NGDS 2 CHEMDX - ChemDx MS C

NGDS 2 MPDS - Man Portable Dx System

(MPDS) Prototype Development

NGDS 2 MPDS - Man Portable Dx System MS

NGDS 2 MPDS - Man Portable Dx System

EMD

NGDS 2 MPDS - Man Portable Dx System

(MPDS) MS C / LRIP

Volume 4 - 292

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 133 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

NGDS 2 MPDS - Man Portable Dx System

(MPDS) FRP

DBPAP - Expand Select Biological Threat

Agent Reference Material

DBPAP - Development and Implementation of

Quality Initiatives

DBPAP - Optimization and Development of

Nucleic Acid Assays

DBPAP - ISO Certification

DBPAP - PCR assay validation

DBPAP - Enabling early warning tools and

information exchange

DBPAP - Surveillance capabilities

AV TX - Milestone B (Ebola Zaire)

AV TX - Animal Efficacy Studies (Ebola Zaire)

AV TX - BLA/NDA Preparation/Submission

(Ebola Zaire)

AV TX - FDA Licensure/Approval (Ebola Zaire)

AV TX - Milestone C (Ebola Zaire)

AV TX - OCONUS Clinical Capabilities

(JMEDICC)

JMEDICC - OCONUS Clinical Capabilities

VAC BOT - Manufacturing, Testing Efforts/

Regulatory

VAC BOT - Activities to terminate pursuit of

FDA licensure

CONG - Animal Efficacy Studies

Volume 4 - 293

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 134 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

CONG - Phase 3 Clinical Trial

VAC PLG - Manufacturing, Testing Efforts/

Regulatory

VAC PLG - Activities to terminate pursuit of

FDA licensure

VAC SIP - Storage, distribution, potency

testing, biosurety compliance activities

Volume 4 - 294

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 135 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

Schedule Details

Start End

Events Quarter Year Quarter Year

BOT MAB - Platform development 1 2021 4 2025

CBIPR-ADM - MCM Enabling Manufacturing Technologies 1 2020 4 2024

CBIPR-ADM - MCM Development and Manufacturing Support 1 2020 2 2023

CMDR-B - Pharmacokinetic Studies 1 2019 4 2019

CMDR-B - Bacterial Therapeutics Core Program Evaluation of BAXDELA 1 2019 4 2019

CMDR-B - Animal Efficacy Studies 1 2020 4 2020

MCMPT - ADAMANT 1 2019 4 2024

NGDS Increment 2 - Man Portable Dx System (MPDS) Prototype Development 1 2019 4 2019

NGDS Increment 2 - Man Portable Dx System MS B 4 2019 4 2019

NGDS Increment 2 - Man Portable Dx System EMD 4 2019 4 2020

NGDS 2 CHEMDX - ChemDx MS B 2 2021 2 2021

NGDS 2 CHEMDX - ChemDx EMD 2 2021 1 2024

NGDS 2 CHEMDX - ChemDx MS C 1 2024 1 2024

NGDS 2 MPDS - Man Portable Dx System (MPDS) Prototype Development 1 2019 4 2019

NGDS 2 MPDS - Man Portable Dx System MS B 4 2019 4 2019

NGDS 2 MPDS - Man Portable Dx System EMD 4 2019 1 2024

NGDS 2 MPDS - Man Portable Dx System (MPDS) MS C / LRIP 4 2021 4 2021

NGDS 2 MPDS - Man Portable Dx System (MPDS) FRP 1 2024 1 2024

DBPAP - Expand Select Biological Threat Agent Reference Material 1 2019 4 2024

DBPAP - Development and Implementation of Quality Initiatives 1 2019 4 2024

DBPAP - Optimization and Development of Nucleic Acid Assays 1 2019 4 2024

DBPAP - ISO Certification 1 2019 4 2024

Volume 4 - 295

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 136 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MB5 / Medical Biological Defense (SDD)

Start End

Events Quarter Year Quarter Year

DBPAP - PCR assay validation 1 2019 4 2024

DBPAP - Enabling early warning tools and information exchange 1 2019 4 2024

DBPAP - Surveillance capabilities 1 2019 4 2024

AV TX - Milestone B (Ebola Zaire) 2 2019 2 2019

AV TX - Animal Efficacy Studies (Ebola Zaire) 3 2019 2 2021

AV TX - BLA/NDA Preparation/Submission (Ebola Zaire) 2 2021 4 2021

AV TX - FDA Licensure/Approval (Ebola Zaire) 4 2021 4 2021

AV TX - Milestone C (Ebola Zaire) 1 2022 1 2022

AV TX - OCONUS Clinical Capabilities (JMEDICC) 1 2019 4 2019

JMEDICC - OCONUS Clinical Capabilities 4 2019 4 2020

VAC BOT - Manufacturing, Testing Efforts/Regulatory 1 2019 4 2020

VAC BOT - Activities to terminate pursuit of FDA licensure 3 2020 4 2020

CONG - Animal Efficacy Studies 1 2019 2 2020

CONG - Phase 3 Clinical Trial 4 2019 4 2020

VAC PLG - Manufacturing, Testing Efforts/Regulatory 1 2019 4 2020

VAC PLG - Activities to terminate pursuit of FDA licensure 3 2020 4 2020

VAC SIP - Storage, distribution, potency testing, biosurety compliance activities 1 2019 4 2025

Volume 4 - 296

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 137 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

COST ($ in Millions)

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete

Total

Cost

MC5: Medical Chemical Defense

(SDD)

- 43.648 60.220 54.392 - 54.392 52.813 31.441 15.215 15.019 Continuing Continuing

Quantity of RDT&E Articles - - - - - - - - - -

A. Mission Description and Budget Item Justification

This project supports efforts in the Engineering and Manufacturing Development (EMD) phase of the acquisition strategy for prophylactic, pre-treatment, and therapeutic

drugs and diagnostic medical devices for the protection, treatment, detection, and medical management of chemical warfare agent exposures. This project provides for

the research and development of safety studies, manufacturing scale-up, process validation, drug interaction, performance test, and submission of the Food and Drug

Administration (FDA) drug licensure application(s).

Efforts included in this project are:

(1) Advanced Anticonvulsant System (AAS),

(2) Alternative Autoinjector Manufacturer Capability (AUTOINJ),

(3) Bioscavenger (BSCAV-P),

(4) Improved Nerve Agent Treatment System (INATS),

(5) Improved Nerve Agent Treatment System Centrally Acting (INATS CA), and

(6) Rapid Opioid Countermeasure System (ROCS)

AAS consists of Midazolam in an autoinjector for treatment of nerve agent induced seizures. Midazolam, injected intramuscularly, will treat traditional nerve agent and

non-traditional agent-induced seizures and prevent subsequent neurological damage. Midazolam is more water-soluble than diazepam (the currently fielded medication

to control nerve agent-induced seizures) and terminates nerve agent-induced seizures more quickly than diazepam. AAS will not eliminate the need for other protective

and therapeutic systems.

AUTOINJ consists of investigating an FDA approved alternative source(s), beyond the single current Department of Defense (DoD) source, for autoinjectors that deliver

DoD nerve agent antidote and treatment capabilities to the warfighter; mitigates capability fielding and operational readiness risks. This resulted from the manufacturing

and quality issues for the fielded Antidote Treatment Nerve Agent Auto-injector (ATNAA) product, the oxime (2-PAM) and atropine in a dual chambered autoinjector.

This program augments legacy autoinjectors, ATNAA, 2-PAM, and CANA by providing alternative commercial sources which include Dual Drug Delivery Device (D4), the

atropine autoinjector, and anti-convulsant autoinjector.

BSCAV-P was intended to be a new capability for use as a prophylaxis against nerve agents. This program is pursuing closeout activities during FY19 and FY20.

Volume 4 - 297

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 138 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

INATS Pre-Breakout advanced development in FY19 and FY20 provides an enhanced capability treatment regimen offering greater protection over a broader spectrum

of toxic nerve agent threats. The development includes insertion of a CA anticholinergic agent to the treatment regimen to increase survivability and decrease morbidity.

The INATS treatment regimen both improves the performance of, and eventually replaces the Antidote Treatment Nerve Agent Auto-injector (ATNAA).

INATS CA advanced development in FY21 provides a centrally-acting anticholinergic agent to increase survivability and decrease morbidity after exposure to toxic nerve

agent threats. Scopolamine was selected for development after an extensive analysis of alternatives and review of data by the Science and Technology community.

Added to the currently fielded system, the INATS CA program will improve overall medical outcomes and will be utilized as both a vial for use at definitive care and a

stand-alone auto-injector for use in the field.

ROCS is specifically supporting the discovery, characterization, development, and fielding of FDA-approved therapeutic MCMs to protect the Joint Service warfighter

against operational exposures to the opioid class of pharmaceutical-based agents (PBAs), a high priority. The first increment of the ROCS program will develop a

naloxone autoinjector as a rescue treatment that will counteract the adverse effects from exposure to opioids.

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Title: 1) Advanced Anticonvulsant System (AAS)

Description: New Drug Application (NDA) Resubmission Activities

FY 2021 Plans:

Continue NDA resubmission activities.

FY 2020 to FY 2021 Increase/Decrease Statement:

Increase due to fact of life change in the program/project. The Contractor will need to initiate and complete studies that comply

with new Food and Drug Administration (FDA) requirements for manufacturing and quality for autoinjector products.

4.898 - 4.048

Title: 2) Alternative Autoinjector Manufacturer Capability (AUTOINJ)

Description: Manufacturing

FY 2020 Plans:

Complete manufacturing of autoinjector consistency lots; initiate prototype tooling for dual chambered autoinjector; initiate

manufacturing, validation for dual chamber auto-injector.

FY 2021 Plans:

Continue prototype tooling.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. No longer doing consistency lots in FY21.

1.000 4.800 2.500

Title: 3) AUTOINJ - - 1.000

Volume 4 - 298

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 139 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Description: Development

FY 2021 Plans:

Continue manufacturing and validation for dual drug chamber autoinjector. Initiate engineering lots for Dual Drug Delivery Device

(D4). Initiate manufacturing lots for diazepam.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

Title: 4) AUTOINJ

Description: Testing

FY 2020 Plans:

Complete reliability, continue stability studies for atropine. Initiate functional testing for dual chamber auto injector. Continue

prototype development of single autoinjector.

FY 2021 Plans:

Continue stability studies for atropine. Continue functional testing for dual chamber auto injector. Continue prototype development

of single autoinjector.

FY 2020 to FY 2021 Increase/Decrease Statement:

Decrease due to change in program/project technical parameters. No longer doing reliability studies in FY21.

8.194 17.000 9.300

Title: 5) AUTOINJ

Description: FDA Coordination

FY 2020 Plans:

Continue FDA preparation, filing, and meetings for single and dual drug autoinjectors.

FY 2021 Plans:

Continue FDA preparation, filing, and meetings for single and dual drug autoinjectors.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

0.500 2.068 1.200

Title: 6) AUTOINJ

Description: Clinical

1.000 1.000 0.931

Volume 4 - 299

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 140 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

FY 2020 Plans:

Continue human factors and environmental testing for single and dual drug autoinjectors.

FY 2021 Plans:

Continue human factors and environmental testing for single and dual drug autoinjectors.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

Title: 7) Bioscavenger (BSCAV-P)

Description: Closeout

FY 2020 Plans:

Complete Program Close Out.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project terminated in FY 2020.

17.669 0.500 -

Title: 8) Improved Nerve Agent Treatment System (INATS)

Description: Manufacturing & Non-Clinical & Clinical- Scopolamine

FY 2020 Plans:

Initiate clinical efforts and continue manufacturing and non-clinical.

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred to another funding line. Transferring to INATS CA (MC5).

10.387 21.113 -

Title: 9) Improved Nerve Agent Treatment System Centrally Acting (INATS CA)

Description: Manufacturing/Auto-Injector

FY 2021 Plans:

Continue Auto-Injector Development and Manufacturing Activities

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred from another funding line. INATS-CA was created from the INATS funding line.

- - 7.100

Title: 10) INATS - CA - - 19.896

Volume 4 - 300

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 141 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Description: Non-Clinical

FY 2021 Plans:

Initiate Non-Clinical Animal Studies

FY 2020 to FY 2021 Increase/Decrease Statement:

Program/project funding transferred from another funding line. INATS-CA was created from the INATS funding line.

Title: 11) Rapid Opioid Countermeasure System (ROCS)

Description: Development

FY 2020 Plans:

Initiate & complete naloxone formulation studies.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Study will complete in FY20.

- 2.304 -

Title: 12) Rapid Opioid Countermeasure System (ROCS)

Description: Manufacturing

FY 2020 Plans:

Initiate manufacturing activities.

FY 2021 Plans:

Continue manufacturing activities.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Expecting manufacturing to ramp down in FY21.

- 6.166 4.800

Title: 13) Rapid Opioid Countermeasure System (ROCS)

Description: Clinical Studies

FY 2020 Plans:

Initiate Phase 1 human clinical studies.

FY 2021 Plans:

- 5.269 3.617

Volume 4 - 301

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 142 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Complete Phase 1 human clinical studies.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments. Data Analysis & Reports require less funding.

Accomplishments/Planned Programs Subtotals

43.648 60.220 54.392

C. Other Program Funding Summary ($ in Millions)

Line Item FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete Total Cost

• JM6677: ADVANCED

ANTICONVULSANT

SYSTEM (AAS)

0.000 3.152 0.000 - 0.000 4.885 8.052 7.862 1.394 Continuing Continuing

Remarks

D. Acquisition Strategy

ADVANCED ANTICONVULSANT SYSTEM (AAS)

The Advanced Anticonvulsant System (AAS), consists of Midazolam in an autoinjector for treatment of seizures, to include those caused by nerve agent. A contractor

shall be responsible for conducting activities associated with drug development in a manner consistent with eventual approval by the Food and Drug Administration

(FDA). The contractor shall sponsor the drug to the FDA and hold all approvals and/or licenses. The Contractor will need to initiate and complete studies that comply

with new FDA requirements for manufacturing and quality for autoinjector products, ultimately leading to FDA approval. Upon FDA approval, sufficient quantities of

product to meet Initial Operational Capability (IOC) and Full Operational Capability (FOC) will be purchased. Subsequent purchases for product sustainment will be

made by the Defense Logistics Agency. Post marketing commitments and requirements are anticipated as a result of the FDA approval and will be the responsibility of

the contractor and the government

ALTERNATE AUTOINJECTOR MANUFACTURER CAPABILITY (AUTOINJ)

The Alternative Autoinjector Manufacturer Capability (AUTOINJ) will identify an alternative source(s) to develop and provide required FDA-approved autoinjector-

delivered nerve agent antidote and treatment capabilities to the DoD. Currently, a single DoD source provides all of these capabilities.

The AUTOINJ effort leverages novel technologies and industrial base expansion in order to develop the autoinjector products. AUTOINJ uses contracts and Other

Transactional Agreements (OTAs) in which the performer shall be responsible for conducting development and testing activities consistent with current Food and Drug

Administration (FDA) regulations. The contractor shall sponsor the drug to the FDA and hold all approvals and/or licenses. Upon FDA approval, purchases for product

sustainment will be made by the Defense Logistics Agency.

Volume 4 - 302

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 143 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

AUTOINJ (MC7) Post marketing commitments and requirements are anticipated as a result of the FDA approval and will be the responsibility of the contractor and the

government.

BIOSCAVENGER (BSCAV)

The Bioscavenger program employed a serial evaluation of candidates to achieve competitive prototyping in the Technology Maturation and Risk Reduction (TM&RR)

phase, culminating in a down-select decision. The Bioscavenger program then issued a Request for Proposal (RFP) to select the best value for the government

for a prophylaxis to support an initial limited user group. During the Engineering and Manufacturing Development (EMD) phase, the program continued to meet its

performance objectives and produced a current Good Manufacturing Practice (cGMP) drug product for use in further development.

The program will end activities in FY20. In FY19, the program initiated termination of acquisition activities and program close out, will be completed in FY20. The

program will continue to work with the Joint Science & Technology Office in their efforts to advance potential candidates and will monitor Health and Human Service

programs, international programs, and the commercial sector for potential materiel solutions for this capability gap.

IMPROVED NERVE AGENT TREATMENT SYSTEM (INATS)

The INATS (MC4) program concludes as INATS in FY19.

In the Technology Maturation and Risk Reduction (TM&RR) phase, close collaborations will occur with the science/ technology, and user communities to assess

technical viability, capability delivery options, and to refine operational concepts; the Government will be the systems integrator overseeing the conduct of centrally

acting formulation development efforts, nonclinical toxicology and efficacy studies and clinical safety studies. In the Engineering and Manufacturing Development

(EMD) phase, the Government will engage with commercial partner(s) to ensure that INATS CA development and manufacture is in accordance with Food and Drug

Administration (FDA) regulations. In FY21 and beyond, the Defense-Wide Review (DWR) reduced this program for higher priorities, resulting in only the INATS CA

component being pursued.

The INATS (MC7) line initiates in FY20 and transitions to INATS CA (MC7) in FY21. INATS (MC7) will support the modernization of Soman Nerve Agent Pretreatment

Pyridostigmine (SNAPP) using contract actions to extend operational shelf-life and generate data to expand storage temperature conditions.

IMPROVED NERVE AGENT TREATMENT CENTRALLY ACTING (INATS CA)

(MC5) In the Technology Maturation and Risk Reduction (TM&RR) phase, close collaborations will occur with the science/ technology, and user communities to assess

technical viability, capability delivery options, and to refine operational concepts; the Government will be the systems integrator overseeing the conduct of centrally

acting formulation development efforts, nonclinical toxicology and efficacy studies and clinical safety studies. In the Engineering and Manufacturing Development (EMD)

Volume 4 - 303

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 144 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

phase, the Government will engage with commercial partner(s) to ensure that development and manufacture is in accordance with Food and Drug Administration (FDA)

regulations.

RAPID OPIOID COUNTERMEASURE SYSTEM (ROCS)

Rapid Opioid Countermeasure System (ROCS) is a Joint ACAT III Medical Countermeasure (MCM) Middle Tier acquisition Program of Record (POR) in the Prototype

Phase of development. The ROCS program will use existing naloxone autoinjector capabilities identified from focused Market Research. ROCS is a Middle Tier

acquisition program. The development of the autoinjector will be conducted under Other Transaction Authority (OTA) agreement. Once FDA approval has been granted

the program will transition from Rapid Prototyping to Rapid Fielding or a traditional production and fielding pathway.

Volume 4 - 304

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 145 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

AAS - SW S - NDA

Resubmission Activities

C/CPIF

Meridian Medical

Technologies Inc. :

Columbia, MD

1.630 3.262 Jan 2019 0.000 3.555 Nov 2020 - 3.555 Continuing Continuing 0.000

AUTOINJ - HW S - Device

Inovation

C/FFP Various : Various 0.000 0.142 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

AUTOINJ - HW C -

Regulatory Support

C/CPFF Ology : Alachua, FL 0.000 0.697 Mar 2019 0.000 0.200 Nov 2020 - 0.200 Continuing Continuing 0.000

AUTOINJ - HW S -

Diazepam Autoinjector

C/CPFF

Emergent

Biosolutions :

Gaithersburg/

Rockville, MD

0.000 0.301 Aug 2019 0.000 3.800 Nov 2020 - 3.800 Continuing Continuing 0.000

AUTOINJ - HW S - Dual

Drug Delivery Device (D4)

Prototype Development

C/CPFF

Emergent

Biosolutions :

Gaithersburg/

Rockville, MD

9.198 4.910 Nov 2018 10.202 Nov 2019 3.987 Nov 2020 - 3.987 Continuing Continuing 0.000

AUTOINJ - HW

S - Autoinjector -

Manufacturing of

Consistency Lots

C/CPFF

Battelle Memorial

Institute : Columbus,

3.498 0.523 Dec 2018 8.000 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

BSCAV-P - HW S -

cGMP Manufacturing and

Process Validation

C/CPFF

DynPort Vaccine

Company (DVC)

LLC. : Frederick, MD

46.682 9.015 Jan 2019 0.500 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

INATS - HW C - Large-

Scale Manufacturing

C/CPFF TBD : N/A 0.000 0.000 3.494 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

INATS - HW C - Animal

Efficacy Studies

C/CPFF

Battelle Memorial

Institute : Columbus,

0.000 0.795 Nov 2018 2.888 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

INATS - HW C - Centrally-

Acting AutoInjector Efforts

C/CPFF

Battelle Memorial

Institute : Columbus,

0.000 0.000 7.639 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

INATS - HW C - Pilot

Scale Development of

Drug Product

C/CPFF

Battelle Memorial

Institute : Columbus,

2.842 0.250 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 305

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 146 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

INATS - HW C -

Scopolamine cGMP

Efforts and Manufacture of

Material

C/CPFF Various : Various 9.343 2.657 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

INATS - HW C -

Reformulation Efforts &

Bridging Studies

C/CPFF Various : Various 4.972 0.225 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

INATS CA - HW C -

Manufacturing

C/CPFF TBD : N/A 0.000 0.000 0.000 7.100 Dec 2020 - 7.100 Continuing Continuing 0.000

INATS CA - HW C - Non-

Clinical

C/CPFF TBD : N/A 0.000 0.000 0.000 13.650 Nov 2020 - 13.650 Continuing Continuing 0.000

ROCS - 1. Initiate

naloxone formulation

studies

C/CPFF

kaleo : Richmond,

0.000 0.000 1.860 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

ROCS - 2. Initiate

development of

autoinjector and large

scale manufacturing

process

C/CPFF

kaleo : Richmond,

0.000 0.000 4.979 Feb 2020 3.000 Dec 2020 - 3.000 Continuing Continuing 0.000

ROCS - 3. Initiate Human

Clinical Studies

C/CPFF

kaleo : Richmond,

0.000 0.000 4.255 Aug 2020 2.560 Dec 2020 - 2.560 Continuing Continuing 0.000

Subtotal

78.165 22.777 43.817 37.852 - 37.852 Continuing Continuing N/A

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

AAS - ES C - Office of

Regulated Activities

Support (ORA)

MIPR

US Army

Medical Materiel

Development Activity

(USAMMDA) : Fort

Detrick, MD

0.000 0.045 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 306

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 147 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

Support ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

BSCAV-P - ES C - Office

of Regulated Activities

Support (ORA)

MIPR

US Army

Medical Materiel

Development Activity

(USAMMDA) : Fort

Detrick, MD

0.000 0.218 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

INATS - ILS S - Regulatory

Support

C/CPFF

Battelle Memorial

Institute : Columbus,

1.010 0.923 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

INATS - ES C - Office

of Regulated Activities

Support - (ORA)

MIPR

US Army Medical

Research Material

Command

(USAMRMC) : Fort

Detrick, MD

0.000 0.645 Nov 2018 0.713 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

Subtotal

1.010 1.831 0.713 0.000 - 0.000 Continuing Continuing N/A

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

AUTOINJ - DTE C -

Autoinjector Testing

MIPR

US Army Medical

Research Material

Command

(USAMRMC) : Fort

Detrick, MD

0.000 0.050 Apr 2019 0.000 0.278 Nov 2020 - 0.278 Continuing Continuing 0.000

INATS - DTE S - Centrally

Acting Phase 2 Trial

C/CPFF Various : Various 2.240 0.000 2.140 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

Subtotal

2.240 0.050 2.140 0.278 - 0.278 Continuing Continuing N/A

Volume 4 - 307

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 148 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

AAS - Program

Management (MCS)

Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

1.727 0.853 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

AAS - Program

Management (CDP)

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

1.727 0.190 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

AAS - Program

Management (OPETS)

C/FFP Various : Various 0.000 0.548 Nov 2018 0.000 0.185 Nov 2020 - 0.185 Continuing Continuing 0.000

AAS - Program

Management (JPEO)

Various

JPEO Chem : Bio,

Rad, and Nuc

Defense (JPEO-

CBRND)

0.370 0.000 0.000 0.308 Nov 2020 - 0.308 Continuing Continuing 0.000

AUTOINJ - ADMc

Sustainment

C/CPFF Ology : Alachua, FL 3.661 2.221 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

AUTOINJ - Program

Management (JPEO)

Various

JPEO Chem : Bio,

Rad, and Nuc

Defense (JPEO-

CBRND)

1.277 1.211 Dec 2018 2.823 Dec 2019 2.823 Dec 2020 - 2.823 Continuing Continuing 0.000

AUTOINJ - Program

Management (MCS)

Support

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.594 0.000 1.741 Nov 2019 1.741 Nov 2020 - 1.741 Continuing Continuing 0.000

AUTOINJ - Program

Management (OPETS)

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.639 Dec 2018 1.598 Nov 2019 1.598 Nov 2020 - 1.598 Continuing Continuing 0.000

AUTOINJ - Program

Management (CDP)

Various

JPM Medical

Countermeasure

Systems (JPM

0.000 0.000 0.504 Nov 2019 0.504 Nov 2020 - 0.504 Continuing Continuing 0.000

Volume 4 - 308

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 149 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

MCS) : Fort Detrick,

BSCAV-P - Program

Management (CDP)

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.655 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

BSCAV-P - Program

Management (MCS)

Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

6.974 3.966 Mar 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

BSCAV-P - ADMc

Sustainment

PO Ology : Alachua, FL 3.080 0.300 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

BSCAV-P - Product

Management (OPETS)

C/FFP

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

6.989 1.237 Jun 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

BSCAV-P - Product

Management Support

MIPR

Edgewood Chemical

Biological Center

(ECBC) : Aberdeen

Proving Ground, MD

1.876 0.242 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

BSCAV-P - Program

Management (JPEO)

Various

JPEO Chem : Bio,

Rad, and Nuc

Defense (JPEO-

CBRND)

9.001 2.036 Mar 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

INATS - Product

Managment Support

MIPR

Edgewood Chemical

Biological Center

(ECBC) : Aberdeen

Proving Ground, MD

0.000 0.078 Nov 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

INATS - Product

Management (MCS)

Support

Various

JPM Medical

Countermeasure

Systems (JPM

6.263 2.777 Dec 2018 2.576 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 309

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 150 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

MCS) : Fort Detrick,

INATS - Program

Management (JPEO)

Various

JPEO Chem : Bio,

Rad, and Nuc

Defense (JPEO-

CBRND)

2.970 2.037 Dec 2018 1.663 Mar 2020 0.000 - 0.000 Continuing Continuing 0.000

INATS CA - Program

Management (JPEO)

Various

JPEO Chem : Bio,

Rad, and Nuc

Defense (JPEO-

CBRND)

0.000 0.000 0.000 2.604 Dec 2020 - 2.604 Continuing Continuing 0.000

INATS CA - Program

Management (MCS)

Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 0.000 1.606 Dec 2020 - 1.606 Continuing Continuing 0.000

INATS CA - Program

Management (CDP)

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 0.000 0.549 Dec 2020 - 0.549 Continuing Continuing 0.000

INATS CA - Program

Management (OPETS)

C/FFP Various : Various 0.000 0.000 0.000 1.487 Dec 2020 - 1.487 Continuing Continuing 0.000

ROCS - Program

Management (Chem

Defense Pharm)

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 0.000 0.175 Dec 2020 - 0.175 Continuing Continuing 0.000

ROCS - Program

Management (OPETS)

C/FFP Various : Various 0.000 0.000 0.000 0.161 Dec 2020 - 0.161 Continuing Continuing 0.000

ROCS - Program

Management (JPEO)

Various

JPEO Chem : Bio,

Rad, and Nuc

Defense (JPEO-

CBRND)

0.000 0.000 0.996 Nov 2019 1.559 Dec 2020 - 1.559 Continuing Continuing 0.000

Volume 4 - 310

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 151 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

ROCS - Program

Management (MCS)

Support

Various

JPM Medical

Countermeasure

Systems (JPM

MCS) : Fort Detrick,

0.000 0.000 0.907 Nov 2019 0.962 Dec 2020 - 0.962 Continuing Continuing 0.000

ROCS - ADMc

Sustainment

C/CPFF Ology : Alachua, FL 0.000 0.000 0.742 Nov 2019 0.000 - 0.000 Continuing Continuing 0.000

Subtotal

46.509 18.990 13.550 16.262 - 16.262 Continuing Continuing N/A

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost To

Complete

Total

Cost

Target

Value of

Contract

Project Cost Totals

127.924 43.648 60.220 54.392 - 54.392 Continuing Continuing N/A

Remarks

Volume 4 - 311

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 152 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

BSCAV - Program Close Out Activities

AAS - NDA Resubmission Activities

AUTOINJ - Manufacturing of Consistency Lots

AUTOINJ - Prototyping and Testing

AUTOINJ - FDA Coordination

AUTOINJ - Clinical

AUTOINJ - Development

INATS - Manufacturing (CA)

INATS - Milestone B (CA)

INATS - Non Clinical Studies (CA)

INATS - Clinical Trials (CA)

INATS CA - Manufacturing/Auto-Injector

INATS CA - Non-Clinical

INATS CA - Clinical

ROCS - Naloxone Formulation Studies

ROCS - Manufacturing Activities

ROCS - Human Clinical Studies

ROCS - FDA

Volume 4 - 312

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 153 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

MC5 / Medical Chemical Defense (SDD)

Schedule Details

Start End

Events Quarter Year Quarter Year

BSCAV - Program Close Out Activities 2 2019 4 2020

AAS - NDA Resubmission Activities 1 2019 3 2022

AUTOINJ - Manufacturing of Consistency Lots 1 2019 4 2022

AUTOINJ - Prototyping and Testing 1 2019 1 2024

AUTOINJ - FDA Coordination 1 2019 1 2024

AUTOINJ - Clinical 1 2019 3 2022

AUTOINJ - Development 1 2020 1 2022

INATS - Manufacturing (CA) 1 2019 4 2020

INATS - Milestone B (CA) 3 2020 3 2020

INATS - Non Clinical Studies (CA) 2 2019 4 2020

INATS - Clinical Trials (CA) 1 2020 4 2020

INATS CA - Manufacturing/Auto-Injector 1 2021 4 2024

INATS CA - Non-Clinical 3 2021 4 2023

INATS CA - Clinical 1 2021 2 2021

ROCS - Naloxone Formulation Studies 4 2019 1 2020

ROCS - Manufacturing Activities 1 2020 4 2020

ROCS - Human Clinical Studies 3 2020 2 2021

ROCS - FDA 3 2021 4 2022

Volume 4 - 313

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 154 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

TE5 / Test & Evaluation (SDD)

COST ($ in Millions)

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete

Total

Cost

TE5: Test & Evaluation (SDD)

- 8.792 7.684 6.352 - 6.352 5.878 5.879 5.879 6.371 Continuing Continuing

Quantity of RDT&E Articles - - - - - - - - - -

A. Mission Description and Budget Item Justification

Chemical Biological Material Assessment Infrastructure (CBMAI) addresses test infrastructure needs with improvements, modifications, and/or new critical test

capabilities for chemical, biological, and emerging threat products across the CBDP. The CBMAI funding (BA4-5) is required to provide existing and future test fixtures

and methodology to support advanced development test and evaluation intended to meet a changing threat regardless of the test site/location. These activities support

current PoRs (e.g., UIPE FoS, NBCRV SSU, etc.) as well as future PoRs such as interdependent contamination mitigation (C3PO, WADS, SEDS), future protective

mask programs (i.e., M50 Tech Refresh), remote detection (air to ground/C-SIRP) and integrated early warning (IEW).

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Title: 1) CBMAI

Description: Government Integrated Product Team program management and IPT Support to all CBDP programs and external

partners.

FY 2020 Plans:

Continue Program Management including Government system engineering, program/financial management, costing, personnel

support, travel and overhead.

FY 2021 Plans:

Continue Program Management including Government system engineering, program/financial management, costing, personnel

support, travel and overhead.

FY 2020 to FY 2021 Increase/Decrease Statement:

Defense-Wide Review (DWR): The Chemical Biological Defense Program FY 2021 funding request was reduced to account for

program being or restructured.

1.014 2.940 1.350

Title: 2) CBMAI

Description: CBMAI provides test infrastructure modification build and integration to address detection, protection, and

decontamination requirements and milestone schedules. Provide analysis and testing of innovative technologies and rapid

prototyping of equipment to expedite the infrastructure development process. Execution of infrastructure modifications and

modernization efforts allow test facilities to expand productivity and reduce costs while providing critical test data.

FY 2020 Plans:

7.778 4.744 5.002

Volume 4 - 314

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 155 of 160 R-1 Line #126

Exhibit R-2A, RDT&E Project Justification: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

TE5 / Test & Evaluation (SDD)

B. Accomplishments/Planned Programs ($ in Millions)

FY 2019 FY 2020 FY 2021

Complete validation and accreditation of aerosol biological agent chamber.

Complete integration of upgraded data management system and transition to Dugway.

Initiate infrastructure upgrades to address additional PBAs and emerging threat.

FY 2021 Plans:

Complete the integration and validation of a data management system to allow the test community and users to easily change and

configure equipment and securely share test data on outdoor test ranges.

Continue the integration and validation of referee equipment to provide accurate protective ensemble performance data.

Initiate additional upgrades to JABT, ASC, Staging Facility.

Complete validation and accreditation of aerosol biological agent chamber.

FY 2020 to FY 2021 Increase/Decrease Statement:

Minor change due to routine program adjustments.

Accomplishments/Planned Programs Subtotals

8.792 7.684 6.352

C. Other Program Funding Summary ($ in Millions)

Line Item FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total FY 2022 FY 2023 FY 2024 FY 2025

Cost To

Complete Total Cost

• TE7: Test & Evaluation

(Op Sys Dev)

6.179 5.403 0.000 - 0.000 0.000 0.000 0.000 0.000 0.000 11.582

Remarks

D. Acquisition Strategy

CHEMICAL BIOLOGICAL MATERIEL ASSESSMENT INFRASTRUCTURE (CBMAI)

CBMAI efforts are supported through competitive contract actions, academia, and other Government agencies. Infrastructure solutions will leverage commercially

available systems to provide state-of-the-art capabilities that address current and future CBDP test and evaluation needs. In FY21 and beyond, the Defense-Wide

Review (DWR) reduced this program for higher priorities.

Volume 4 - 315

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 156 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

TE5 / Test & Evaluation (SDD)

Product Development ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CBMAI - HW S - Joint

Ambiant Breeze Tunnel

(JABT)

C/CPFF

MRIGlobal : Kansas

City, MO

0.000 0.197 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

CBMAI - HW S - Test Grid C/CPFF Various : Various 0.000 1.504 Dec 2018 0.000 0.000 - 0.000 Continuing Continuing 0.000

CBMAI - HW S -

Upgrades, V&V, Transition

Various Various : Various 0.000 0.433 Dec 2018 1.000 Dec 2019 0.253 Dec 2020 - 0.253 Continuing Continuing 0.000

CBMAI - HW C - JABT,

ASC, Staging Facility

Upgrades

C/CPFF

MRIGlobal : Kansas

City, MO

0.000 0.000 0.000 1.300 Oct 2020 - 1.300 Continuing Continuing 0.000

CBMAI - HW S - NTA

Defense Test System

Fabrication/Installation

MIPR

Edgewood Chemical

Biological Center

(ECBC) : Aberdeen

Proving Ground, MD

0.000 0.300 Dec 2018 0.270 Jan 2020 0.000 - 0.000 Continuing Continuing 0.000

CBMAI - HW S - Open

Architecture Data

Management System

(OADMS) Software

Modifications

C/CPFF Various : Various 0.000 2.871 Dec 2018 1.100 Dec 2019 1.200 Dec 2020 - 1.200 Continuing Continuing 0.000

CBMAI - HW S - Ballistic

Gas Chromatograph (GC)

C/CPFF

MRIGlobal : Kansas

City, MO

0.000 0.286 Dec 2018 1.474 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

CBMAI - HW S -

Government SE &

Technical Management

Team

MIPR

Edgewood Chemical

Biological Center

(ECBC) : Aberdeen

Proving Ground, MD

0.000 1.261 Dec 2018 1.538 Nov 2019 1.590 Dec 2020 - 1.590 Continuing Continuing 0.000

Subtotal

0.000 6.852 5.382 4.343 - 4.343 Continuing Continuing N/A

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CBMAI - Data Collection

from Regression Test #2

MIPR

Army Materiel

Systems Analysis

0.000 0.081 Feb 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

Volume 4 - 316

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 157 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

TE5 / Test & Evaluation (SDD)

Test and Evaluation ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

Activity : Aberdeen

Proving Ground, MD

CBMAI - DTE C - SCA-V MIPR

S3i Engineering :

LLc, Silver Spring,

0.000 0.103 Mar 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

CBMAI - OTH C - JABT

Dissemination System

Testing

C/CPFF Various : Various 0.000 0.075 Mar 2019 0.000 0.000 - 0.000 Continuing Continuing 0.000

CBMAI - OTHT C - Whole

System Live Agent Test

(WSLAT) Chamber

MIPR

West Desert Test

Center : Dugway, UT

0.000 0.000 0.400 Dec 2019 0.500 Dec 2020 - 0.500 Continuing Continuing 0.000

CBMAI - OTE S - Test Grid

Sustainment

C/CPFF

MRIGlobal : Kansas

City, MO

0.000 0.667 Mar 2019 0.500 Dec 2019 0.000 - 0.000 Continuing Continuing 0.000

Subtotal

0.000 0.926 0.900 0.500 - 0.500 Continuing Continuing N/A

Management Services ($ in Millions)

FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost Category Item

Contract

Method

& Type

Performing

Activity & Location

Prior

Years Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Award

Date Cost

Cost To

Complete

Total

Cost

Target

Value of

Contract

CBMAI - PM/MS C - Core

Support

MIPR

JPEO Chem/Bio

Defense (JPEO-

CBD) : Aberdeen

Proving Ground, MD

0.000 0.000 Dec 2018 0.150 Dec 2019 0.159 Dec 2020 - 0.159 Continuing Continuing 0.000

CBMAI - PM/MS S -

IPT Support/Program

Management

MIPR

JPM NBC

Contamination

Avoidance (JPM

NBC CA) : JPEO,

Aberdeen Proving

Ground, MD

0.000 1.014 Feb 2019 1.252 Dec 2019 1.350 Dec 2020 - 1.350 Continuing Continuing 0.000

Subtotal

0.000 1.014 1.402 1.509 - 1.509 Continuing Continuing N/A

Volume 4 - 317

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 158 of 160 R-1 Line #126

Exhibit R-3, RDT&E Project Cost Analysis: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

TE5 / Test & Evaluation (SDD)

Prior

Years FY 2019 FY 2020

FY 2021

Base

FY 2021

OCO

FY 2021

Total

Cost To

Complete

Total

Cost

Target

Value of

Contract

Project Cost Totals

0.000 8.792 7.684 6.352 - 6.352 Continuing Continuing N/A

Remarks

Volume 4 - 318

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 159 of 160 R-1 Line #126

Exhibit R-4, RDT&E Schedule Profile: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

TE5 / Test & Evaluation (SDD)

FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025

1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4

CBMAI - NTA Defense Test System(NTADTS)

Facility Upgrades for Next Class of Agents

CBMAI - Joint Ambient Breeze Tunnel(JABT)-

Upgrades

CBMAI - Ballistic GC

CBMAI - Test Grid

CBMAI - Open Architecture Data Management

System (OADMS) Complete Develop. &

Integrate

CBMAI - JABT, ASC, Staging Facility Upgrades

CBMAI - Upgrades, V&V, Transitions

Volume 4 - 319

UNCLASSIFIED

PE 0604384BP: CHEMICAL/BIOLOGICAL DEFENSE (EMD)

UNCLASSIFIED

Chemical and Biological Defense Program Page 160 of 160 R-1 Line #126

Exhibit R-4A, RDT&E Schedule Details: PB2021Chemical and Biological Defense Program

Date: February 2020

Appropriation/Budget Activity

0400 / 5

R-1 Program Element (Number/Name)

PE 0604384BP / CHEMICAL/BIOLOGICAL

DEFENSE (EMD)

Project (Number/Name)

TE5 / Test & Evaluation (SDD)

Schedule Details

Start End

Events Quarter Year Quarter Year

CBMAI - NTA Defense Test System(NTADTS) Facility Upgrades for Next Class of

Agents

1 2019 3 2019

CBMAI - Joint Ambient Breeze Tunnel(JABT)- Upgrades 1 2019 3 2019

CBMAI - Ballistic GC 1 2019 4 2020

CBMAI - Test Grid 1 2019 4 2020

CBMAI - Open Architecture Data Management System (OADMS) Complete Develop. &

Integrate

1 2019 3 2021

CBMAI - JABT, ASC, Staging Facility Upgrades 1 2021 1 2023

CBMAI - Upgrades, V&V, Transitions 1 2019 4 2025

Volume 4 - 320